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CHAPTER 1 
 
 
GENERAL OVERVIEW 
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1.1. Medicinal Plants 
 
Plants have been used as primary sources of medicine for thousands of years and were 
our very first medicines. Plants have been selected and used empirically as drugs for 
centuries, initially as traditional preparations and then as pure active principles (Taylor, 
Rabe, McGaw, Jager and van Staden, 2001). Out of the 250,000 identified higher plants 
in the world, about 35,000-70,000 have at one time or another, been used by some people 
or cultures for medicinal purpose (Hoareau, DaSilva and Edgar, 1999).  
 
The investigation of original traditional medicines and phytotherapies are once again 
receiving scientific attention; the aim being to develop effective new drugs that are non-
toxic and inexpensive, with the latter being most important to developing countries.  
 
A large proportion of the population of developing countries use traditional medicines, 
either as a result of the high cost of Western pharmaceuticals and health care, or because 
the traditional medicines are more acceptable from a cultural and spiritual perspective 
(Cunningham, 1998). The study of African medical plants has not in the past been taken 
as seriously, or documented as fully, as Indian and Chinese treatments (Taylor et al., 
2001), even though over 5000 plants are known to be used for medicinal purposes in 
Africa; only a few have been described or studied. Documentation of traditional 
medicinal plants and remedies is becoming increasingly important owing to the rapid loss 
of natural habitats, with many endemic medicinal plants becoming extinct before they 
can be investigated (Iwu, 1993). 
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Ethnopharmacology is defined as the interdisciplinary scientific exploration of 
biologically active agents traditionally employed or observed by man (Holmstedt and 
Bruhn, 1995). The aim of this field of study is the validation of traditional preparations 
either through the isolation of active substances, or through pharmacological findings on 
indigenous drug preparations. The identification of biologically active principles needs to 
be interpreted in light of the traditional use and preparation of the plant (Holmstedt and 
Bruhn, 1995). This should include an analysis and chemical and pharmacological 
evaluation of original drug preparations (e.g. water infusions) in order to establish dose-
effect relationships for the quantitative use of the remedy.  
 
Medicinal plants have been used, since times immemorial in virtually all cultures as a 
source of medicine. Herbal remedies and plant-based healthcare preparations obtained 
from traditionally used plants have been traced to the occurrence of natural products with 
medicinal properties. Moreover, medicinal plants and herbal remedies are re-emerging 
medical aids whose contribution and significance in the maintenance of good health and 
well-being is widely accepted (Hoareau et al., 1999). In industrialized societies, the use 
of traditional medicine and medicinal plants in the treatment of minor ailments is now 
more acceptable since such use helps lower the increasing costs of personal health 
maintenance. 
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The increased interest in herbal medicine is due to the recognition that diseases of the 
immune system have increased (e.g. AIDS), the number of people suffering from 
incurable viral conditions is increasing, more and more bacterial infections are becoming 
resistant to commonly used antibiotics, allergies to foods and other common substances 
are becoming more prevalent, chronic disability is affecting people more frequently at 
younger ages, and mental disease is affecting more and more people. 
 
Herbal medicines are an important part of the culture and traditions of African people. 
Today, most of the population in urban South Africa, as well as smaller rural 
communities, is reliant on herbal medicines for their health care needs. Apart from their 
cultural significance, this is because herbal medicines are generally more accessible and 
affordable (Fennel, Lindsey, McGaw, Sparg, Stafford, Elgorashi, Grace and van Staden, 
2004). As a consequence, there is an increasing trend, worldwide, to integrate traditional 
medicine with primary health care. 
 
It is estimated that more than 80% of the world’s population utilise plants as their 
primary source of medicinal agents (Cordell, 1995) and that moreover, traditional 
medicine is still the only health resource available to about 60% of the world population 
(Le Grand and Wondergem, 1989). Estimates by WHO state that between 60 and 90% of 
Africa’s population rely on medicinal plants to totally or partially meet their health care 
needs. This is true also of South Africa where up to 60% of the population consult one of 
an estimated 200 000 traditional healers (Van Wyk, Oustshoorn and Gericke, 1997), 
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especially in rural areas where traditional healers are more numerous and accessible than 
Western doctors (Cunningham, 1988). 
 
In general, the demand for medicinal plants and herbal remedies and especially its 
renaissance in the developed countries, is driven by the following factors amongst others 
(Hoareau et al., 1999; and Leaman, 2002): 
 
? Increasing costs of institutional, pharmaceutical-based healthcare 
? Interest of individuals, communities and national governments in greater self-
reliance in health care 
? Interest of communities and national governments in small and large-scale 
industrial development based on local/national biodiversity resources 
? Increasing success in validating the safety and efficacy of herbal remedies 
? Legislation improving the status of the herbal medicine industry 
? Renewed interest of companies in isolating useful compounds from plants 
? Search for new drugs and treatments of serious and drug-resistant diseases 
? Marketing strategies by companies dealing in herbal medicine 
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1.1.1. Plant-based natural products in drug discovery 
Natural products have provided, and continue to provide, essential materials for shelter, 
furniture, food, clothing, writing, coloring materials, weapons, gifts, and for the treatment 
of numerous diseases (Balick and Cox, 1996). Bioactive principles were sought in earnest 
in the very early part of the nineteenth century, when, in a period of fifteen or so years, 
the investigation of several renowned medicinal plants led to the discovery of a number 
of the most significant biologically active alkaloids (Cordell, 1981; and Sneader, 1985). 
Some of these alkaloids; morphine, atropine, papaverine and codeine, subsequently 
became the cornerstones of many aspects of drug discovery today (Sneader, 1985; and 
Foye, Lemke and Williams, 1995). Farnsworth and colleagues (1985) indicated that 
globally there were 119 compounds from 90 plants that were used as single entity 
medicinal agents. Significantly, 77% of these were obtained as a result of examining the 
plant based on ethnomedical use, and are employed in a manner that approximates that 
use (Farnsworth, Akerele, Bingel, Soejarto and Guo, 1985).  
 
Modification of natural products, with a view to enhancing activity or selectivity and 
reducing side effects or toxicity, developed as organic chemistry grew in the late 19th 
century (Sneader, 1985). Aspirin was one of the earliest of these chemically modified 
natural products and recently celebrated 100 years as a commercial entity (Reisch, 1997). 
Such modifications of natural products are rarely so simple today, and frequently the 
relationship to a natural product may be barely discernible. However, as O'Neill and 
Lewis (1993) have pointed out, half of the best-selling pharmaceuticals in 1991 were 
actually based on a natural product precursor or pharmacophore. 
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1.1.2. Nutraceuticals 
 
An additional important opportunity for natural products, which has emerged in recent 
years, is their role as nutraceuticals. A nutraceutical is any substance that is a food or a 
part of a food, and provides medical or health benefits, including the prevention and 
treatment of disease. Such products may range from isolated nutrients, dietary 
supplements and specific diets to genetically engineered designer foods, herbal products, 
and processed foods such as cereals, soups and beverages.  
 
Nutritional status determines normal health and functioning of all systems in the body, 
including the immune system, which is responsible for host resistance to various 
infectious diseases. TB co-exists with malnutrition in many parts of the world. The 
incidence of tuberculosis is unusually high among malnourished people even in 
developed countries, including the elderly, homeless, alcoholics, drug abusers and HIV-
infected individuals (Dolin, Raviglione and Kochi, 1994). The health benefits of garlic 
include antimicrobial, antineoplastic, anticardiovascular, immuno-stimulatory, and 
hypoglycemic properties (Ankri and Mirelman, 1999). Such properties make garlic an 
attractive compound to be included in the daily diet, not only for its unique flavor, but 
also for its medicinal benefits. 
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1.1.3. Garlic (Allium sativum) 
 
Garlic, Allium sativum (Fig 1), is a member of the lily family that has been cultivated by 
humans as a food plant for over 10,000 years. Commercial garlic (Allium sativum) is one 
of the edible plants, which has generated a lot of interest throughout human history as a 
medicinal panacea. Egyptian records dating to about 1550 BC mention garlic as a remedy 
for a variety of diseases (Block, 1985). The health benefits of garlic are varied and many. 
Nature has ingeniously packaged a chemical factory in garlic; it contains a collection of 
sulfur and selenium aroma compounds that have developed in the plant to protect it from 
predators such as animals and soil-borne organisms (Foster, 1998). It is these chemicals, 
released upon cutting or crushing garlic, that provide its health-giving benefits (Foster, 
1998).  
 
        
 
Fig.1. Allium sativum  
Bulb 
Cloves 
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Since the 1980s, scientists have discovered that garlic possesses numerous medicinal 
properties. A variety of biological activities have been reported for garlic including 
effects on tumorigenesis, atherosclerosis, microbial growth and blood sugar modulation 
(Milner, 2001; Siegel, 2004; Tsao, 2001; Iimuro, 2002). The antitumorigenic effects of 
garlic have been related to induction of apoptosis in tumor cells (Ledezma, 2004; 
Knowles, 2001; Oommen, 2004; Robert, 2001; Wu, 2001).  
 
A wide range of microorganisms, including bacteria, fungi, protozoa and viruses, have 
been shown to be sensitive to crushed garlic preparations (Ankri and Mirelman, 1999). 
Analysis of steam distillations of crushed garlic cloves (Fig.1) performed over a century 
ago showed a variety of allyl sulfides. However, it was not until 1944 that 
researchers isolated and identified the component responsible for the remarkable 
antibacterial activity of crushed garlic cloves (Cavallito and Bailey, 1994).  
 
The compound turned out to be an oxygenated sulfur compound, which they termed 
allicin, from the Latin name of the garlic plant, Allium sativum. Researchers then 
isolated, identified, and synthesized an oxygenated sulfur amino acid that is present in 
large quantities in garlic cloves and which they named alliin (Stoll and Seebeck, 1951). 
Alliin was found to be the stable precursor that is converted to allicin by the action of an 
enzyme termed alliinase, which is also present in the cloves (Ellmore and Feldberg, 
1994). 
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Cross-section studies have indicated that the substrate alliin and the enzyme alliinase are 
located in different compartments (Koch and Lawson, 1996; and Ellmore and Feldberg, 
1994). This unique organization suggests that it is designed as a potential defense 
mechanism against microbial pathogens of the soil. Invasion of the cloves by fungi and 
other soil pathogens begins by destroying the membrane which encloses the 
compartments that contain the enzyme and the substrate. This causes the interaction 
between alliin and alliinase that rapidly produces allicin and which in turn inactivates the 
invader. 
 
Garlic has antimicrobial, antineoplastic, anticardiovascular, immuno-stimulatory and 
hypoglycemic properties. The antimicrobial properties of crushed garlic have been 
known for a long time and reported frequently (Farbman, Barnett, Bolduc and 
Klein,1993; Johnson and Vaughn, 1969; Cavallito and Bailey 1944; Timonin and 
Thexton, 1950; and Jonkers, van den Broek and van Dooren, 1999). Various garlic 
preparations have been shown to exhibit a wide spectrum of antibacterial activity against 
Gram-negative and Gram-positive bacteria including species of Escherichia, Salmonella, 
Staphylococcus, Streptococcus, Klebsiella, Proteus, Bacillus, and Clostridium. Even 
acid-fast bacteria such as Mycobacterium tuberculosis are sensitive to garlic (Uchida, 
Takahashi and Sato, 1975).  
 
In one study, a synergistic effect of allicin against M. tuberculosis was found with 
antibiotics such as streptomycin or chloramphenicol (Gupta and Viswanathan, 1955). A 
very interesting aspect of the antibacterial activity of allicin is the apparent inability of 
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most bacteria to develop resistance to it because the mode of action is completely 
different from that of other antibiotic substances. It has been proposed that the 
development of resistance to beta-lactam antibiotics is 1000-fold easier than development 
of resistance to allicin (Gupta and Viswanathan, 1955). 
 
Garlic also has immuno-stimulatory property. Garlic extract or its components, diallyl 
trisulfide and diallyl sulfide, stimulates T cell proliferation (Lau, Yamasaki and Gridley, 
1991; Feng, Zhang and Hao, 1994) and macrophages' cytotoxicities on tumor cell lines 
(Feng et al., 1994). Pretreatment with diallyl sulfide restores suppression of the antibody 
response, induced by N-nitrosodimethylamine in a dose dependent manner (Jeong and 
Lee, 1998). Thus, garlic stimulates both humoral and cellular immunity.  
 
 
1.1.4. African Garlic (Tulbaghia alliaceae) 
 
Tulbaghia alliaceae is an indigenous garlic species that occurs mainly in the Eastern 
Cape and Southern KwaZulu-Natal (Van Wyk, Van Oudtshoorn and Gericke, 2000). Its 
common names include wild garlic (English), wilde knoffel (Afrikaans) and isihaqa 
(Zulu).  
 
Botanical description: Wild garlic is a bulbous plant with long, narrow, hairless leaves 
arising from several white, fleshy bases (Fig.2). Pale orange flowers occur in groups of 
about 10 or more at the tip of a slender stalk (Van Wyk et al., 2000). 
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 Fig.2. Tulbaghia alliacea  
 
Traditional medicinal uses: Tulbaghia alliaceae is commonly used for fever, colds, 
asthma, tuberculosis and stomach problems. In Cape Dutch tradition, it is used as a 
purgative, and for fits, rheumatism and paralysis (Van Wyk et al., 2000). 
 
Preparation and dosage: The bulbs and leaves are the plant parts used medicinally. The 
freshly harvested bulbs are boiled in water and the decoctions are either taken orally or as 
an enema. The leaves are also eaten as vegetables (Van Wyk et al., 2000). 
 
Pharmacological effects: Wild garlic (Tulbaghia alliaceae) may prove to have the same 
or similar antimicrobial properties as has been scientifically verified for commercial 
garlic (Allium sativum). 
Leaves 
Stem 
Bulbs 
Roots 
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1.2. Candidiasis  
Candidiasis is the most common oral fungal infection in humans and manifests in a 
variety of clinical guises ranging from pseudomembraneous (thrush), erythematous, and 
hyperplastic variants to linear gingival erythema associated with HIV infection 
(Samaranayake and Scully, 1989; Ellepola and Samaranayake, 2000). Oropharyngeal 
candidiasis (OPC) is the most prevalent oral complication in HIV/AIDS patients 
(Samaranayake, 1992; Glick, Muzyka, Lurie and Salkin, 1994; Blignaut, Messer, Hollis 
and Pfaller, 2002), and it is generally accepted that Candida albicans (Fig.3) is the most 
commonly isolated species from clinical specimens (Pfaller, 1994). 
 
       
         
  
      Fig.3. Candida albicans  
      (Source: http://naturesvictory.fanspace.com/photo.html) 
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1.2.1. Predisposing factors for candidal infection 
 
Candida albicans and several related Candida species are opportunistic pathogens that 
live as benign commensal organisms in the oral cavities of healthy individuals. Candida 
are normal inhabitants of the human gastrointestinal tract and may be recovered from up 
to one third of the mouths of normal individuals and two thirds of those with advanced 
HIV disease (Fichtenbaum, Koletar, Yiannoutsous, Holland, Pottage, Cohn, Walawander, 
Frame, Feinberg, Saag, Van der Horst and Powderly, 2000). These microorganisms may 
change from commensal to pathogenic microorganisms in the mouth in relation to the 
oral and systemic conditions (Kadir, Uygun and Akyuz, 2005). These are known to 
include mucosal disorders, intraoral prosthetic devices, diet, smoking, antibacterial drug 
therapy, and immunocompromising conditions (Arendorf and Walker, 1979; Dreizen, 
1984; Arıkan, Kulak and Kadir, 1995; Kadir, Pisiriciler, Akyuz, Yarat, Emekli and 
Ipbuker, 2002).   
 
Certain patients may be predisposed to the development of oral thrush (white plaque on 
the buccal mucosa, gums, or tongue), such as patients who are immunocompromised, 
those with diabetes mellitus, or pernicious anemia. In addition, the use of oral antibiotics, 
broad-spectrum antibiotics, corticosteroids, or immunosuppressives may predispose 
individuals to infection (Bruce and Rogers, 2004).  
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These factors disrupt the balance between the healthy host and the Candida organism, 
which under normal circumstances, may be present in the gastrointestinal flora but is not 
disease producing (Bruce and Rogers, 2004). 
 
The increasing prevalence of other compromised patient groups in the community, 
common endocrine disorders such as diabetes mellitus, and nutritional deficiencies have 
also contributed to the resurgence of oral candidiasis as a relatively common affliction 
(Ellepola and Samaranayake, 2000). The inter-current administration of antibiotics for the 
management of infections associated with malignancies may further aggravate 
candidiasis.  For instance, it is well established that broad-spectrum antibiotics such as 
tetracycline or combination therapy with antibiotics suppress the oral bacterial flora 
thereby providing the growth of commensal Candida species to a very high degree 
(Samaranayake, Cheung and Samaranayake, 2002). 
 
Oral colonization with inherently drug-resistant organisms is more common in advanced 
HIV infection (CD4-lymphocyte counts <50 cells/mm3) (Fichtenbaum et al., 2000). 
Although not usually associated with severe morbidity, OPC can be clinically significant 
as it can interfere with the administration of medications and adequate nutritional intake, 
and may spread to the esophagus (Tavitian, Raufman and Rosenthal, 1986). Symptoms of 
OPC may include burning pain, altered taste sensation, and difficulty swallowing liquids 
and solids.  
 
 
 
 
 
 16
1.2.2. HIV infection and Oral Candidiasis 
From the initial description of early cases (Gottlieb, Van der Hedien and Thompson, 
1981), candidiasis of the mucosae has been associated with HIV disease. From the 
beginning of the AIDS epidemic, it was determined that oropharyngeal candidiasis is a 
marker of dysfunction of the immunological system, and is also a prognostic marker for 
the development of other resulting infections (Klein, 1984). Candidiasis of the esophagus 
or of the lungs and bronchi is considered one of the  indicator diseases for AIDS.  
 
Oropharyngeal candidiasis (OPC) was among the initial manifestations of HIV-induced 
immunodeficiency to be recognized (Gottlieb et al., 1981) and typically affects the 
majority of persons with advanced untreated HIV infection. Presenting months or years 
before more severe opportunistic disease, oropharyngeal candidiasis may be a sentinel 
event indicating the presence or progression of HIV disease (Klein, Harris and Small, 
1984; Dodd Greenspan, Katz, Westenhouse, Feigal and Greenspan, 1991; Katz, 
Greenspan, Westenhouse, Heesol, Bichbinder, Lifson, Shiboski, Osmond, Moss and 
Samuel, 1992).  
 
Candidiasis in HIV patients is strongly related to deficiency of anti-candida defense 
mechanisms, both topical and systemic, due to the induced immunodeficiency related to 
HIV infection (Yeh, Fox and Ship, 1988; McCarthy, 1992; Epstein, 1984; McCarthy, 
Mackie and Koval, 1991). Changes of the standard levels and the efficiency of topical 
factors, such as secretory IgA globulin, lactoperoxidase, lactoferin, and lysozyme have 
been proven in HIV patients, and are potentially related to the development of candidiasis 
(Yeh et al., 1988 and Rigopoulous, Paparizos and Katsambas, 2004). 
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1.2.3. Chemotherapy and Candidiasis   
 
Early studies have shown that Candida species are responsible for approximately one half 
of oral infections that arise during antileukaemic chemotherapy, and for almost two thirds 
in patients on antineoplastic drugs for solid tumours (Soysa, Samaranayake and Ellepola, 
2004). The majority of cancer patients, particularly those with haematological 
malignancies, are intrinsically colonized by Candida species by virtue of their systemic 
disease, even before they receive chemotherapy or radiotherapy (Soysa et al., 2004).   
 
Cytotoxic drugs have a major dampening effect on the cell-mediated arm of the immune 
component (Soysa et al., 2004) and patients receiving such therapy are particularly 
vulnerable to fungal and viral infections. In one prospective cohort study on orofacial 
complications of combination chemotherapy (cyclophosphamide, methotrexate, 
flurouracil, vincristine and prednisone) in women with breast cancer. McCarthy and 
Skillings (1992) found intra-oral candidiasis in 12% of their cohort. The increased 
incidence of oral candidiasis seen in patients with malignancies stems partly from such 
therapeutic measures and partly from radiotherapy, which are either used singly or in 
combination depending on factors such as the type, stage, and severity of malignancy 
(Soysa et al., 2004). In addition, the concurrent administration of broad-spectrum 
antibiotics may further predispose the patient to oral candidiasis (Bergmann, 1991). 
 
The mechanisms by which therapeutic procedures for oral and other forms of cancer 
favor the oral yeast carriage or infection are indeed complex. It is highly likely that the 
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yeast proliferation (infestation) as well as the subsequent infection is related to both the 
host factors related to the cancer itself and, the side-effects of antineoplastic therapy 
(Soysa et al., 2004).   
 
From a host perspective, cytotoxic action of chemotherapeutic agents on rapidly dividing 
oral mucosal cells results in atrophy, thinning and inflammation (mucositis) of the 
epithelium, which in turn may aggravate the mucosal susceptibility to trauma and 
infection (Prentice, 1989). The pathogenic mechanisms associated with oral candidiasis 
consequential to malignant disorders and their therapeutic measures appear to be rather 
complex and related both to the host as well as the commensal yeasts residing on the oral 
mucosa as pathogens that are ready to strike when an opportunity arises. 
 
1.2.4. The use of fluconazole in the treatment of     
           Candidiasis 
 
Since its introduction, fluconazole has been used to prevent and treat Candida infections 
in HIV-1-infected patients because of its efficacy and good tolerability (Koks, 
Crommentuyn, Mathot, Mulder, Meenhorst and Beignen, 2002). However, after the use 
of fluconazole for the treatment and prophylaxis of fungal infections became wide-
spread, reports began to appear which suggested reduced effectiveness of the standard 
fluconazole therapy and also side effects (Ng and Denning, 1993).  
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The side effects of many azole antifungals such as ketoconazole, itraconazole, 
fluconazole, posaconazole, and voriconazole are similar; the more common being 
headache, dyspepsia, diarrhea, nausea, vomiting, hepatitis, and skin rash (Munoz, 
Moreno, Berenuer, Bernaldo de Quiros and Bouza, 1991). 
 
The clinical response to fluconazole in patients with OPC is usually good but because of 
incomplete eradication of the fungi due to the fungistatic rather than fungicidal effect of 
azoles, relapses occur frequently (Rex, Rinaldi and Pfaller, 1995). The prolonged and 
repeated treatment of OPC in AIDS patients has resulted in an increasing frequency of 
therapy failures caused by the emergence of fluconazole-resistant C. albicans strains 
(Ruhnke, Eigler, Tennagen, Geiseler, Engelmann and Trautmann, 1994). 
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1.3. Tuberculosis 
 
Tuberculosis (TB) caused by infection with Mycobacterium tuberculosis (Fig.4) or 
Mycobacterium bovis remains one of the most important infectious diseases of humans 
and animals respectively, and continues to inflict a huge cost in both health and financial 
terms (Hogarth, Jahans, Hecker, Hewinson and Chambers, 2003). Despite the existence 
of specific antimicrobial agents and the Bacille Calmette-Guérin (BCG) vaccine, it is 
estimated that a third of the world's population is infected with M. tuberculosis (Dye, 
Scheele, Dolin, Pathania and Raviglione, 1999), with 8 million newly diagnosed cases of 
TB and up to 2.5 million deaths occurring each year (World Health Organization, 2001).  
 
      
      
    
Fig.4. Mycobacterium tuberculosis (Scanning electron micrograph) 
   (Source: http://medicineworld.org/images/blogs/11-2007/mycobacterium-tuberculosis-299290.jpg) 
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Epidemiological data suggest that up to one-third of the world's population may be 
latently infected with M.tuberculosis and about 5–10 % of these people will become sick 
or infectious at some time during their life (Olsen and Andersen, 2003). In the Western 
Cape Province of South Africa, the TB incidence has reached an alarming proportion of 
589/100 000 population (Schaaf, Shean and Donald, 2003). Globally, there were an 
estimated 9.2 million new cases and 1.7 million deaths in 2006 (World Health 
Organisation, 2008).  
 
Treatment of TB is complex due to the need to use several medications over extended 
periods of time, and the existence of resistant strains. The current vaccine against TB, 
Bacille Calmette-Guerin, (BCG) prevents the childhood manifestations of TB but as the 
efficacy wanes over a period of 10–15 years, it does not prevent the most prevalent 
disease form, pulmonary TB in adults (World Health Organization, 2004). Considering 
the overwhelming worldwide problem of TB, it is now clear that the development of a 
more effective vaccination and therapeutic strategy is urgently needed. 
 
1.3.1. The Scourge of HIV and TB  
 
HIV/AIDS is a global public health emergency demanding effective action. It is fuelling 
the TB epidemic in sub-Saharan Africa, as individuals infected with Human 
Immunodeficiency Virus (HIV) are very susceptible to TB and often develop this disease 
before other manifestations of Acquired Immune Deficiency Syndrome (AIDS) become 
apparent (Grange and Davey, 1990). TB is therefore, the leading killer of people living 
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with HIV/AIDS (UNAIDS, 2000). Worldwide, 34.3 million people are living with HIV 
(Gilks, Katabira and De Cock, 1997). Of these, 24.5 million (71%) live in sub-Saharan 
Africa (UNAIDS, 2000) and approximately one third are co-infected with TB. Many 
countries have seen an increase in TB case fatality rates (Dye et al., 1999) and a four-fold 
rise in their TB caseload (Mukadi, Maher and Harries, 2001). Some countries have 
documented that up to 70% of TB patients are HIV positive (Raviglione, Harries, Msiska, 
Wilkinson and Nunn, 1997). Between 1990 and 2003, TB incidence rates tripled in 
African countries with high HIV prevalence (Corbett, Watt, Walker, Maher, Williams, 
Raviglione and Dye, 2003).  
 
Unlike other HIV-1-related opportunistic infections, Tuberculosis occurs at all levels of 
CD-4 count (Mukadi, Perriens, Louis, Brown, Prignot, Williame and Pouthier, 1993; and 
Ackah, Coulibaly and Digbeu, 1995), is infectious, and its prevention is a major public-
health priority. Up to 50% of people with HIV in sub-Saharan Africa develop TB; this 
rapid increase of TB cases in sub-Saharan African countries has challenged their ability 
to maintain adequate supplies of TB drugs. Moreover, people infected with HIV and TB 
are more likely to develop drug-resistant forms of the infection, because compliance is an 
issue (Organization of African Unity Summit, 2001). 
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1.3.2. Pathogenesis of Tuberculosis 
 
Mycobacterium tuberculosis is one of the most successful bacterial parasites of humans, 
infecting over one-third of the population of the world. This remarkable success is 
because pathogenic mycobacteria can survive in the hostile habitat of a macrophage, even 
in the face of a specific T-cell immune response (Silva, Bonato, Lima, Coelho-Castelo, 
Faccioli, sartori, De Souza and Leao, 2001).  
 
M. tuberculosis infections are acquired through inhalation of infective bacilli. Bacteria 
are internalized by alveolar macrophages and set up infection foci in the lung tissue. 
These foci expand through bacterial growth and recruitment of macrophages and 
lymphocytes that build the granuloma that defines this infection. The granuloma seems to 
support limited bacterial growth and prevents metastasis of the infection. Nonetheless, 
the granuloma also protects the bacterium from the immune response and is probably 
responsible for the persistent or latent nature of the infection. Clinical disease develops 
when this immune-mediated constriction is abrogated through immune compromise. 
Even in individuals in whom infection is controlled at the granulomatous state or earlier, 
any later imbalance of the host's immune system may promote reactivation of the disease  
(Silva et al., 2001).  
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TB has an uncanny ability to persist, despite the host immune response to infection and 
long periods of chemotherapy. TB's slow progression and the need for long periods of 
treatment make the disease difficult to eradicate. Chemotherapy for TB is notoriously 
slow compared to other bacterial infections (McKinney, Honer and Munoz-Elias, 2000). 
 
1.3.3. The host cell – pathogen relationship 
 
The etiologic agent Mycobacterium tuberculosis is an acid-fast bacillus characterized by 
a wax rich cell wall. The relevant components comprise long-chain fatty acids, mostly 
mycolic acids, glycolipids like lipoarabinomannan, phenolic and peptido glycolipids, 
sulpholipids and others (Brennan and Besra, 1997). The wall is also rich in characteristic 
polysaccharides, in particular peptidoglycans and arabinogalactans. This highly 
hydrophobic cell wall is not only responsible for the acid-fastness but also for resistance 
against complement, acidic or alkaline chemicals, and simple disinfectants, as well as for 
the high adjuvanticity of the cell wall (Kaufmann and Hess, 2000).  
 
Moreover, the robust cell wall promotes mycobacterial replication within phagosomes of 
resting macrophages. This is further supported by the capacity of M. tuberculosis to arrest 
phagosome maturation at an early stage (Kaufmann and Hess, 2000).  In this way, 
mycobacterial phagosomes are not acidified and prevented from fusing with lysosomes. 
Consequently, mycobacteria accommodate an intracellular niche where they can persist 
for long periods of time within the macrophages – one of the most efficacious host 
effector cells against other microbial invaders (Schaible, Collins and Kaufmann, 1999).  
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1.3.4. Antimicrobial drug resistance 
 
Antimicrobial resistance is a naturally occurring biological phenomenon amplified many-
fold due to human misuse and neglect of antimicrobial drugs (WHO, 2000). The effect of 
antimicrobial resistance is that it can reduce the curative power of once life-saving 
medicines to that of a sugar pill.  
 
The social causes fuelling the spread of antimicrobial resistance are paradoxical. In some 
settings – especially in poorer countries – the under-use of drugs encourages the 
development of resistance. For example, where patients are unable to afford the full 
course of the medicines to be cured of their illnesses, or can only afford to purchase 
counterfeit drugs on the black market, the weakest microbes in the body may be killed by 
these insufficient doses while the more resistant microbes are given an opportunity to 
survive and multiply (WHO, 2000). In wealthy countries, resistance is emerging for the 
opposite reason – the overuse of drugs. Unnecessary demands for drugs by patients are 
often eagerly met by health services prone to over-prescription (WHO, 2000). 
 
Resistance has been a problem since humans began to use antibiotics, and reflects the 
Darwinian principle of natural selection, whereby these drugs kill susceptible bacteria but 
allow resistant ones to survive. Four processes contribute to the accumulation of 
resistance: firstly, species with inherent resistance are advantaged; secondly, resistant 
mutants of hitherto susceptible strains are selected; thirdly, transferable resistance genes 
disseminate among bacterial strains, carried by plasmids, transposons and integrons; and, 
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last, some resistant strains achieve epidemic spread among patients, hospitals and 
countries (Livermore and Dudley, 2000). The relative importance of these processes 
varies with the pathogen and setting.  
 
The rise of antimicrobial resistance in human pathogens poses a growing challenge to 
medicine and public health. Increasing resistance to preferred therapies has limited the 
options for treating such diverse infections as HIV and malaria, as well as a variety of 
hospital- and community-acquired bacterial infections (Bloland, 2000; and Bartlett, 
2000). Resistance not only makes treatment of individual patients more complicated and 
more expensive; it also compromises the effectiveness of disease control programs for 
those infections where effective case detection and treatment are central to the prevention 
of disease transmission notably in tuberculosis and some sexually transmitted infections 
(Farmer and Kim, 1998).  
 
 
1.3.5. Antimicrobial drug resistance and TB 
Strategies to control resistance in TB differ considerably from those contemplated for 
other community-acquired infections. There are several reasons for these differences: the 
high case-fatality rate of untreated disease, the importance of treatment in preventing 
transmission, and the need for sustained multi-drug therapy to prevent emergence of 
resistance in treated patients (Bloch, 1994). 
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Highly effective drugs for treating TB were introduced over 30 years ago, yet deaths 
from the disease continue to increase. New tools are needed, including drugs with activity 
against multi-drug resistant strains of Mycobacterium tuberculosis. Agents that reduce 
the duration and complexity of the current therapy would have a major impact on 
compliance and overall cure rate (Duncan, 2003). 
 
Many TB patients fail to comply with the therapy, particularly when their symptoms 
subside as the drugs exert their effect, or when the side effects become unbearable 
(Spigelman and Gillespie, 2006). This leads to treatment failure, and worse, to the 
emergence of drug resistance. Many of the multi-drug resistant TB (MDR-TB) strains 
encountered today are resistant to the majority of antimycobacterial agents. Treating 
patients harbouring such organisms is difficult and they are an enormous drain on already 
strained healthcare resources in many parts of the world (Duncan, 2003). The economic 
consequences of antimicrobial resistance can be staggering. The cost of treating one 
person with multidrug-resistant TB is a hundred times greater than the cost of treating 
non-resistant cases (WHO, 2000). 
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1.3.6. Drug resistant tuberculosis 
 
Drug resistance arises following inadequate chemotherapy which selects for mutated 
strains with increased survival capabilities. Multi-drug resistant tuberculosis (MDR-TB) 
has been defined in terms of resistance to at least the two major anti-TB drugs, 
rifampicin and isoniazid, and requires long and expensive chemotherapy using second-
line drugs of higher toxicity (Zager and McNerney, 2008). Extremely drug resistant 
tuberculosis (XDR-TB) has been reported in all regions of the world and involves 
resistance to at least Rifampicin, Isoniazid, a second-line injectable drug (capreomycin, 
kanamycin or amikamycin) and a fluoroquinolone (CDC, 2006). 
 
Insufficient case management of MDR-TB, which allows partially treated and relapsed 
patients to become sequentially resistant, may play a significant role in the development 
of XDR-TB (Jones, Hesketh and Yudkin, 2008). Effective treatment of XDR-TB is 
challenging for various reasons, including an extended period of treatment of up to 2 
years, lack of accessibility to and the elevated expense of the relevant drugs, low 
adherence owing to toxicity of second-line drugs, and the difficulty of co-administration 
of the medication with antiretroviral therapy in HIV positive patients (Jones et al., 2008). 
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1.3.7. Current TB treatment and problems  
 
By contrast with other infectious diseases, there are relatively few antimicrobial agents 
clinically effective against M tuberculosis. Currently, tuberculosis treatment requires 
lengthy courses of medication due to the ability of M tuberculosis to enter a dormant, 
persistent, antimicrobial-resistant phase. Furthermore, adherence to treatment of 
tuberculosis is limited by a multitude of clinical, social, financial and behavioural factors 
(Ginsburg, Grossett and Bishai, 2003). 
 
Control of the TB epidemic linked with HIV infection will depend largely on the 
adequate treatment of TB, and possibly on effective chemoprophylaxis, not just for HIV-
infected persons but for the community as well (WHO/IUATLD Working Group, 1989). 
TB therapy has been revolutionized and the present treatment regimes are based on 
multidrug therapy usually with three or four anti-tuberculosis drugs. However, the 
problem of multidrug-resistant tubercle bacilli is emerging for various drugs, such as 
isoniazid, ethambutol, rifampin, streptomycin (Girling, 1989 and Grange and Davey, 
1990). Drug-resistant TB is very difficult to treat and requires more and different 
medications for a longer period of treatment. Sometimes, surgery is needed to remove 
areas of destroyed lungs that are heavily infected by mycobacteria and inaccessible to 
drugs (National Jewish Medical and Research Center, 1994). 
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The need for new anti-tuberculosis agents is urgent because of the increasing resistance 
of mycobacteria to classic anti-tuberculosis drugs. A recent World Health Organization 
report states that, globally, 2% of all cases of Tuberculosis are multidrug-resistant - by 
definition, resistance to rifampicin plus isoniazid (plus/minus other resistances). Such 
cases can be treated in the USA and other high resource regions but at a great cost 
(>US$250000 per case) and using very long courses of rather toxic drugs, thereby raising 
serious problems of compliance (Lall and Meyer, 1999). South Africa is currently 
witnessing an explosion in the number of cases of drug-resistant tuberculosis. In some 
parts of the country, one in ten cases of TB is resistant to treatment (Lall and Meyer, 
1999). The recent discovery of extremely drug-resistant (XDR) Mycobacterium 
tuberculosis strains further complicates and exacerbates the problem of drug resistance.  
 
1.3.8. Objectives for TB drug development 
 
Current objectives for TB drug development include shortening the total duration of 
effective treatment and/or significantly reducing the total number of doses needed to be 
taken; improving the treatment of MDR-TB; and providing a more effective treatment of 
latent TB (O’ Brien, 2001). 
 
It is essential to have new anti-tuberculosis agents, preferably those that can be readily 
and simply produced from some local source. The use of antimicrobials from natural 
vegetation has a great impact on human health care in undeveloped countries. Herbal 
medicine has been used for centuries in rural areas by local healers and has been 
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improved in industrialized countries. A number of substances used in modern medicine 
for the treatment of serious diseases have originated from research on medicinal plants 
(Irobi, Moo-Young, Anderson and Daramola, 1994). 
 
Natural products continue to play a very significant role in the drug discovery and 
development process (Newman and Cragg, 2007), and plants are recognized as a useful 
source of highly active antimycobacterial metabolites (Gibbons, 2005; Pauli, Case, Inui, 
Wang, Cho, Fsicher and Franzblau, 2005). 
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1.3.9. Immune responses to M. tuberculosis infection 
 
The acquired cellular immune response to M. tuberculosis infection is complex and 
involves multiple cellular subsets: CD4 and CD8 T cells, as well as unconventional T 
cells such as T cells and double-negative T-cell subsets. Th1 cytokine responses 
also play an important role in the control of TB in humans, as is demonstrated by the fact 
that individuals with genetic deficiencies in IFN-γ and IL-12 receptors have enhanced 
susceptibility to disseminated mycobacterial disease (Olsen and Andersen, 2003).  
 
As one-third of the world's population is estimated to be infected with M. tuberculosis 
(World Health Organization, 2001) a vaccine which will control not only initial infection 
but also disease reactivation is needed.  Research on animal models of latency and 
reactivation of M. tuberculosis has demonstrated an important role for CD8 cells as well 
as IFN-γ in maintaining control of the latent stage of M. tuberculosis infection (Tascon, 
Stavropoulos, Lukacs and Colston, 1998 and van Pinxteren, Cassidy, Smedegaard, Agger 
and Andersen, 2000).  
 
The fact that 5–10% of latently-infected individuals develop clinical disease at some time 
during their life further suggests that the antigen repertoire primed during the primary 
infection might not be sufficient to prevent reactivation (Olsen and Andersen, 2003). 
Antigens expressed in the latent phase of infection could therefore be very relevant 
components in a future vaccine. 
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Protection against disease is associated with a Th1 T-cell response involving interferon-
gamma-producing CD4+ T-cells. Interferon-gamma (IFN- γ) has a key role in protective 
immunity through activation of macrophages. In fact, Mtb-stimulated whole-blood 
production of IFN- γ is currently the assay most closely associated with protection. T-cell 
cytokines and, in particular, IFN-γ play key roles in determining susceptibility to TB 
disease, disease severity, and the reatment outcome (Hussain, Talat, Shahid, Dawood, 
2007). 
 
Evidence from mouse experiments suggests a major role of CD8 T cells, in conjunction 
with CD4 T cells, in protection against tuberculosis (Flynn, Goldstein, Triebold, Koller 
and Bloom, 1992). The T lymphocytes participate in the acquired immune response by 
means of two major functions. First, they produce cytokines that activate effector 
functions. Notably, interferon-gamma (IFN-γ) is a major activator of antimicrobial 
macrophage functions. This cytokine is produced by all T cells stimulated in response to 
mycobacterial infection, i.e. CD4 T cells, CD8 T cells, T cells and CD1-restricted T 
cells (Schaible et al., 1999).  
 
Secondly, these cells also exhibit cytolytic activities, i.e. they lyse infected target cells 
(Kaufmann, 1999). Lysis of infected macrophages, themselves insufficiently equipped for 
mycobacterial killing, could allow release of micro-organisms that are then attacked by 
more proficient monocytes. (Kaufmann and Hess, 2000). More recently, an additional 
function of killer cells has been elucidated; CD8 T cells possess granulysin, which can 
directly attack mycobacteria. The early cytokine response by the innate immune system 
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has a decisive influence on the host response to infectious agents (Fearon and Locksley, 
1996; and Trinchieri, 1995). Of the early cytokines, IL-12 plays a critical role by 
generating the Th1 responses required to eliminate intracellular pathogens, such as M. 
tuberculosis.  
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1.4. Apoptosis 
 
Apoptosis describes the process by which cells are "silently" removed under normal 
conditions when they reach the end of their life span, are damaged, or superfluous (Israels 
and Israels, 1999). It is a general tissue phenomenon necessary for development and 
homeostasis: elimination of redundant cells during embryogenesis, cell atrophy upon 
endocrine withdrawal or loss of essential growth factors or cytokines, tissue remodelling 
and repair, and removal of cells that have sustained genotoxic damage (Cohen, 1993). 
Inappropriate apoptosis is implicated in many human diseases, including 
neurodegenerative diseases such as Alzheimer's disease and Huntington's disease, 
ischaemic damage, autoimmune disorders and several forms of cancer (Thompson, 1995; 
Cohen, 1997). 
 
Apoptotic cell death occurs in two phases: first a commitment to cell death, followed by 
an execution phase characterized by dramatic stereotypic morphological changes in cell 
structure (Takashi and Earnshaw, 1996), suggesting the presence in different cells of a 
common execution machinery (Jacobson, Burne and Raff, 1994). 
 
Apoptosis is a physiologically programmed mechanism by which cells die; it leads to cell 
death through a tightly regulated process resulting in the removal of damaged or 
unwanted tissue (Lowe, 2000). It is associated with a distinct set of biochemical and 
physical changes involving the cytoplasm, nucleus and plasma membrane (Fig.5) 
(Lawen, 2003), and is characterized by chromatin condensation, membrane blebbing, cell 
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shrinkage, and DNA fragmentation (Wyllie, 1980).  Early in apoptosis, the cells round 
up, losing contact with their neighbors, and shrink. In the cytoplasm, the endoplasmic 
reticulum dilates and the cisternae swell to form vesicles and vacuoles. In the nucleus, 
chromatin condenses and aggregates into dense compact masses, and is fragmented 
internucleosomally by endonucleases (Johnson and Vaughn, 1996). The nucleus becomes 
convoluted and buds off into several fragments, which are encapsulated within the 
forming apoptotic bodies. In the plasma membrane, cell junctions are disintegrated, 
whereby the plasma becomes activate and convoluted, eventually blebbing. The cell 
breaks up in a florid manner leading to the “falling away” of several membrane spheres 
containing the “packaged” cellular contents identified as apoptotic bodies of various sizes 
(Lawen, 2003). 
 
1.4.1. Pathways leading to apoptosis 
Induction of apoptosis can occur via two general pathways: the receptor or extrinsic 
pathway, and the mitochondrial or intrinsic pathway. Both apoptotic signaling pathways 
converge at the level of the specific proteases – the caspases. 
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      Fig.5. Schematic diagram illustrating key molecular events in programmed cell death   
                 (apoptosis) in mammalian cells. (Source: Graham and Chen, 2001)  
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1.4.2. Caspases: the regulators of apoptosis 
The processes that elicit activation of the apoptotic program are diverse. It can be 
initiated by oxidative stress, which in turn is mediated by the generation of Reactive 
Oxygen Species (ROS) (Buttke, 1994). Oxidative stress activates caspases, a family of 
cysteine proteases that are involved in the induction of cell death by apoptosis (Grimm, 
1996; Polverino, 1997). Generally, caspases exist in cells as inactive precursor forms 
(Thornberry, 1998; Enari, 1996). Caspase activation is tightly regulated by an apoptosis 
activating complex, requiring proteolytic removal of an amino-terminal domain of 
procaspase to produce an active caspase (Chinnaiuan, 1997; Vaux, 1997; Zou, 1997; Li, 
1997).  
 
Once activated, caspase-3 cleaves many substrate proteins including PARP, ICAD, and 
structural proteins such as actin, fodrin, or lamin to generate the characteristic apoptotic 
morphology (Lazebnik, 1994; Mashima, 1997; Kothakota, 1997). Caspases are classified 
as either initiators (caspase 2, 8, 9, 10), or effectors (caspase 3, 6, 7) of proteolysis - the 
effector caspases activated downstream of the initiator caspases (Israels, 1999).  
 
Caspase activity results in: cleavage of cytoskeletal proteins, disruption of the nuclear 
membrane, disruption of cell-cell contact, and the freeing of the DNA nuclease (CAD, 
caspase-activated deoxyribonuclease) from its associated protein inhibitor (ICAD) to 
allow DNA fragmentation (Thornberry and Lazebnik, 1998). The functions of caspases 
can be summarized as to: (1) arrest the cell cycle and inactivate DNA repair; (2) 
inactivate the inhibitor of apoptosis; and (3) dismantle the cellular cytoskeleton (Wang, 
Liu and Cui, 2005). 
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1.4.3. The role of the mitochondria in Apoptosis 
 
The caspase-independent mechanism for commitment to cell death involves the 
mitochondria.  At least three general mechanisms are known, and their effects may be 
interrelated, including (i) disruption of electron transport, oxidative phosphorylation, and 
adenosine triphosphate (ATP) production; (ii) release of proteins that trigger activation of 
caspase family proteases; and (iii) alteration of cellular reduction-oxidation (redox) 
potential (Green and Reed, 1998). 
 
Mitochondria undergo two major changes during apoptosis induced by neoplastic agents, 
UV radiation, growth factor withdrawal, and DNA damage (Wang, Liu, Cui., 2005). 
First, the mitochondrial outer membranes become permeable to proteins, resulting in the 
release of proteins normally found in the space between the inner and outer membranes 
(including cytochrome c, apoptosis inducing factor, and others). Second, the inner 
mitochondrial membrane's transmembrane potential is reduced (Chang and Yang, 2000; 
Green and Kroemer, 1998; Green and Reed, 1998). The release of cytochrome c leads to 
the formation of a heptameric wheel-like caspase-activating complex, which has been 
termed as apoptosome; this is a high molecular weight complex composed of cytochrome 
c, Apaf-1, deoxyadenosine triphosphate (dATP), and procaspase-9, which forms a 
platform for the efficient processing and activation of caspase-9 (Wang et al., 2005).  
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Caspase-9 has a caspase-associated recruitment domain (CARD) in the N-terminus, and 
this is a key site when it associates with Apaf-1 and cytochrome c (Chang and Yang, 
2000; Acehan, Jiang, Morgan, Heuser, Wang and Akey, 2002; Zou, Henzel, Liu, Lutschg 
and Wang, 1999). Activation of caspase-9, in turn, cleaves effector caspases such as 
caspase-3, -6, and -7 (Nicholson and Thornberry, 1997). Then the effector caspases 
cleave their target proteins and culminate in the orderly demise of the cell. In this 
pathway of apoptosis, caspase-3 and -9 may be the most important as their activities 
influence the process of apoptosis as well as the type of cell death (Martelli, Cappellini, 
Tazzari, Billi, Tassi, Ricci, Fala and Conte, 2004; Coelho, Holl, Weltin, Lacornerie, 
Magnenet, Dufour, Bischoff, 2000).  
 
1.4.4. Gene regulation of Apoptosis 
 
1.4.4.1. The p53 tumor suppressor 
Cell injury resulting in genotoxic events activates p53, a transcription regulator gene 
(Israels and Israels, 1999). The p53 protein product is a regulator of DNA transcription; it 
binds directly to DNA, recognizes DNA damage (single- or double-strand breaks), and 
mediates at least two important cellular events: it can induce cell cycle arrest in G1 or it 
can promote apoptosis. If cellular damage is "considered" reparable, p53-induced cell 
cycle arrest allows time for DNA repair (Prives, 1998). With more extensive damage, to 
prevent the cell with an impaired DNA sequence from proliferating as a defective or 
malignant clone, p53 moves the cell into the apoptotic pathway (Prives, 1998).  
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As a sensor of cellular stress, p53 is a critical initiator of the intrinsic apoptotic pathway 
(Lowe and Lin, 2000). The importance of the p53 gene in suppressing tumor 
development is illustrated by the fact that it is disrupted in roughly 50% of all human 
tumors (Hickman, Moroni and Helin, 2002), and loss of p53 function has been shown to 
both disable apoptosis and accelerate tumor development (Attardi and Jacks, 1999; Ryan, 
Phillips and Vousden, 2001). 
 
1.4.4.2. Bcl-2/ Bax 
A major downstream regulation of the apoptotic death signal resides with the bcl-2/bax 
gene family (Israels and Israels, 1999). Sixteen members of this family have been 
recognized: some (including Bcl-2 and Bcl-XL) are apoptosis-inhibitory proteins, others 
(such as Bax, Bad, and Bid) are promoters of apoptosis (Kumar, 1997). Areas of 
commonality of structure allow these proteins to homo- and hetero- dimerize. A high 
expression of the Bax group promotes apoptosis; a high expression of the Bcl-2 group 
inhibits apoptosis — p53 regulates the ratios of the Bax/Bax, Bax/Bcl-2, and Bcl-2/Bcl-2 
groups (Johnstone, Ruefli and Lowe, 2002). 
 
The Bcl-2 group of proteins resides on the outer mitochondrial membrane oriented toward 
the cytosol – they govern ion transport and protect against breaches in the membrane. The 
Bax proteins reside in the cytosol. Upon receipt of the apoptotic signal, Bax proteins 
migrate and bind to the mitochondrial membrane "permeability transition pore," inducing 
loss of selective ion permeability (Green and Reed, 1998). As a result of the membrane 
changes, there is release into the cytosol of the contents of the intermembrane space, 
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including cytochrome c and apoptosis-inducing factor (AIF): AIF moves directly to the 
nucleus, where it produces chromatin condensation and nuclear fragmentation, while 
cytosolic cytochrome c sets in motion the terminal events of apoptosis (Green and Reed, 
1998). 
 
Given the importance of the Bcl-2 family members in regulating the intrinsic apoptotic 
pathway, it is not surprising that these genes are altered in tumor samples (Johnstone et 
al., 2002). Bcl-2 is over-expressed in a variety of cancers (Reed, 1999), and its over-
expression has been shown to accelerate tumorigenesis in transgenic mice (Adams, 
Wilkinson, Weiss, Diella, Gale, Deutsch, Risau and Klein, 1999).  
 
1.4.5. Apoptosis and Cancer 
 
Numerous studies have demonstrated that evasion of apoptosis is one of the most 
important mechanisms of uncontrolled growth of tumor cells and resistance to the 
immune system. Hence, apoptosis of initiated and/or neoplastic cells represents a 
protective mechanism against neoplastic transformation and development of tumors 
through elimination of genetically damaged cells or cells that may have been 
inappropriately induced to divide by mitogenic and proliferative stimuli (Owuor 2002). 
 
Considerable attention has been focused on manipulation of apoptosis as a novel and 
promising strategy for cancer chemoprevention and therapy (Fesus 1995, Holzman 1996, 
Krzystyniak 2002, Cal 2003, Dong 2003). To achieve this goal, different naturally 
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occurring compounds such as resveratrol, curcumin and genistein have been identified 
and were found to induce apoptosis in malignant cells (Surh, 1999; Kuo, 1996; Lian, 
1999). Many such compounds exist in vegetables or fruits that are consumed by humans 
on a daily basis. Therefore, apoptosis induction by these agents in pre-cancerous and 
cancerous cells will undoubtedly prevent cancer.  
 
1.4.6. The Cell Cycle 
 
The cell cycle is a conserved mechanism by which eucaryotic cells replicate themselves 
(MacLachlan, 1995). In metazoans, the process of cell loss and cell gain must be 
homeostatically balanced in order to generate and maintain the complex architecture of 
tissues, and also to allow adaptation to changing circumstances (Pucci, Kasten and 
Giordano, 2000). 
  
Cell cycle deregulation is regarded as an essential step in the multi-step process of 
tumorigenesis. Many cell cycle regulators controlling the correct entry and progression 
through the cell cycle are altered in tumors; most, if not all, human cancers show a 
deregulated control of progression through the cell cycle (Garrett, 2001; Malumbres and 
Carnero, 2003). The vast majority of tumors have suffered defects that derail the cell 
cycle machinery, leading to increased cell proliferation. Such defects can target either 
components of the cell cycle itself or elements of upstream signalling cascades that 
eventually converge to trigger cell cycle events (Malumbres and Carnero, 2003). 
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In a normal cell cycle (Fig 6), S-phase is always preceeded by M-phase and M-phase 
does not occur until S-phase is complete. Between the S- and M-phases, there are two 
preparatory gaps. G1 separates M from S, and G2 is between S and M. When the cell 
undergoes differentiation, it exits from the G1 phase of the cell cycle to enter into a 
quiescent state referred to as G0 (Garrett, 2001). Transmission of genetic information 
from one cell generation to the next requires genome replication during the S-phase, and 
its segregation to the two new daughter cells during mitosis or M-phase. S- and M-phases 
are crucial events rigorously ordered in a cyclic process that allows for the correct 
duplication of the cell without accumulating genetic abnormalities (Pucci et al. 2000). 
 
 
 
                Fig.6. The cell cycle  
                (Source: http://images1.clinicaltools.com/images/gene/cellcycle.jpg) 
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The timing and order of cell cycle events are monitored during cell cycle checkpoints that 
occur at the G1/S boundary, in S-phase, and during the G2/M-phases (MacLachlan 
1995). The checkpoints are a series of control systems enabling proliferation only in the 
presence of stimulatory signals such as growth factors, they also contribute to the fidelity 
with which genetic information is passed from one generation to the next (Pucci et al. 
2000). The checkpoints are also activated by DNA damage and by mis-aligned 
chromosomes at the mitotic spindle. In this case, the growth arrest caused by checkpoints 
allows the cell to repair the damage. After damage repair, progression through the cell 
cycle resumes. If the damage cannot be repaired, the cell is eliminated through a form of 
cell death called apoptosis (Pucci et al. 2000).  
 
There is accumulating evidence that manipulation of the cell cycle may prevent or induce 
an apoptotic response depending upon the cellular context (Evan, Brown, Whyte, 
Harrington, 1995). Many genes involved in cell cycle regulation are also involved in 
regulation of apoptosis (e.g. c-myc, c-fos, p53, many kinases and phosphatases) (Jarpe, 
Widmann, Knall, Schlesinger, Gibson, Yujiri, Fanger, Gelfand, Johnson, 1998). Thus, 
signals that promote proliferation can also promote apoptosis. If apoptosis is blocked by 
survival signals, increase in cell numbers occurs, which can manifest in cancer (Salvesen, 
2002).   
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1.4.7. Plants as a source of anti-cancer agents 
 
Plants have a long history of use in the treatment of cancer. Drug discovery from 
medicinal plants has played an important role in the treatment of cancer and most new 
clinical applications of plant secondary metabolites and their derivatives over the last half 
century have been applied towards combating cancer (Newman, Cragg, Snader, 2000; 
2003; Butler, 2004). Some of the more well-know plant-derived chemotherapeutic agents 
are vinblastine and vincristine which were isolated from Catharanthus roseus and have 
been used clinically in the treatment of cancer for over 40 years (van Der Heijden, 
Jacobs, Snoeijer, Hallard, Verpoorte, 2004). Paclitaxel (Taxol®) was initially isolated 
from the bark of the Pacific Yew, Taxus brevifolia (Wall and Wani, 1996; Oberlies and 
Kroll, 2004). Paclitaxel is used in the treatment of breast, ovarian, and non-small cell 
lung cancer (NSCLC), and has also shown efficacy against Kaposi sarcoma (Cragg and 
Newman, 2005). Another important addition to the anti-cancer drug armamentarium is 
the class of clinically active agents derived from camptothecin, which is isolated from the 
Chinese ornamental tree, Camptotheca acuminate (Rahier, Thomas, Hecht, 2005). Its 
derivatives Topotecan and Irinotecan are used in the treatment of ovarian and small cell 
lung cancers and colorectal cancers (Cragg and Newman, 2005).   
 
Many experimental investigations have demonstrated that several naturally occurring 
agents and plant extracts have shown antioxidant and anticancer potential in a variety of 
bioassay systems and animal models, having relevance to human disease (Azi, Kumae, 
Ahmad, 2003; Primchanien Nuttavut, Sineenart, Omboon, Narongchai, Neelobol, 2004; 
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Wang, Zhang, Song, Wang, Ni, Luo, Aung, Xie, Tong, He, Yuan, 2006). In light of the 
continuing need for effective anticancer agents, and the association of fruit and vegetable 
consumption with reduced cancer risk, edible plants are increasingly being considered as 
sources of anticancer drugs (Ferguson, Kurowska, Freeman, Chambers, Koropatnick, 
2004). There is significant scientific evidence showing that fruits and vegetables lower 
the risk of cancer (Chen, Chen, Dou, 2004). Furthermore, cancer chemoprevention, 
including the use of  foods and medicinal herbs have been regarded as one of the most 
visible fields for cancer control (Jo, Hong, Ahn, Jung, Yang, park, Kim, Lee, Kang, 
2004). 
 
1.4.8. Natural products as inducers of apoptosis 
 
A successful anticancer drug should kill or incapacitate cancer cells without causing 
excessive damage to normal cells. This ideal situation is achievable by inducing 
apoptosis in cancer cells. The lifespan of both normal and cancer cells is significantly 
affected by the rate of apoptosis (Taraphdar, Roy, Bhattacharya, 2001). Thus, modulating 
apoptosis may be useful in the management and therapy of cancer. Certain products from 
plants are known to induce apoptosis in neoplastic cells but not in normal cells (Hirano, 
Abe, Gotoh, Okah, 1995; Jiang,Yang-Yen, Yen, Lin, 1996; Chiao, Carothers, 
Grunberger, Solomon, Preston, Barrett, 1995).  
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It has become increasingly evident that apoptosis is an important mode of action for 
many anti-tumor agents, including ionizing radiation, alkylating agents such as cisplatin 
and 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) (D’Amico and McKenna, 1994), 
topoisomerase inhibitor etoposide (Kauffman, Desnoyers, Ottaviano, Davidson, Poirier, 
1993), cytokine tumour necrosis factor (TNF) (Shih and Stutman, 1996), taxol (Gibb, 
Taylor, Wan, O’ Connor, Doering, Gercel-Taylor,  1997), and N-substituted benzamides 
such as metoclopramide and 3-chloroprocainamide (Pero, Olsson, Simanaitis, Amiri, 
Anderson, 1997). Apoptotic induction is thus a target for innovative mechanism-based 
drug discovery (Fisher, 1996; Workman, 1996; Taraphdar et al., 2001).  
 
1.4.9. Anti-cancer potential of Garlic  
 
Garlic (Allium sativum) consumption is correlated to reduced cancer risk, and its extracts 
and components have been shown to effectively block experimentally induced tumors in 
a variety of sites including skin, breast, lung, oesophagus, uterus, cervix and colon, 
suggesting a general mechanism of action (Hussain, Jannu, Rao, 1990; Milner, 1996; 
Milner, 2001; Wargovich, 1988; Sumiyoshi, 1990; Liu, 1992; Amagase, 1993; Shukla, 
1999; Song, 1999).  
 
A report by Balasenthil, Rao and Nagini (2002) suggested that aqueous garlic extract 
might exert its chemo-preventive effect by inducing apoptosis. Many organosulfur 
compounds, the major active principles in garlic, have been shown to inhibit the 
proliferation of cancer cells, and some of them induced apoptosis in tumor cells of 
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different tissue origin (Dirsch, Gerbes, Vollmar, 1998; Kwon, Yoo, Ryu, Yang, Rho, 
Kim, Park, Kim, Park, 2002; Pinto, Lapsia, Shah, Santiago, Kim, 2001; Shirin, Pinto, 
Kawabata, Soh, Delohery, Moss, Murty, Rivlin, Holt, Weinstein, 2001; and Sigounas, 
Hooker, Anagnostou, Steiner, 1997). Epidemiological studies have shown that enhanced 
garlic consumption is closely related with reduced cancer incidence (Buiatti, 1989; 
Haenszel, 1972; You, 1989; Steinmetz, 1994; Dorant, 1996; Fleischauer, 2001; Hsing, 
2002). Several animal experiments have shown that garlic treatment and aged garlic, in 
particular, counteracts formation and the development of various forms of experimentally 
induced tumors (Khanum, Anilakumar, Viswanathan, 2004).  
 
Epidemiological investigations in China, Italy, and America have provided evidence that 
the risks of stomach and colon cancers are inversely related to regular consumption of 
garlic and garlic products. Experimental carcinogenesis studies indicate that components 
of garlic (e.g., allyl sulfides) inhibit both the initiation and promotion stages of 
tumorigenesis for various types of cancer, including colorectal, lung, and skin cancers 
(Xiao, Pinto, Soh, Deguchi, Gundersen, Palazzo, Yoon, Shirin, Weinstein,  2003). 
 
Tulbaghia violacea, commonly known as wild garlic is indigenous to South Africa. This 
plant is used in traditional medicine for the treatment of fever, asthma, hypertension and 
oesophageal cancer (Hutchings, Scott, Cunningham, 1996; Van Wyk and Wink, 2004). A 
study by Bungu, Frost, Brauns, and Van de Venter, (2006) demonstrated that extracts of 
T. violacea exhibited anti-proliferative and pro-apoptotic effects in four human cancer 
cell lines. 
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1.5. Toxicity 
 
Toxicity is defined as “the potential of a substance to exert a harmful effect on humans or 
animals, and a description of the effect and the conditions or concentration under which 
the effect takes place” (Walum, 1998). 
 
In order to support an application for a clinical trial or for the registration of a new drug, 
it is necessary to satisfy legislation that requires that certain data should be produced 
from a variety of toxicological investigations that show the safety profile of the 
compound to which humans may be exposed (Pascoe, 1983; Loomis and Hayes, 1996). 
Therefore, in the majority of cases of evaluation of the toxicity of most substances, 
rodents and non-human primates are first used in preclinical animal safety studies before 
further studies are done in humans. These animals are mainly used because of their 
biological similarity to humans that allows them to be regarded as suitable metabolic 
models for humans in a broad range of investigations (Pascoe, 1983; Loomis and Hayes, 
1996). 
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1.5.1. Use of the mouse model in toxicological assessments 
 
The mouse is the most commonly used vertebrate species in biomedical research, because 
it is small and therefore easier to handle and manipulate, can be maintained cost-
effectively, and has a short gestation period (~ 19-20 days) (Rosenthal and Brown, 2007; 
Peters, Robledo, Bult, Churchill, Paigen, Svenson, 2007). In addition, mice are mammals 
and share a high degree of homology with humans (~99% of their genes) (Waterston, 
2002); mice and humans share most physiological and pathological features: similarities 
in nervous, cardiovascular, endocrine, immune, muscoskeletal and other internal organ 
systems (Rosenthal and Brown, 2007).  
 
1.5.2. Acute and sub-acute toxicity 
 
Acute toxicity: Adverse effects are observed within a short time of exposure to the 
chemical. This exposure may be a single dose, or a short continuous exposure, or 
multiple doses administered over 24 hours or less. 
 
Subacute toxicity Adverse effects are observed following repeated daily exposure to a 
chemical, or exposure for a significant part of an organism's lifespan (usually not 
exceeding 10%).  
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An adverse effect is “any effect that results in functional impairment and/or biochemical 
lesions that may affect the performance of the whole organism or that reduce the organ’s 
ability to respond to an additional challenge” (Walum, 1998).  
 
An acute toxicity test is a single test that is conducted in a suitable animal species and 
may be done for essentially all chemicals that are of any biologic interest. Its purpose is 
to determine the symptomatology consequent to administration of the compound and to 
determine the order of lethality of the compound. The test consists of administering the 
compound to the animals on one occasion (Pascoe, 1983; Loomis and Hayes, 1996; 
Timbrell, 2002). 
 
Furthermore, acute toxicity tests are those designed to determine the effects, which occur 
within a short period after dosing. They serve to establish the lethal dose range of the test 
substance and provide prompt warning if a highly toxic compound is being dealt with 
(Poole and Leslie, 1989). They also provide information on the limiting toxicity arising 
from the pharmacological effects of the compound on target organs and, often, on the 
maximum dose to be used in subsequent sub-acute studies (chronic studies). This latter 
information is particularly important for predicting the amount of chemical required for 
future toxicological studies (Poole and Leslie, 1989). 
 
The initial procedure, in an acute toxicity test programme, is to test a series of range-
finding single doses of the compound in a single animal species. This necessitates 
selection of a route of administration, preparation of the compound in a form suitable for 
administration via the selected route and selection of an appropriate experimental animal 
species (Poole and Leslie, 1989). 
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After exposure to single doses of the test compound (or treatment), the animals are 
monitored for a minimum of 24 hours for any clearly recognized effect (such as changes 
in locomotor activity; bizarre reactions; sensitivity to pain, sound and touch; changes in 
social interaction; aggressive behavior; convulsions; paralysis, etc.) seen, as an index of 
toxicity, shortly or/and consistently after the administration of the chemical (Timbrell, 
2002; Loomis and Hayes). However, the most easily recognized and certainly the most 
significant of effects is that of death and this outcome is usually used as a primary 
measure of acute toxicity. If the animals appear to be healthy at the end of 24 hours, they 
are monitored at daily intervals for at least a further one to two weeks for the appearance 
of delayed toxicity (Loomis and Hayes, 1996; Pascoe, 1983; Timbrell, 2002). 
 
The acute toxicity test is also used to establish the lethal median dose or LD50.  The 
animals are given a single dose of test compound and, at the end of 14-days observation 
period, the major organs and abnormal tissues of the surviving animals are collected and 
subjected to histopathological investigation. The LD50 and its confidence limits are 
calculated from the lethality data using probit analysis (Pascoe, 1983). Since a great 
range of concentrations or doses of various chemicals may be involved in the production 
of harmful effects, the LD50 has been used by some authors to devise categories of 
toxicity on the basis of the amounts of the chemicals necessary to produce harm. An 
example of such a categorization, along with respective lethal doses, is given in Table 1. 
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  Table 1. Classificiation of toxicity based on LD50 ranges. 
Category LD50 (mg/kg) LD50 (mg/kg) Classification 
 
Extremely toxic 
 
Highly toxic 
 
Moderately toxic 
 
Slightly toxic 
 
Practically non-toxic 
 
Relatively harmless 
 
 
1 or less 
 
1 to 50 
 
50 to 500 
 
500 to 5000 
 
5000 to 15000 
 
More than 15000 
 
 
< 5 
 
5- 50 
 
50- 500 
 
500- 5000 
 
5000- 15000 
 
> 15000 
 
 
Super-toxic 
 
Extremely toxic 
 
Very toxic 
 
Moderately toxic 
 
Slightly toxic 
 
Practically non-toxic 
 
(Loomis and Hayes, 1996) (Pascoe, 1983) 
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1.5.3. Toxicity of medicinal plants 
 
The use of traditional medicines and complementary and alternative medicine, in 
particular herbal medicinal products, continues to grow world-wide. In many parts of the 
world, policy-makers, health professionals and the public are wrestling with questions 
about the safety, quality, availability, preservation and further development of this type of 
health care. Although many medicinal plant therapies have promising potential, and are 
increasingly used, many of them are untested and their use not monitored. As a result, 
knowledge of their potential side-effects is limited. This makes identification of the safest 
and most effective therapies, and promotion of their rational use more difficult (WHO, 
2002).   
 
The extensive traditional use of plants as medicines has enabled those medicines with 
acute and obvious signs of toxicity to be well recognised and their use avoided. However, 
the premise that traditional use of a plant for perhaps many hundreds of years establishes 
its safety does not necessarily hold true (De Smet, 1995; De Smet, 1997). There is a 
mythical yet predominant view that herbal medicines are harmless and free of side effects 
because they are “natural” (Bateman, Chapman, Simpson, 1998; Stickel, Egerer Seitz, 
2000).  
 
The safety of several commercially available herbs, have over recent years, come into 
question due to reports of adverse reactions and potential interactions with prescription 
drugs (De Smet, 1997; Fugh-Berman, 2000; Ernst, 1999; Johns-Cupp, 1999; O’Hara, 
 
 
 
 
 56
Kiefer, Farrell, Kemper, 1998). The effective and safe use of medicinal herbs has 
therefore been identified as a top research priority; and the implementation of regulatory 
procedures and investigations on safety are currently underway in developed countries 
(Popat, Shear, Malkiewicz, Stewart, Steenkamp, Thomson, Neuman, 2001). 
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1.6. Research Questions 
 
Given the lack of scientific evidence for the indigenous use of Tulbaghia alliacea as a 
traditional garlic medicine to combat bacteria, fungi, and cancer, as well as our limited 
understanding of its potential toxicity, this investigation aimed at addressing the 
following questions: 
 
(i) What effect does Tulbaghia alliacea phytotherapy have on Candidal fungi? 
(ii) What effect does Tulbaghia alliacea have on mycobacteria and the 
modulation of the immune biomarker IFN-γ? 
(iii) What effect does Tulbaghia alliacea phytotherapy have on apoptosis in cancer 
cells? 
(iv) What toxicity effect, if any, does Tulbaghia alliacea phytotherapy have in 
mice?  
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Tulbaghia alliacea phytotherapy: 
A potential anti-infective remedy for Candidiasis 
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2.1. Abstract 
The reproductive health of individuals is severely compromised by HIV infection, with 
candidiasis being the most prevalent oral complication in patients. Although not usually 
associated with severe morbidity, oropharyngeal candidiasis can be clinically significant, 
as it can interfere with the administration of medications and adequate nutritional intake, 
and may spread to the esophagus. Azole antifungal agents are commonly prescribed for 
the treatment and prophylaxis of candidal infections. However, the emergence of drug 
resistant strains and dose limiting toxic effects have complicated the treatment of 
candidiasis. Consequently, safe and effective and affordable medicine is required to 
combat this fungus. Commercial garlic (Allium sativum) has been used time since 
immemorial as a natural antibiotic, however very little is known about the antifungal 
properties of two indigenous South African species of garlic, namely Tulbaghia alliacea 
and Tulbaghia violacea, that are used as folk medicines for a variety of infections. This 
study compares the in vitro anti-candidal activity of Tulbaghia alliacea, Tulbaghia 
violacea and Allium sativum extracts. It was found that the greatest concentrations of 
inhibitory components were extracted by chloroform or water. The IC50 concentrations of 
Tulbaghia alliacea were between 0.007 – 0.038% (w/v). Assays using S. cerevisiae 
revealed that the T. alliacea extract was fungicidal, with a killing half-life of 
approximately 2 hours. This inhibitory effect of the T. alliacea extracts was observed via 
TLC, and may be due to an active compound called Marasmicin, that was identified using 
NMR. This investigation confirms that extracts of T.alliacea exhibit anti-infective 
activity against candida species in vitro.  
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2.2. Introduction 
 
The reproductive health of individuals is severely compromised by HIV infection, with 
candidiasis being the most prevalent oral complication in patients. HIV/AIDS is a public 
health emergency in Africa and according to the UN, South Africa has the fastest 
growing epidemic in the world, with more than 4.5 million HIV-positive people, 
thousands of AIDS deaths, 2500 new infections daily and 100,000–150,000 AIDS 
orphans annually (Stegmann, 2001). Studies of AIDS all over the world show that 58–
81% of all patients contract a fungal infection at some time during the primordial stage or 
after developing AIDS, and 10–20% have died as a direct consequence of fungal 
infections (Drouhent and Dupont, 1989).  
 
Candidiasis is the most common oral fungal infection in humans and manifests in a 
variety of clinical guises ranging from pseudomembraneous (thrush), erythematous, and 
hyperplastic variants to linear gingival erythema associated with HIV infection 
(Samaranayake and Scully, 1989; Ellepola and Samaranayake, 2000). Oropharyngeal 
candidiasis (OPC) is the most prevalent oral complication in HIV/AIDS patients 
(Samaranayake, 1992; Glick, Muzyka, Lurie, Salkin, 1994; Blignaut, Messer, Hollis, 
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Pfaller, 2002), and it is generally accepted that Candida albicans is the most commonly 
isolated species from clinical specimens (Pfaller, 1994). Candida species are normal 
inhabitants of the human gastrointestinal tract and may be recovered from up to one third 
of the mouths of normal individuals and two thirds of those with advanced HIV disease 
(Fichtenbaum, Koletar, Yiannoutsos, Holland, Pottage, Cohn, Walawander, Frame, 
Feinberg, Saag, Van Der Horst, Powderly, 2000). Oral colonization with inherently drug-
resistant organisms is more common in advanced HIV infection (CD4-lymphocyte counts 
<50 cells/mm3) (Fichtenbaum et al., 2000).  
 
Although not usually associated with severe morbidity, OPC can be clinically significant 
as it can interfere with the administration of medications and adequate nutritional intake, 
and may spread to the esophagus (Tavitian, Raufman, Rosenthal, 1986). 
 
The increasing prevalence of other compromised patient groups in the community, 
together with common endocrine disorders such as diabetes mellitus, and nutritional 
deficiencies have also contributed to the resurgence of oral candidiasis as a relatively 
common affliction (Ellepola and Samaranayake, 2000). In addition, the use of oral 
antibiotics, broad-spectrum antibiotics (Samaranayake, Cheung, Samaranayake, 2002), 
corticosteroids, or immunosuppressives may predispose individuals to infection (Soysa, 
Samaranayake, Ellepola, 2004). These factors disrupt the balance between the healthy 
host and the Candida, which under normal circumstances, may be present in the 
gastrointestinal flora but is not disease producing (Bruce and Rogers, 2004) 
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Since its introduction, fluconazole has been used to prevent and treat Candida infections 
in HIV-1-infected patients because of its efficacy and good tolerability (Koks, 
Crommentuyn, Mathot, Mulder, Meenhorst, Beijnen, 2002). However, after the use of 
fluconazole for the treatment and prophylaxis of fungal infections became widespread, 
reports began to appear which suggested reduced effectiveness of the standard 
fluconazole therapy and also side effects (Ng and Denning, 1993). The side effects of 
many azole antifungals such as ketoconazole, itraconazole, fluconazole, posaconazole, 
and voriconazole are similar; the more common being headache, dyspepsia, diarrhea, 
nausea, vomiting, hepatitis, and skin rash (Munoz, Moreno, Berenuer, Bernaldo de 
Quiros, Bouza, 1991). 
 
Emergence of drug resistant strains and dose limiting toxic effects has further 
complicated the treatment of infectious diseases. These complications have necessitated 
the search for new antimicrobial substances from various sources. Extracts of plants and 
phytochemicals have been shown to possess activity against many infectious diseases, 
and may thus be a good source of new active agents (Mekkawy, Meselhy, Kusumoto, 
Kadota, Hattori, Namba, 1995; Vlietinck, Bruyne, Apers, Pieters, 1998; Matsuse, Lim, 
Hattori, Correa, Gupta, 1999). One of the most widely used medicinal plants is garlic 
(Allium sativum), which is reported to be effective against a wide range of 
microorganisms, including bacteria, fungi, protozoa and viruses (Ankri and Mirrelman, 
1999). Tulbaghia alliacea and Tulbaghia violacea are two indigenous South African 
garlic species, which are traditionally used as remedies for a variety of infections and 
ailments (Van Wyk et al., 2000).  
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This investigation therefore aimed to assess the antifungal properties of T.alliacea, with a 
view to using this indigenous phytotherapy as a potential anti-candidal remedy. 
 
2.3. Materials and Methods 
 
2.3.1. Plant material 
Bulbs of Tulbaghia alliacea were obtained from Rastafarian herbal traders in Cape 
Town, South Africa; Tulbaghia violacea was obtained from the Educational and 
Environmental Resources Unit (EERU) at the University of the Western Cape, while a 
commercial garlic brand of Allium sativum was purchased from a retail store. All three 
species were verified by a botanist at the University of the Western Cape Herbarium 
where voucher specimens (Thamburan001 for T.alliacea, Thamburan002 for T.violacea 
and Thamburan003 for A.sativum) were deposited. 
 
2.3.2. Preparation of plant extracts 
Bulbs of T. alliacea and T.violacea and cloves of A. sativum were washed with distilled 
water, peeled and chopped into tiny pieces (Eloff, 1998). Solvent extractions of different 
concentrations (0.06, 0.15 and 0.30 %) of the bulbs and cloves were prepared using 
solvents of differing polarity (water, methanol and chloroform). Extracts were prepared 
by soaking the chopped plant material in the solvents overnight, and then vacuum 
filtering it. 
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2.3.3. Microorganisms and growth media  
For the preliminary antifungal screening, a culture of Candida albicans was obtained 
from the Department of Medical Biosciences at the University of the Western Cape, 
South Africa. C.albicans was maintained on Sabouraud dextrose agar. Subcultures of 
C.albicans were inoculated in nutrient broth and spread onto prepared agar plates using 
sterile swab sticks under aseptic conditions. Plated cultures were incubated at 37 ºC for 
24 hours. The agar plate method for plant extract susceptibility testing is well 
standardized and widely used (Vanden Berghe and Vlietinck, 1991). 
 
For more detailed antifungal analyses, the broth dilution antifungal susceptibility testing 
method (Agarwal, Rogers, Baerson, Jacob, Barker, Cleary, Walker, Nagle, Clark, 2003) 
was used to assess the growth inhibitory activity of T.alliacea extracts on a variety of 
pathogenic fungi. The yeast strains: Saccharomyces cerevisiae (JC746-9D), Candida 
albicans (ATCC 90028), Candida glabrata (ATCC 90030), Candida krusei (ATCC 
6258) and Cryptococcus neoformans (ATCC 90113) were obtained from the National 
Center for Natural Products Research, University of Mississippi, Oxford. YPD medium 
contained 10g yeast extract, 20g peptone and 20g glucose per liter. Minimal medium 
contained 7g yeast nitrogen base, 20g glucose, 10g succinic acid, 4.5g NaOH per liter and 
was supplemented with amino acids (Guthrie and Fink, 1991). Solid media contained 20g 
agar per liter. 
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2.3.4. Antifungal screening 
 
2.3.4.1. Disk diffusion assays 
All solvent (aqueous, methanol and chloroform) extracts of T. alliacea, T.violacea and A. 
sativum were tested for in vitro antifungal activity against C.albicans using the agar plate 
disk diffusion method. The pharmaceutical drug, fluconazole (40 µg/disk) was used as a 
positive control, as it is a broad-spectrum antibiotic. Filter paper disks (9mm) (Schleider 
and Schuell) were autoclaved at 120°C in a Speedy Autoclave (Lasec) for 20 min, and 
then incubated at 37°C overnight.  
 
Each disk was impregnated with 50µl of a particular extract and was allowed to dry 
overnight. Fluconazole served as a positive control, and the extraction solvents (water, 
methanol, and chloroform) served as a negative control. The dried impregnated disks 
were placed on the surface of agar plates inoculated with the candidal culture. Each plate 
consisted of the following disks: a positive control (Fluconazole), a negative control 
(particular solvent) and a different extraction of each solvent (e.g. 0.30 % water). Each 
extract was tested in triplicate. After being accurately labeled, the agar plates were 
inverted and incubated at 37°C for 24 hours. After incubation, inhibition zones were 
recorded as the diameter of the growth-free zones around the disk. 
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2.3.4.2. Minimum Inhibitory Concentrations (MIC) 
The MIC’s for each extraction were calculated by preparing serial dilutions of the 
original extractions. The extract concentration exhibiting a 1mm zone of inhibition was 
taken to be the MIC value for that solvent extraction, as a 1mm zone is the smallest zone 
that can be detected as growth inhibition of microorganisms in vitro using the agar plate 
disk diffusion method. 
 
2.3.4.3. Broth dilution antifungal susceptibility testing 
After establishing the anti-fungal growth inhibitory effect of T.alliacea using the disk 
diffusion assay method, further analyses using the more sensitive optical density growth 
inhibition method, which closely approximates the dynamics of the fungus in biological 
fluid, was used for assessments..  
 
The fungal strains [Saccharomyces cerevisiae (JC746-9D), Candida albicans (ATCC 
90028), Candida glabrata (ATCC 90030), Candida krusei (ATCC 6258), and 
Cryptococcus neoformans (ATCC 90113)] were grown overnight in YPD medium. The 
YPD medium was diluted to 3 x 106 cells/ml in yeast minimal medium and 175µl of 
diluted cells was placed in each of the wells of a 96-well plate (Nunc) with the extract 
dilution.  
 
Absorbance at 630 nm was measured at zero time and after 24 hours of growth using a 
Dynatech MR5000 microplate reader. The plate wells were sealed with Parafilm and the 
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plate was shaken at 250 rpm at 30°C. Dilutions of chloroform extracts were made in a 
final volume of 50µl chloroform in 1.5ml polypropylene tubes (Sarstedt).  
 
Chloroform was evaporated from the uncapped tubes in a chemical hood for three hours 
at 22°C. Tubes were filled with 400µl of diluted cells from above, capped, and shaken at 
250 rpm at 30°C. Cell densities were measured from 200µl aliquots placed into a 96-well 
plate as above. All assays were done in triplicate and the average data were plotted. 
 
2.3.4.4. Viability assay 
A viability assay to determine the mechanism of action (fungistatic or fungicidal) of 
T.alliacea extracts was carried out. An S. cerevisiae culture was diluted to 3 x 106 cells / 
ml in 400µl yeast minimal medium in a 1.5ml polypropylene tube. Aqueous T. alliacea 
extract was added to a final 0.075% (w/v) (four-fold dilution of aqueous extract stock). 
The capped tube was incubated at 30°C with 250 rpm shaking. Samples of cells were 
removed before extract addition and after 5 and 24 hours of growth were diluted and 
plated on YPD plates. Viable cell numbers were calculated from the colony forming units 
after three days of growth. 
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2.3.5. Thin-Layer Chromatography–Bioautographic Assay             
For direct bioassay on TLC plates, a 30µl aliquot of each extract was applied to 5 x 20 cm 
silica F254 (Merck) glass backed plates in duplicate for fingerprinting. All plates were 
developed in hexane: ethyl acetate (1:2 v/v) (Wagner and Blade, 1996). The developed 
TLC plates were dried overnight and then viewed under ultraviolet (UV) light (366 nm).  
 
Thereafter, one set of plates (of each extract) was sprayed with vanillin-sulphuric acid 
reagent, made up by dissolving 3g vanillin in 30ml ethanol, to which 5ml concentrated 
sulphuric acid was added. Some compounds that are not visible under UV light become 
visible upon spraying and heating (for approximately 20 min) of the developed plates.  
 
The duplicate plates were used for the bioautographic assay (inoculated TLC), whereby 
Sabouraud dextrose agar inoculated with C.albicans was poured over the plates under 
aseptic conditions. These plates were placed on damp paper towels in a plastic tray, 
covered with cling wrap and incubated at 37 °C for 24 hours. To detect the antimicrobial 
activity on the plates, they were sprayed with a 0.2mg/ml solution of 2,5-
diphenyltetrazolium bromide (MTT) (Sigma Chemicals Co.). Clear zones on the 
chromatogram indicated inhibition of growth (Beugue and Kline, 1972). 
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2.3.6. Nuclear Magnetic Resonance (NMR) analyses 
The active compound from the chloroform extract was isolated by preparative TLC using 
a mixture of hexane and ethyl acetate (4:1) as mobile phase. The 1H NMR spectrum was 
recorded on a Gemini Varian 200 instrument at 200MHz, in deuteriochloroform as 
solvent and tetramethylsilane as internal standard; the chemical shifts were reported in (δ) 
ppm. 
 
2.3.7. Statistical analyses 
Inhibition zones were statistically compared by conducting an unpaired t-test using the 
MedCalc (version 7.1, 2000) statistical programme. Means ± SEM (standard error of the 
mean) were considered significant at  P<0.05. 
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2.4. Results 
 
2.4.1. Disk diffusion assays 
Fluconazole (2 %) served as a positive control and inhibited the growth of C.albicans 
with a zone of 7mm. The negative controls (extraction solvents) did not have any effect 
on the fungus and thus no zones of inhibition were observed around these disks. 
Inhibition zones caused by extracts of A.sativum, T.alliacea and T.violacea were 
compared using an unpaired t-test (Table 1).  
 
At 0.06% concentration, aqueous extracts of T. violacea had no effect on C.albicans, 
whereas A. sativum and T. alliacea had similar inhibitory effects (P = 0.1012), however 
at both 0.15 and 0.30% T. alliacea exhibited a statistically bigger zone of inhibition than 
A. sativum (P<0.05) and T. violacea (P<0.0001). T. alliacea methanol extracts at all 
concentrations exhibited statistically bigger zones of inhibition than A. sativum and T. 
violacea (P<0.05). Chloroform extracts of T. violacea only became active at the highest 
concentration (0.30%), whereas A. sativum and T. alliacea inhibited Candida at all 
concentrations, with T. alliacea exhibiting the biggest zone of inhibition (10.67mm) at 
0.30%.  
 
In general, extracts of T. violacea were poorest in inhibiting the growth of the fungus; 
they were inactive at the lowest concentration of 0.06% and only exhibited small zones of 
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inhibition at the higher concentrations. In contrast, all extracts of T. alliacea at all 
concentrations exhibited antifungal activity.  
 
Table 1. The anti-infective activity of  Tulbaghia alliacea,  Tulbaghia violacea and  Allium  
                sativum extracts against Candida albicans 
 
 
Zone of Inhibition (mm ± SEM) 
 
Statistical significance* 
Extract Concentration    
        (%) A. sativum (a) T. alliacea (b) T. violacea (c) ab ac bc 
0.06 3.33 ± 0.33 4.33 ± 0.33 0 0.1012 0.0006 0.0002 
0.15 4.00 ± 0.00 6.33 ± 0.33 0 0.0022 0.0002 0.0001 
Aqueous 
(H2O) 
0.30 5.33 ± 0.33 8.33 ± 0.33 1.00 ± 0.00 0.0031 0.0002 0.001 
0.06 1.67 ± 0.33 4.00 ± 0.00 0 0.0023 0.0075 0.0002 
0.15 3.67 ± 0.33 5.33 ± 0.33 0.66 ± 0.33 0.0241 0.0031 0.0006 
Methanol 
(MeOH) 
0.30 5.33 ± 0.33 7.33 ± 0.33 3.33 ± 0.33 0.0132 0.0132 0.0011 
0.06 4.00 ± 0.00 5.33 ± 0.33 0 0.1012 0.0006 0.0002 
0.15 4.33 ± 0.33 7.33 ± 0.33 0 0.0031 0.0002 0.0001 
Chloroform 
(CHCl3) 
0.30 5.33 ± 0.33 10.67 ± 0.33 2.33 ± 0.33 0.0004 0.0031 0.0001 
 
* P values for comparing main effects: ab = A. sativum and T. alliacea, ac = A. sativum and T. violacea,    
bc = T. alliacea and T. violacea.   
 
         # Fluconazole (2%) inhibited C.albicans with a 7mm zone of inhibition.  
Negative controls (water, methanol and chloroform) did not inhibit C.albicans, hence no  zone of inhibition 
was observed.                             
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An MIC value is defined as the lowest concentration of an extract, which visibly inhibits 
the growth of the micro-organism after incubation. T.alliacea extracts were shown to 
have lower MIC values than both A.sativum and T.violacea (Table 2). The lowest MIC 
value against C.albicans was obtained with the 0.024 % chloroform extract of T.alliacea. 
 
Table 2: The minimum inhibitory concentrations (MIC) for Tulbaghia alliacea, Tulbaghia  
                violacea and Allium sativum extracts against Candida albicans* 
 
 
Extract Concentration (%)  
Solvent A. sativum T. alliacea T. violacea 
Zone of Inhibition 
(mm) 
Aqueous (H20) 0.132 0.036 0.300 1 
Methanol (MeOH) 0.048 0.048 0.150 1 
Chloroform (CHCl3) 0.048 0.024 0.060 1 
 
* The MIC for Fluconazole was 0.25 % (1mm zone of inhibition). 
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2.4.2. Broth dilution antifungal susceptibility testing 
All five yeast species grew well in YPD and minimal medium normally used for S. 
cerevisiae growth. Therefore, these media were used for growth inhibition assays 
following a described method (Agarwal et al., 2003). Chloroform extracts required a 
significant alteration in protocol because chloroform dissolved the 96-well plates. Growth 
inhibition by chloroform extracts was assayed by growth in polypropylene tubes after 
chloroform was evaporated. The methanol extraction solvent and evaporated chloroform 
residue did not inhibit yeast growth. 
 
Cell densities after 24 hour growth in the presence of extracts were estimated by 630 nm 
light scattering. According to the estimated IC50 concentrations (Table 3), C. neoformans 
was the most sensitive strain to the T. alliacea extracts because its growth was inhibited 
at the lowest concentrations. In contrast, C. glabrata was slightly more resistant. In all 
cases, the methanol extracts were the poorest in inhibiting microbial growth. On the other 
hand, the chloroform and aqueous extracts appeared to be similarly potent. With all but 
the exception of the C. glabrata strain, the chloroform extract was slightly more potent 
than the aqueous extract.  
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         Table 3:  IC50 concentrations of Tulbaghia alliacea extracts for five fungal species 
 
 
Tulbaghia  alliacea extracts  
Fungal species 
Aqueous 
(H20) 
Methanol 
(MeOH) 
Chloroform 
(CHCl3) 
Saccharomyces cerevisiae 
 
0.038 
 
0.150 
 
0.038 
Candida albicans 0.075 0.150 0.028 
Candida glabrata 0.056 0.230 0.110 
Candida krusei 0.056 0.230 0.038 
Cryptococcus neoformans 0.019 0.056 0.007 
 
 
Figure 1 (A-E) provides the data for the effect of the various aqueous, methanol and 
chloroform concentrations of Tulbaghia alliacea extracts, on the growth of 
Saccharomyces cereviseae, Candida albicans, Candida glabrata, Candida krusei and 
Cryptococcus neoformans, and includes a TLC profile of the phytotherapy. These data 
indicate that the IC50 concentrations of Tulbaghia alliacea extracts were between 0.007 – 
0.038% (w/v), and identifies Marasmicin as the active compound with the most potent 
antifungal effect, using NMR analyses. 
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Fig.1. The antifungal activity (A-E) and TLC profile (F) of T. alliacea phytotherapy. 
 
A. The growth inhibitory effect of T.alliacea    
     extracts on Saccharomyces cerevisiae 
  
B. The growth inhibitory effect of T.alliacea extracts on     
    Candida krusei 
 
C. The growth inhibitory effect of T.alliacea    
     extracts on Candida glabrata 
 
 D. The growth inhibitory effect of T.alliacea extracts on  
    Cryptococcus neoformans 
E. The growth inhibitory effect of T.alliacea  
     extracts on Candida albicans 
 
 
 
                    
                        
 
(i)  Developed TLC plate of the T.alliacea chloroform extract sprayed 
with vanillin-sulphuric acid reagent. NMR analysis identified  the 
active compound as Marasmicin , with chemical shift values (ppm) of 
2.38, 4.07, 4.18, 4.25 and 2.27. 
 
(ii)  Developed TLC plate of the T.alliacea chloroform extract 
inoculated with Candida albiacans and sprayed with 2,5-
diphenyltetrazolium bromide. 
Compound 
Active 
Compound 
Compound 
Zone of 
inhibition 
   F (i)                        F(ii) 
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2.4.3. Nuclear Magnetic Resonance (NMR) analysis  
NMR spectral analysis of the T. alliacea inhibitory fraction (Fig.1F), showed prominent 
signals at 2.38, 4.07, 4.18, 4.25 and 2.27, which are due to the methyl and methylene 
groups of Marasmicin. These chemical shift values are in agreement with those reported 
for the same compound, previously isolated from the related Tulbaghia violacea (Kubec 
et al. 2002).  
 
2.4.4. Mechanism of antifungal action of T.alliacea extract 
Preliminary experiments were performed to analyze the killing mechanism of the T 
alliacea extract. An S. cerevisiae culture was prepared with minimum concentration of 
aqueous extract (0.075%, w/v) that allowed no detectable growth.  
 
Cell viability was measured by comparing the total cells (by hemacytometer) and viable 
cells (colony forming units). It was found that after five hours of exposure, cell viability 
had decreased to about one-half. After 24 hours, there was a greater than 1000-fold drop 
in viable cells. Had the action of the extract been fungistatic, no reduction in the number 
of viable cells would have been observed. Therefore, T. alliacea extracts kill yeast cells 
rather than merely inhibiting growth. Furthermore, the death rate that would reduce the 
viable cells by 1000-fold in 24 hours, gave a half-life of about two hours. These 
outcomes are stated in orders of magnitude, since these experiments were not 
quantitative.  
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2.4.5. Antifungal activity of T.alliacea extracts on TLC 
The aqueous, methanol and chloroform extracts of T.alliacea separated with one major 
inhibitory fraction, which was indicated as zones of growth inhibition on the 
bioautograms. TLC separations showed the compounds present in the extracts under UV-
366nm are the same as the antifungal compounds visible on the bioautograms, based on 
the distance they traveled on the TLC plates (Fig. 1F). 
 
2.5. Discussion 
This investigation aimed at comparing the antifungal effect of the indigenous South 
African garlic plants T.alliacea and T.violacea, to the commercial variety A.sativum. This 
comparison was made because of the reputed antimicrobial effects of the commercial 
garlic species (Uchida, Takahashi, Sato, 1975) and traditional use of the indigenous 
varieties. Allium sativum is quite expensive while the indigenous forms (Tulbaghia 
alliacea and Tulbaghia violacea), are significantly more affordable to the poorer 
communities afflicted by opportunistic fungal infections like candidiasis.  
 
Table 1. reflects the anti-infective value of the aqueous, methanol and chloroform 
extracts of Tulbaghia alliacea, using the disk diffusion assay. There is a dose-dependant 
increase in the anti-infectivity of the extacts, with the most striking inhibition of Candida 
albicans being induced by:  
(1) 0.030% T.alliacea aqueous extract (8.33mm); P<0.0031 vs A.sativum,  
                P<0.0001 vs T.violacea. 
(2) 0.030% T.alliacea methanol extract (7.33mm); P<0.0132 vs A.sativum,  
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               P<0.0011 vs T.violacea 
(3)    0.030% T.alliacea chloroform extract (10.67mm); P<0.0004 vs  
               A.sativum; P<0.00001 vs T.violacea 
 
The disk diffusion method was well suited for preliminary screening and has the 
advantage of allowing for the use of small sample sizes (Rios, Recio, Villar, 1988).  
Chloroform extracts of T.alliacea were more potent than A.sativum and T.violacea, in 
inhibiting the growth of C.albicans (P<0.05).  
 
Further analyses of fungal growth inhibition, were carried out using the more sensitive 
broth dilution susceptibility test. The broth micro-dilution method has been shown to be 
reproducible and clinically useful, with good in vitro-in vivo correlation in the setting of 
oropharyngeal candidiasis in HIV-infected patients (Revankar, Kirkpatrick, McAtee, 
Fothergill, Redding, Rinaldi, Patterson, 1998). The chloroform extract of T.alliacea was 
more potent than the aqueous and methanol extract in inhibiting the growth of the yeast 
strains (Saccharomyces cereviseae, Candida albicans, Candida glabrata, Candida krusei 
and Cryptococcus neoformans). 
 
Bioautography is a method that facilitates the localization of antimicrobial activity on a 
chromatogram, and provides qualitative information about the active components of 
plants. By separating extracts on TLC plates, it is possible to secure information on the 
bioactive compounds present in the mixture. Aqueous, methanol and chloroform extracts 
of T.alliacea showed one major inhibiting fraction, indicated as a zone of inhibition on 
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the bioautograms. TLC separations showed that the fraction present in the extract under 
UV-366nm was the same as the compound exhibiting antifungal activity, which was 
visible on the bioautograms (Fig. 1F)). NMR spectral analysis of the T. alliacea 
inhibitory fraction indicated the presence of the methyl and methylene groups of 
Marasmicin. These chemical shift values are in agreement with those reported for the 
same compound, previously isolated from the related Tulbaghia violacea (Kubec, 
Velisek, Musah, 2002).  
 
A preliminary viability assay revealed T.alliacea extract to be fungicidal (kills yeast cells 
rather than merely inhibiting growth). Future experiments that address the mechanism of 
T. alliacea fungicidal activity, will require the comprehensive assessment of mutants 
resistant to the extracts. Initial experiments showed that the assay plates that were 
incubated for up to three days did not show any increase in cell density. This observation 
is consistent with the fungicidal action of the extracts. It also shows that spontaneous 
mutants resistant to the extract occur at a frequency less than 10-6. These observations are 
indeed very important in the development of a mutant isolation scheme, and creation of a 
scientifically proven phytotherapeutic remedy for candidiasis. 
 
This investigation has indicated that T. alliacea might be of value in the continuing 
struggle to control opportunistic fungal infections, which are especially important in HIV 
and AIDS. Furthermore, it also verifies the traditional use of indigenous garlic as an anti-
infective herbal medicine. This study provides useful leads for the development of novel 
pharmaceuticals, in the ongoing search for effective and affordable anti-fungal remedies. 
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CHAPTER 3 
 
Tulbaghia alliacea: 
A potential antimycobacterial and  
immune-modulating phytotherapy 
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3.1. Abstract 
Tuberculosis (TB) is the leading cause of morbidity and mortality among HIV-1-infected 
patients. Conventional medication for this TB epidemic is expensive, and limited patient 
compliance leads to the development of MDR-TB and XDR-TB. Consequently, safe, 
effective and affordable medicine is required to combat the disease. Very little is known 
about the antimycobacterial properties of Tulbaghia alliacea, a species of garlic that is 
indigenous to South Africa and has been used in folk medicine as a treatment for TB. 
This study compares the in vitro antimycobacterial effect of Allium sativum and 
Tulbaghia alliacea, whilst also profiling the active antimycobacterial compounds of these 
medicinal plants, and assessing their ability to stimulate the expression of IFN-γ. Extracts 
of varying polarities of A.sativum and T.alliacea were comparatively tested for in vitro 
antimycobacterial activity against Mycobacterium smegmatis. T.alliacea does have 
antimycobacterial effects, as was shown by growth inhibition zones on M.smegmatis 
inoculated agar plates.  Aqueous and ethanolic extracts of T. alliacea at higher 
concentrations exhibited greater inhibition of M.smegmatis than A.sativum (P<0.003 and 
P<0.002). The 10mg/ml chloroform extract of T. alliacea most potently inhibited the 
development of the pathogen (P<0.0001), when compared to A.sativum. This inhibitory 
effect is due to three active compounds in T. alliacea that were observed using TLC. One 
of these compounds was identified as Marasmicin (Rf 0.44), a potent anti-infective 
compound previously isolated from T. alliacea. Cytokine measurements in whole blood 
cultures after exposure to the plant extracts showed that the T.alliacea aqueous extract is 
more potent in stimulting the expression of IFN-γ than the chloroform extract (P<0.05). 
This investigation confirms that extracts of T. alliacea that are used as indigenous TB 
medicines, do exhibit antimycobacterial activity in vitro, and are also capable of 
stimulating the immune response via IFN-γ expression. 
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3.2. Introduction 
 
Tuberculosis (TB), a chronic contagious disease caused by infection with Mycobacterium 
species, has become an increasingly serious worldwide health concern in recent years 
(Mcgaw, Lall, Meyer, Ellof, 2008). TB is largely a disease of poverty, with the highest 
incidence of the disease (more than 80% of cases) occurring in Asia and Africa (Zager 
and McNerney, 2008). In sub-Saharan Africa, nine countries recently reported estimated 
annual incidences over 600 cases per 100 000 (Corbett, Marston, Churchyard, De Cock, 
2006). Globally, there was an estimated 9.2 million new cases and 1.7 million deaths in 
related to TB in 2006 (World Health Organisation, 2008).  
 
Together with the spread of HIV infection and the emergence of multi-drug resistant 
(MDR) and more recently, extremely drug resistant (XDR) strains of Mycobacterium 
tuberculosis (Mtb) (Jones, Hesketh, Yudkin, 2008), TB is becoming rampant, especially 
in countries lacking adequate health care systems to provide the required expensive and 
lengthy treatment (World Health Organization, 2008; Zager and McNerney, 2008). 
Adherence to treatment of TB is limited by a multitude of clinical, social, financial and 
behavioral factors (Ginsburg, Grossett, Bishai, 2003). Failure of patients to comply with 
conventional drug therapy has resulted in treatment failure and the emergence of drug 
resistance. This is compounded by bacterial mutation and the extrusion of 
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chemotherapeutics, via multi-drug resistant protein pumps in these pathogens (Walsh, 
2000). In addition, fewer new antibiotics are being produced, owing partly to the high 
costs of development and licensing.  
 
The World Health Organization estimates that one third of the world’s population are 
latent carriers of the TB agent but only 10% of them develop clinical tuberculosis (WHO, 
2008). More than 90% of infected individuals are therefore thought to develop a 
protective response to Mtb and successfully control Mtb growth (Chan and Kaffman, 
1994). The risk of developing disease is greatly increased by acquired immunodeficiency 
syndrome (AIDS) and other immune-compromising conditions, demonstrating that 
protective immunity works in the majority of M.tuberculosis-infected individuals to 
suppress the infection (Korbel, Schneider, Schaible, 2008).  
 
The protective response of hosts against Mtb is mediated by cell-mediated immunity, in 
which several cytokines including IFN-γ play a crucial role (Ottenhof, Verreck, Hoeve, 
van de Visse, 2005). Mycobacterium tuberculosis is a facultative intracellular pathogen 
that resides and multiplies within human macrophages. IFN-γ is the predominant inducer 
of macrophage-mediated microbicidal functions (Singhal, 2007) and has been shown to 
be required for the prevention of progressive Mtb infection (Cooper, Dalton, Stewart, 
Griffin, Russell, Orme, 1993; Flynn, Chan, Triebold, Dalton, Stewart, Bloom, 1993).  
Individuals who have genetic defects in their IFN-γ system are known to be highly 
sensitive to mycobacterial infection (Ottenhof, Verreck, Hoeve, van de Vosse, 2005). 
Thus, Mtb infection generally induces Mtb-antigen specific IFN-γ responses to protect 
hosts from developing TB. 
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The global prevalence of drug-resistant TB (Jones et al., 2008) and the impact of HIV 
worldwide (Gutierrez-Lugo and Bewley, 2008) make the identification of potent new 
agents for the treatment of TB critically important. 
 
Medicinal plants have been used, since time immemorial, in virtually all cultures as a 
source of medicine, and are recognized as a useful source of highly active 
antimycobacterial metabolites (Gibbons, 2005; Pauli, Case, Inui, Wang, Cho, Fischer, 
Franzblau, 2005). Many medicinal plants are also believed to enhance the natural 
resistance of the body to infections (Atal, Sharma, Kaul, Khajuria, 1986; Tiwari, Rastogi, 
Singh, Saraf, Vyas, 2004). The modulation of the immune response with the aid of 
various bioactives, in order to alleviate certain diseases is an active area of interest. 
(Tiwari, Rastogi, Singh, Saraf, Vyas, 2004). A number of plant products have being 
investigated for immune response modifying activity (Estrada, Katselis, Laarveld, Barl, 
2000; Mediratta, Sharma, Singh, 2002) and a plethora of plant-derived materials (such as 
proteins, lectins, polysaccharides etc.) have been shown to stimulate the immune system 
(Tzianabos, 2000). 
 
The commercial garlic species, Allium sativum L. (Liliaceae) has generated significant 
interest throughout human history as a medicinal panacea. A wide range of 
microorganisms including bacteria, fungi, protozoa and viruses has been shown to be 
sensitive to crushed garlic preparations (Ankri and Mirelman, 1999). Garlic contains a 
collection of sulfur and selenium aromatic compounds that have developed in the plant to 
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protect it from predators such as animals and soil-borne organisms (Sendl, 1995). It may 
well be the aforementioned natural actives that are responsible for garlic’s natural 
antibiotic effects.   
 
In a review of Indian medicinal plants as a source of antimycobacterial agents, Gautam, 
Saklani, and Jachak (2007) reported that, interestingly, many of the plant species 
surveyed showed a strong positive correlation between antimycobacterial activity results 
and ethnomedical use for TB and TB-related diseases. This provides support for 
investigating plants customarily used in other cultures to treat symptoms relating to TB. 
 
In South Africa, members of the genus Tulbaghia are commonly referred to as 
“indigenous garlic,” which are invariably species of the sub-family Alliaceae. 
Interestingly, it is believed that the indigenous garlic, Tulbaghia alliacea L.f. (Liliaceae) 
might have some antimycobacterial activity since it is traditionally used for fever, colds, 
asthma and tuberculosis (TB) more specifically (Van Wyk et al., 2000; Bamuamba, 
Gammon, Meyers, Dijoux-Franca, Scott, 2008).  
 
Tulbaghia alliacea extracts have been shown to have anti-infective activity against a 
variety of Candidal species in vitro, and a very potent antifungal compound called 
Marasmicin was recently discovered in T.alliacea (Thamburan, Klaasen, Mabusela, 
cannon, Folk, Johnson, 2006). This investigation therefore aimed to assess the 
antimycobacterial properties of T.alliacea phytotherapy, as well assessing its ability to 
modulate the cytokine IFN-γ. 
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3.3. Materials and Methods 
 
3.3.1. Plant material 
Bulbs of T. alliacea were obtained from Rastafarian herbal traders in Cape Town, South 
Africa, while a commercial garlic brand of A. sativum was purchased from a retail store. 
Both species were verified by a botanist at the University of the Western Cape Herbarium 
where voucher specimens (Thamburan001 for T.alliacea and Thamburan003 for 
A.sativum) were deposited. 
 
3.3.2. Preparation of plant extracts 
Bulbs of T. alliacea were washed with distilled water and chopped into tiny pieces, whilst 
cloves of A. sativum were peeled and finely chopped (Eloff, 1998). Solvent extractions of 
different concentrations of the bulbs and cloves were prepared using solvents of differing 
polarity (water, methanol, ethanol, hexane, and chloroform). Extractions were prepared 
by soaking the chopped plant material in the solvents overnight and then vacuum filtering 
it. 
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3.3.3. Analysis of the antimycobacterial activity of   
         Tulbaghia alliacea extracts 
 
3.3.3.1. Microorganism and growth media  
For the antimycobacterial screening, Mycobacterium smegmatis was used as a test model 
organism due to its similarity to Mycobacterium tuberculosis genetically, but lack of 
virulence as an infectious organism (Mitscher and Baker, 1998; Gillespie, Morrissey, 
Everett, 2001, Gibbons, 2005). A culture of M.smegmatis was obtained from the 
Department of Medical BioSciences at the University of the Western Cape, South Africa, 
and maintained on Mycobacteria 7H11 agar.  
 
Subcultures of M. smegmatis were inoculated in nutrient broth and spread onto prepared 
agar plates using sterile swab sticks under aseptic conditions. Plated cultures were 
incubated at 37ºC for 48 hr. The agar plate method for plant extract susceptibility testing 
is well standardized and widely used (Vanden Berghe and Vlietinck, 1991). 
 
3.3.3.2. Disk Diffusion Assay 
All solvent (aqueous, methanol, ethanol, hexane, and chloroform) extracts of T.alliacea 
and A.sativum were comparatively tested for in vitro antimycobacterial activity against 
M.smegmatis, using the agar plate disk diffusion method. The pharmaceutical drug, 
Ciprofloxacin (40 µg/disk) was used as a positive control, as it is a broad-spectrum 
antibiotic. 9mm filter paper disks (Schleider and Schuell) were autoclaved at 120°C in a 
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Speedy Autoclave (Lasec) for 20 min, and then incubated at 37°C overnight. Each disk 
was impregnated with 50µl of a particular extract and was allowed to dry overnight. 
Ciprofloxacin served as a positive control, and the extraction solvents (water, methanol, 
ethanol, hexane, and chloroform) served as a negative control. The dried impregnated 
disks were placed on the surface of agar plates inoculated with the mycobacterial culture. 
Each plate consisted of the following disks: a positive control (Ciprofloxacin), a negative 
control (particular solvent) and a different extraction of each solvent (e.g. 0.30% water). 
Each extract was tested in triplicate. After being accurately labeled, the agar plates were 
inverted and incubated at 37°C for 48 hr. After incubation, inhibition zones were 
recorded as the diameter of the growth-free zones around the disk. 
 
3.3.3.3. Minimum Inhibitory Concentrations (MIC) 
The MIC’s for each extract were calculated by preparing serial dilutions of the original 
extractions. The extract concentration exhibiting a 1mm zone of inhibition was taken to 
be the MIC value for that solvent extraction, as a 1mm zone is the smallest zone that can 
be detected as growth inhibition of microorganisms in vitro using the agar plate disk 
diffusion method. The disk diffusion method is well suited for preliminary screening and 
has the advantage of allowing for the use of small sample sizes (Rios, Recio, Villar, 
1988).  
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3.3.3.4. Thin-layer chromatography (TLC) – Bioautographic Assay  
For direct bioassay on TLC plates, a 30µl aliquot of the chloroform extract was applied to 
5 x 20 cm silica F254 (Merck) glass backed plates in duplicate for fingerprinting. All 
plates were developed in hexane: ethyl acetate (1:2 v/v) (Wagner and Blade, 1996). The 
developed TLC plates were dried overnight and then viewed under ultraviolet (UV) light 
(366 nm). Thereafter, one set of plates (of each extract) was sprayed with vanillin-
sulphuric acid (VSA) reagent, made up by dissolving 3g vanillin in 30ml ethanol, to 
which 5ml concentrated sulphuric acid was added. Some compounds that were not visible 
under UV light became visible upon spraying and heating (for approximately 20 min) of 
the developed plates.  
 
The duplicate plates were used for the bioautographic assay (inoculated TLC), whereby 
Mycobacteria 7H11 agar inoculated with M. smegmatis was poured over the developed 
plates under aseptic conditions. These plates were placed on damp paper towels in a 
plastic tray, covered with cling wrap and incubated at 37 °C for 48 hours.  
 
To detect the antimycobacterial activity on the plates, they were sprayed with a 0.2mg/ml 
solution of 2,5-diphenyltetrazolium bromide (MTT) (Sigma Chemicals Co.). Clear zones 
on the chromatogram indicated inhibition of growth (Beugue and Kline, 1972). 
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3.3.4. Assessment of the immune-modulation   
          characteristics of Tulbaghia alliacea extracts 
 
3.3.4.1. Whole blood culture assay 
This study received ethical clearance from the University of the Western Cape. Brief 
histories were taken from 8 volunteers to confirm that they were in good general health, 
had had no recent medication or alcohol, and were non-smokers. Informed consent was 
received from the donors, who consisted of males and females between the ages of 20 – 
30 years old. Blood was collected from each donor under good clinical practice, by 
means of venous puncture in 6ml lithium heparin tubes (BD Vacutainer Systems) at the 
UWC Campus Clinic.  
 
The blood was immediately processed in the tissue culture laboratory, where cell culture 
was undertaken under sterile conditions within a laminar flow. Blood was diluted 1 in 9 
with RPMI-1640 (Sigma-Aldrich) medium, and plated in sterile 96-well flat-bottom 
tissue culture plates (Corning Costar, Cambridge, MA). Cells were stimulated in 
duplicate with antigen, mitogen or with medium. Each well consisted of 180µl of diluted 
whole blood, 10 µl of stimulant and 10µl of plant extract, making up a final volume of 
200µl/well.  
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Phytohaemagglutinin (PHA; Sigma-Aldrich) a common T cell mitogen, was used to non-
specifically stimulate the cells. Purified protein derivative from Mycobacterium 
tuberculosis (PPD) obtained from Statens Serum Institut (SSI), Copenhagen, Denmark, 
was used for antigenic-specific stimulation. Negative control wells consisted of 180µl of 
diluted blood, 10µl of stimulant and 10 µl of RPMI-1640 medium. 
 
All samples were incubated at 37ºC with 5% carbon dioxide. Supernatants from the PHA-
stimulated wells were harvested on day 3 after a 72 hour incubation period, while 
supernatatnts from the PPD-stimulated samples were harvested on day 5 after a 96 hour 
incubation period. Supernatant samples were stored at -20ºC until used for cytokine 
analysis.  
 
3.3.3 Cytokine Measurement: Enzyme-linked Immunosorbent Assay  
 A sandwich Enzyme Linked ImmunoSorbent Assay (ELISA) kit (DuoSet, R&D Systems) 
was used in this experiment to measure human IFN-γ concentrations in cell culture 
supernatant. The DuoSet ELISA is designed to detect and quantify IFN-γ captured in a 
specific antibody-antigen interaction. The assay was performed according to the 
manufacturer's instructions. A 96-well plate (Nunc Maxisorp, Amersham) was coated with 
50µl of mouse anti-human IFN-γ capture antibody, diluted to a working concentration of 
4.0µg/ml in phosphate buffered saline (PBS), and incubated overnight at room temperature. 
Plates were then washed in wash buffer (0.05% Tween-20 in PBS) to remove non-
specifically bound material. Unoccupied sites were blocked with 300µl of block buffer (1% 
BSA, 0.05% NaN3 in PBS) per well, and incubated at room temp for 1 hour.  
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After incubation of one hour, the blocking buffer was discarded and the plate was washed 
thrice with wash buffer (0.05% Tween-20 in PBS). Cell culture supernatants and serially 
diluted recombinant human IFN-γ standard (0 – 1000 pg.ml) were then added to the plates at 
50µl per well in duplicate, and incubated at room temperature for 2 hours. The plate was 
washed thrice after incubation, followed by adding 50µl of detection goat anti-human IFN-γ 
antibody diluted in reagent diluent at a concentration of 175ng/ml. After incubation of 2 
hours, 50µl of streptavidin conjugated to horseradish–peroxidase (HRP) enzyme was added 
to the wells and incubated in the dark for 20 minutes.   
 
A colour substrate solution (H2O2 + Tetramethylbenzidine) was then added and incubated in 
the dark for 20 minutes. Without washing, 50µl of stop (2 N H2SO4) solution was then 
added to each well. The intensity of the color change from blue to yellow is proportional to 
the levels of IFN-γ present in the samples. The optical density was determined immediately 
using a microplate reader (Titertek Multicsan) at 450nm.  
 
3.3.7. Statistical analysis 
For the antimycobacterial analyses, inhibition zones were statistically compared by 
conducting an unpaired t-test using the MedCalc (version 7.1, 2000) statistical 
programme. Means ± SEM (standard error of the mean) were considered significant at 
P<0.05. For the immunological analyses, modulatory effects were statistically compared 
using the Wilcoxon Rank Test. Differences between the medians were considered 
significant at P<0.05. 
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3.4. Results 
 
3.4.1. Disk diffusion assays 
Inhibition zones caused by A. sativum  and T. alliacea were compared to those of the 
conventional antibiotic, Ciprofloxacin, which also served as a positive control (Table 1). 
Ciprofloxacin significantly inhibited M. smegmatis when compared to A. sativum  and T. 
alliacea  across all solvent systems (P<0.0001).  
 
Aqueous extracts of T.alliacea  exhibited no antimycobacterial activity at a concentration 
of 2mg/ml, whereas  A.sativum showed a small zone of inhibition. However, at a 
concentration of 5mg/ml and 10mg/ml, T.alliacea exhibited a statistically bigger zone of 
inhibition than A.sativum (P<0.05). 
activity at 2mg/ml, whilst A.sativum 
did (  P<0.001). Both A.sativum  and T.alliacea  showed similar  inhibitory  effects     
 
 at 5mg/ml concentration, however, T.alliacea had a statistically bigger inhibitory effect 
than A.sativum at 10mg/ml (P<0.002).  A.sativum  and   For methanol extracts; 
at 5mg/ml had a bigger zone of inhibition  (P<0.001) than T.alliacea, and both
  plants at 10mg/ml exhibited the same antimycobacterial activity (12mm zone).  
 
T.alliacea did not exhibit Ethanolic extracts of 
T.alliacea exhibited no activity at a concentration of 2mg/ml, but A.sativum    
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T.alliacea hexane extracts did not show any activity at 2mg/ml, compared to A.sativum, 
which had a 2.66mm zone. Furthermore, no significantly different patterns of inhibition 
were detected at 5mg/ml and 10mg/ml concentration of hexane extracts.  
 
The chloroform extract: T.alliacea did not show activity at 2mg/ml, but had statistically 
greater inhibition than A.sativum at 5mg/ml (P<0.002) and 10mg/ml (P<0.0001) 
concentrations.  In general, the antimycobacterial activity of T.alliacea for the 10mg/ml 
chloroform extract (17.66mm) was greater than that of the 10mg/ml aqueous (9.33mm), 
ethanol (12.66mm), methanol (12.00mm), and hexane (10.66mm) extracts. 
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Table 1.  The antimycobacterial activity of A. sativum and T. alliacea extracts. 
 
Zone of Inhibition (mm ± SEM) Statistical significance*  
Extract 
Conc. 
(mg/ml) Ciprofloxacin (a) A. sativum  (b) T. alliacea (c) ab ac bc 
2 24.00 ± 0.00 1.66 ± 0.33 0 0.0001 0.0001 0.0075 
5 24.00 ± 0.00 3.33 ± 0.33 5.00 ± 0.00 0.0001 0.0001 0.0075 
Aqueous 
(H2O) 
10 24.00 ± 0.00 6.33 ± 0.33 9.33 ± 0.33 0.0001 0.0001 0.0031 
2 24.00 ± 0.00 2.66 ± 0.33 0 0.0001 0.0001 0.0013 
5 24.00 ± 0.00 4.33 ± 0.33 4.00 ± 0.00 0.0001 0.0001 0.3739 
Ethanol 
(EtOH) 
10 24.00 ± 0.00 7.33 ± 0.33 12.66 ± 0.66 0.0001 0.0001 0.0020 
2 24.00 ± 0.00 0 0 0.0001 0.0001 NS 
5 24.00 ± 0.00 5.33 ± 0.33 4.00 ± 0.00 0.0001 0.0001 0.0161 
Methanol 
(MeOH) 
10 24.00 ± 0.00 12.00 ± 0.00 12.00 ± 0.00 0.0001 0.0001 NS 
2 24.00 ± 0.00 2.66 ± 0.33 0 0.0001 0.0001 0.0013 
5 24.00 ± 0.00 5.44 ± 0.33 3.66 ± 0.33 0.0001 0.0001 0.1012 Hexane 
10 24.00 ± 0.00 11.33 ± 0.66 10.66 ± 0.33 0.0001 0.0001 0.4216 
2 24.00 ± 0.00 2.66 ± 0.33 0 0.0001 0.0001 0.0013 
5 24.00 ± 0.00 5.00 ± 0.00 9.33 ± 0.33 0.0001 0.0001 0.0020 
Chloroform 
(CHCl3) 
10 24.00 ± 0.00 7.66 ± 0.33 17.66 ± 0.33 0.0001 0.0001 0.0001 
 
* P values for comparing main effects: ab = Ciprofloxacin and  A. sativum, ac = Ciprofloxacin and T. alliaceae,                              
   bc =A. sativum and T. alliaceae.   NS = No Significance. 
 
# Negative controls (water, ethanol, methanol, hexane and chloroform) did not inhibit M.smegmatis, hence    
   no zone of  inhibition was observed.                         
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An MIC value is defined as the lowest concentration, which visibly inhibits growth of the 
microorganism after incubation. A. sativum extracts were shown to have lower MIC 
values than T. alliacea (Table 2).  The lowest MIC value against M. smegmatis was 
obtained with the 1.0mg/ml and 2.4mg/ml chloroform extract of A. sativum and T. 
alliacea, respectively. 
 
 
         Table 2. The minimum inhibitory concentrations (MIC) for Tulbaghia alliacea and     
                        Allium sativum extracts against M. smegmatis. 
 
 
Extract Concentration (mg/ml) 
 
Extract 
A. sativum T. alliacea 
Zone of Inhibition 
(mm) 
Aqueous (H20) 2.0 4.0 1 
Methanol (MeOH) 3.0 4.4 1 
Ethanol (EtOH) 2.0 4.4 1 
Hexane 1.6 4.4 1 
Chloroform  (CHCl3) 1.0 2.4 1 
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3.4.2. Antimycobacterial activity of T. alliacea using  
          TLC–Bio-autography 
The chloroform extract separated as three inhibitory fractions (Fig.1-i) that are indicated 
as zones of inhibition on the bioautogram. TLC separations (Fig.1-ii) sprayed with 
vanillin-sulphuric acid reagent showed the compounds present in the extract; these 
compounds are the same as the antimycobacterial compounds visible on the bioautogram, 
based on the distance they traveled on the TLC plates. Comparing the Rf values from a 
previous study that assessed the antifungal activity of T.alliacea extracts (Thamburan et 
al., 2006), it was possible to identify Compound A (Rf 0.44) as Marasmicin.  
 
  
                                         
                                                             
(i)  Developed TLC plate of the T.alliacea chloroform extract sprayed with vanillin-sulphuric acid 
reagent. NMR analysis identified the active compound A as Marasmicin, with chemical shift values 
(ppm) of 2.38, 4.07, 4.18, 4.25 and 2.27, which have been previously reported for this entity 
(Thamburan et al., 2006). 
 
(ii) Developed TLC plate of the T.alliacea chloroform extract inoculated with Mycobacterium 
smegmatis and sprayed with 2,5-diphenyltetrazolium bromide. 
 
Fig. 1. The antimycobacterial activity of T. alliacea chloroform extract on TLC-bioautography. 
Compound C 
(Rf  0.92) 
 Compound B 
 (Rf  0.55) 
Compound A 
(Rf  0.44) 
Inhibition zone 
Inhibition zone 
Inhibition zone 
     (i)                      (ii)
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3.4.3. Assessment of the immune-modulating   
          characteristics of T.alliacea extracts 
 
3.4.3.1. Standard curve 
A standard curve was generated using eight diffent concentrations, in duplicate, of 
standard IFN-γ, analysed with the same ELISA DuoSet kit employed for the analyses of 
the experimental samples (Table 3). Optical densities were read off a colorimetric reader at 
450 nm. The concentrations of IFN-γ (pg/ml) were plotted against the optical densities 
obtained. A correlation coefficient of 0.99 was obtained (Fig. 2). 
 
Table 3. Standard curve for the evaluation of IFN-γ in whole blood culture supernatants 
IFN-γ 
standard 
Optical 
Density 1 
Optical 
Density 2 
Average 
Optical Density
Standard 
Deviation 
Co-efficient of 
variance 
1000 0.631 0.632 0.632 0.001 0.112 
500 0.347 0.349 0.348 0.001 0.406 
250 0.220 0.220 0.220 0.000 0.000 
125 0.166 0.165 0.166 0.001 0.427 
62 0.139 0.137 0.138 0.001 1.025 
31 0.103 0.102 0.103 0.001 0.690 
15 0.104 0.105 0.105 0.001 0.677 
0 0.106 0.106 0.106 0.000 0.000 
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Standard Curve for IFN-y evaluation 
y = -487.76x2 + 2262.6x - 233.08
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                  Fig.2. Standard curve of IFN-γ.  
 
3.4.3.2. Modulation of IFN-γ expression in whole blood cell cultures      
             stimulated with the mitogen, PHA 
Whole blood cell cultures exposed to TAA extracts only, showed a small but dose-
dependant increase in IFN-γ expression levels; IFN-γ increased from 2.48pg/ml at 
0.63mg/ml of TAA extract to 460.89pg/ml at 10mg/ml (Fig 3). In contrast, exposure to 
the TAC extract did not induce IFN-γ expression; cytokine levels remained at baseline 
(Fig 3). Cultures stimulated with PHA only induced ~2000pg/ml of IFN-γ. Cultures 
stimulated with PHA and exposed to TAA and TAC extracts did not demonstrate much 
difference in the quantity of IFN-γ expressed (Fig 3). However, at 10mg/ml, the TAA 
extract was more potent in inducing IFN-γ expression than the TAC extract (P<0.05) 
(Table 4). The aqueous extracts of both plants Tulbaghia alliacea and Allium sativum had 
similar activity (Fig. 4), except at 10mg/ml where the chloroform extract of A.sativum 
(ASC) was statistically more potent than TAC (P<0.05) (Table 4).   
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Table 4. Comparison of the median values for the modulation of IFN-γ by different  
                garlic extracts in unstimulated whole blood cells (3-day incubation). 
 
IFN-γ expression (pg/ml) Statistical significance* Plant 
extract 
(mg/ml) 
TAA 
(a) 
TAC 
(b) 
ASA 
(c) 
ASC 
(d) 
ab ac bd cd 
0.00 2 0 0 0 0.465 0.465 0.108 0.108 
0.63 74 0 0 0 0.027 0.027 0.285 0.285 
1.25 162 0 3 0 0.017 0.027 0.179 0.715 
2.50 264 0 67 0 0.017 0.026 1.000 0.079 
5.00 350 0 111 0 0.017 0.236 0.285 0.027 
10.00 461 0 149 0 0.017 0.017 0.654 0.043 
 
* P values for comparing main effects:  
ab = T.alliacea aqueous extract and T.alliacea chloroform extract 
ac = T.alliacea aqueous extract and  A.sativum aqueous extract  
bd = T.alliacea chloroform extract and  A.sativum chloroform extract 
 cd = A.sativum aqueous extract and  A.sativum chloroform extract 
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Table 5. Comparison of the median values for the modulation of IFN-γ by different      
               garlic extracts in PHA-stimulated whole blood cells 
 
IFN-γ expression (pg/ml) Statistical significance* Plant 
extract 
(mg/ml) 
TAA+PHA 
(a) 
TAC+PHA 
(b) 
ASA+PHA
(c) 
ASC+PHA
(d) 
ab ac bd cd 
0.00 2193 2033 2203 2038 0.593 0.472 0.312 0.289 
0.63 1940 1748 2141 1924 0.320 0.472 0.125 0.078 
1.25 1947 1713 2155 1954 0.074 0.421 0.074 0.187 
2.50 2081 1778 2168 2027 0.054 0.421 0.074 0.343 
5.00 2176 1825 2195 1965 0.191 0.628 0.054 0.343 
10.00 2225 1826 2203 2060 0.039 0.230 0.027 0.593 
 
* P values for comparing main effects:  
ab = T.alliacea aqueous extract + PHA and T.alliacea chloroform extract + PHA 
ac = T.alliacea aqueous extract + PHA and  A.sativum aqueous extract + PHA 
bd = T.alliacea chloroform extract + PHA and  A.sativum chloroform extract + PHA 
 cd = A.sativum aqueous extract + PHA and  A.sativum chloroform extract + PHA 
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3.4.3.3. Modulation of IFN-γ expression in whole blood cell cultures      
             stimulated with the antigen, PPD 
 
Blood cultures stimulated with PPD and exposed to varying concentrations of TAA and 
TAC extracts showed a dose-dependant increase in the expression levels of IFN-γ (Fig. 
5). At concentrations of 1.25mg/ml, 5mg/ml, and 10mg/ml, the TAA extract induced 
greater expression of IFN-γ than TAC (P<0.05) (Table 5). Similarly, the aqueous and 
chloroform extracts of Allium sativum differed greatly in their ability to modulate 
expression of IFN-γ (Fig. 6); at extract concentrations of 0.63mg/ml, 1.25mg/ml, 5mg/ml, 
and 10mg/ml, ASA was more active than ASC (P<0.05) and hence produced higher 
levels of IFN-γ (Table 5). The ASA extract was also more active than the TAA extract at 
those concentrations (P<0.05) (Table 5). 
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Table 6. Comparison of the median values for the modulation of IFN-γ by different     
               garlic extracts in unstimulated whole blood cells (5-day incubation). 
 
IFN-γ expression (pg/ml) Statistical significance* Plant 
extract 
(mg/ml) 
TAA 
(a) 
TAC 
(b) 
ASA 
(c) 
ASC 
(d) 
ab ac bd cd 
0.00 0 0 0 0 0.317 0.317 0.317 0.317 
0.63 0 0 0 0 0.179 0.179 0.317 0.319 
1.25 0 0 0 0 0.179 0.175 0.317 0.108 
2.50 0 0 31 0 0.179 0.498 0.179 0.017 
5.00 18 0 98 7 0.144 0.042 0.361 0.236 
10.00 26 0 131 5 0.043 0.042 0.108 0.027 
 
* P values for comparing main effects:  
ab = T.alliacea aqueous extract and T.alliacea chloroform extract 
ac = T.alliacea aqueous extract and  A.sativum aqueous extract  
bd = T.alliacea chloroform extract and  A.sativum chloroform extract 
 cd = A.sativum aqueous extract and  A.sativum chloroform extract 
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Table 7. Comparison of the median values for the modulation of IFN-γ by different     
                garlic extracts in PPD-stimulated whole blood cells 
 
IFN-γ expression (pg/ml) Statistical significance* Plant 
extract 
(mg/ml) 
TAA+PPD 
(a) 
TAC+PPD 
(b) 
ASA+PPD 
(c) 
ASC+PPD 
(d) 
ab ac bd cd 
0.00 1 0 3 21 0.187 0.437 0.187 0.406 
0.63 23 4 45 0 0.312 0.031 0.687 0.015 
1.25 68 25 350 1 0.011 0.007 0.718 0.003 
2.50 80 32 399 5 0.054 0.007 0.781 0.003 
5.00 85 43 490 7 0.039 0.007 0.343 0.003 
10.00 95 59 514 14 0.019 0.007 0.687 0.003 
 
* P values for comparing main effects:  
ab = T.alliacea aqueous extract + PPD and T.alliacea chloroform extract + PPD 
ac = T.alliacea aqueous extract + PPD and  A.sativum aqueous extract + PPD 
bd = T.alliacea chloroform extract + PPD and  A.sativum chloroform extract + PPD 
 cd = A.sativum aqueous extract + PPD and  A.sativum chloroform extract + PPD 
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3.5. Discussion 
The domestic garlic plant, Allium sativum, is well known for its antimicrobial 
characteristics (Uchida, Takahashi, Sato, 1975). Whilst there is much indigenous 
knowledge about the traditional use of the South African garlic plant Tulbaghia alliacea, 
as an anti-infective remedy, there is very limited scientific information about this 
phytotherapy. Therefore, this investigation aimed at understanding the antimycobacterial 
effect of Tulbaghia alliacea, and its recently identified active ingredient Marasmicin 
(Thamburan, et al., 2006). More specifically, our investigation compared the 
antimycobacterial effects of Tulbaghia alliacea to Allium sativum and the synthetic 
antibiotic, Ciprofloxacin.   
 
Ciprofloxacin was found to be more effective against M. smegmatis than the aqueous, 
ethanol, methanol, hexane and chloroform extracts of Tulbaghia alliacea and Allium 
sativum. However, it must be remembered that Ciprofloxacin, as a pharmaceutical drug, 
has been completely purified whilst the garlic extracts may still contain compounds that 
masks the true potency of this medicinal herb (Johnson, Weitz, Mabusela, Klaasen, 
Coldrey, Gabielse, 2002). It is generally reported that MIC’s of plant antimicrobials are 
typically in the range of 100 to 1000µg/ml, orders of magnitude weaker than commercial 
broad-spectrum antibiotics.  However, it was discovered that the activity of principal 
antimicrobial plant compounds was potentiated 100- to 2000 fold depending on the 
bacterial species, by disabling multi-drug resistance pumps, which could suggest that 
plants might have developed other means of delivering their antimicrobials more 
effectively into bacterial cells (Tegos, Stermitz, Lomovskaya, Lewis, 2002). 
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Chloroform extracts of T.alliacea were statistically more potent than the A.sativum, in 
inhibiting the growth of M.smegmatis. Consequently, the T.alliacea chloroform extracts 
were subjected to phytochemical analyses, to better understand which compounds may be 
responsible for combating M. smegmatis in vitro. Through bioautography, we determined 
the localization of antimicrobial activity on chromatograms, and provided important 
qualitative information about the active components of the phytotherapy. These outcomes 
were further enhanced, by separating the phytotherapy extracts on TLC plates, which 
provided additional information about the bioactive compounds present in the mixture.  
 
These analyses showed that the chloroform extract of Tulbaghia alliacea contained three 
major inhibitory fractions that were indicated as zones of inhibition on the bioautogram. 
Compound A had the same Rf value (0.44) as Marasmicin, a previously isolated 
compound from Tulbaghia alliacea that exhibited antifungal activity (Thamburan et al., 
2006). This suggests that Marasmicin also has antimycobacterial activity. In addition to 
Marasmicin, a further two compounds that exhibit strong antimycobacterial activity, have 
now been located in Tulbaghia alliacea, and the structural analyses of these moieties are 
the subject of our next advanced study. Consequently, Marasmicin may act singularly or 
in concert with synergistic compounds in Tulbaghia alliacea, as a very significant natural 
antibiotic. 
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The crisis in antimicrobial therapy, which has stemmed from antibiotic overuse, misuse 
and the limited number of new antimicrobial drugs on the near horizon, is well 
documented (Spellberg, Powers, Brass, Miller, Edwards, 2004). However, another area 
that limits the utility of antimicrobial drug-based therapy is that antimicrobial agents are 
frequently ineffective in individuals with impaired immunity, often despite being highly 
active in vitro or in individuals with intact immunity (Pirofski and Casadevall, 2006). 
 
Approximately one-third of the world’s population is latently infected with 
Mycobacterium tuberculosis, and 90% of these individuals will never develop active 
disease, indicating that the human immune system is capable of controlling M. 
tuberculosis infection effectively (Kursar, Koch, Mittrucker, Nouailles, Bonhagen, 
Kamrdat, Kaufmann, 2007). It has long been recognized that cell-mediated immune 
(CMI) responses predominate in TB infection; specifically, a type-1 T-cell response that 
is characterized by production of IFN-γ (Andersen, Doherty, Pai, Wedingh, 2007). IFN-γ 
has been identified as an essential cytokine for controlling and containing TB infection 
(Cooper, Dalton, Stewart, Griffin, Russell, Orme, 1993; Dalton, Pitts-Meek, Keshav, 
Figari, Bradley, Stewart, 1993; Flynn, Chan, Triebold, Dalton, Stewart, Bloom, 1993; 
Kamijo, Le, Shapiro, 1993). Animals and humans that lack the ability to produce or 
respond to IFN-γ show extreme susceptibility and increased mortality to a TB infection 
(Cooper et al., 1993; Dalton et al., 1993, Flynn et al., 1993; Kamijo et al., 1993; 
Jouanguy, Altare, Lamhamedi, 1996; Doffinger, Helbert, Barcenas-Morales, 2004; 
Goldsack and Kirman, 2007).  
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As IFN-γ is required for a Th1 immune response to Mtb infection, this cytokine has been 
measured ex vivo in serum (Vankayalapati, Wizel, Weis, Klucar, Shams, Samten, Barnes, 
2003), bronchoalveolar lavage fluids (Barry, Lipman, Bannister, Johnson, Janossy, 2003) 
and pleural effusions of TB patients (Hirsch, Toossi, Johnson, Luzze, Ntambi, Peters, 
McHugh, Okwera, Joloba, Mugyenyi, 2001), or in culture supernatants of lymphocytes 
isolated from these body fluids and stimulated in vitro with mycobacterial antigens 
(Veenstra, Crous, Brahmbhatt, Lukey, Beyers, van Helden, Walzl,  2007). In the majority 
of the latter studies, secreted IFN-γ was measured by ELISA. 
 
To assess the immune-modulatory effects of Tulbaghia alliacea extracts on IFN-γ 
expression, diluted whole blood was stimulated with the non-specific mitogen PHA and 
the TB-specific antigen PPD, and exposed to varying concentrations of Tulbaghia 
alliacea aqueous and chloroform extracts. The use of whole blood cultures for cytokine 
studies was first described in 1982 (Kirchner, Kleinicke, Digel). Performing a whole 
blood experiment rather than examining peripheral blood mononucleocytes (PBMCs) or 
separated blood cells provides the major advantage that all cellular components of 
peripheral blood are present in their natural proportions and that no preactivation or 
desensitization of immune cells, often brought about by separating PBMCs on a density 
gradient, would occur (Breidhardt, Frohn, Luhm, Kirchner, Brand, 2002; Van Crevel, 
Ven-Jongekrijg, Netea, de Lange, Kullberg, van der Meer, 1999). The dilution of blood 
and incubation in tissue culture wells facilitates the use of much smaller volumes of 
blood and longer incubation periods, both of which may be advantageous for the 
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detection of cytokines with a low production rate (Van Crevel et al., 1999). The study of 
whole blood in vitro, thus, has both practical and theoretical advantages.  
 
PHA was used as a non-specific stimulant, as it is a potent T cell stimulant that can 
activate T cells to produce cytokines like IFN-γ (Goldsby, Kindt, Osborne, 2000; Chang, 
Chiang, Chang, Yeh, Shyur, Kuo, Wu, Yang, 2007). Antigenic-specific stimulation was 
provided by the use of PPD. PPD is prepared by precipitation of proteins from heat-killed 
cultures of M tuberculosis, and has been used for in vitro detection of specific IFN-γ-
secreting lymphocytes sensitised by mycobacterial antigens (Andersen, Munk, Pollock, 
Doherty, 2000). 
  
Assessment of the immune stimulating potential of Tulbaghia alliacea extracts in 
modulating the expression of IFN-γ showed differential patterns of activity between the 
aqueous and chloroform extracts. Interestingly, in the absence of mitogenic or antigenic 
stimulus, TAA induced a dose-dependant increase in IFN-γ expression levels (2.48 pg/ml 
at 0.63mg/ml of TAA extract to 460.89 pg/ml at 10mg/ml), whereas the TAC extract at 
all concentrations did not induce IFN-γ expression (0 pg/ml).  
 
Mitogenic stimulation of whole blood cultures with  PHA and exposure to TAA and TAC 
extracts, resulted in similar  quantities of IFN-γ being expressed (Fig 3a-b), except at 
10mg/ml, where the TAA extract was more potent in inducing IFN-γ expression than the 
TAC extract (P<0.05) (Table 4). Comparison of the two garlic plants Tulbaghia alliacea 
and Allium sativum, also showed similar activity (Fig. 4a-b), except at the highest extract 
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concentration of 10mg/ml where the chloroform extract of A.sativum (ASC) was 
statistically more potent than TAC (P<0.05) (Table 4).   
 
Following antigenic stimulation of whole blood cultures with PPD and subsequent 
exposure to the plant extracts, it was observed that TAA and TAC extracts induced a 
dose-dependant increase in the expression levels of IFN-γ (Fig. 5a-b). The TAA extract 
again induced greater expression of IFN-γ than TAC (P<0.05) (Table 5). Similarly, the 
aqueous and chloroform extracts of Allium sativum differed greatly in their ability to 
modulate expression of IFN-γ (Fig. 6a-b); ASA was more active than ASC (P<0.05) 
(Table 5). Comparing the two garlic plants revealed the ASA extract to be more active 
than the TAA extract (P<0.05) (Table 5). 
 
A noteworthy finding in this study is that the aqueous extract of Tulbaghia alliacea is 
more active than the chloroform extract, in stimulating the expression of IFN-γ. This is 
significant because an aqueous extract is the form in which this phytotherapy is used in 
indigenous cultures, as a remedy for various ailments including TB and TB-related 
conditions (Van Wyk et al., 2000; Bamuamba, Gammon, Meyers, Dijoux-Franca, 2008). 
The aqueous extract also showed considerable antimycobacterial activity against 
Mycobacterium smegmatis in vitro, indicating that administration of the phytotherapy 
during infection could work either by eradicating the pathogen, or by stimulating the 
host’s immune system to mount a protective response via expression of IFN-γ.  
  
 
 
 
 
 154
3.6. Conclusion 
This investigation has indicated that Tulbaghia alliacea could have potential as an anti-
tuberculosis remedy, as it has been shown to possess both antimycobacterial activity as 
well as immune-modulatory effects on IFN-γ expression. This study also validates the 
traditional use of the aqueous extract of this widely-used indigenous phytotherapy. 
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Tulbaghia alliacea phytotherapy: 
A potential anti-cancer remedy  
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4.1. Abstract 
 Tulbaghia alliacea is used in traditional medicine as an anti-cancer remedy. However the 
use of this plant to treat cancer has not yet been tested in a scientific study. Hence the 
objective of this work was to evaluate the potential use of extracts of this plant to treat 
cancer. Since the cytotoxic effects of anti-cancer drugs is often associated with the 
induction of apoptosis, this study aimed to evaluate the anti-cancer activity of the plant 
extracts by assessing the ability of the extracts to induce apoptosis during in vitro cell 
culture conditions. Two extracts (TAA or aqueous extract and TAC or chloroform 
extract) were prepared. Several cell lines including five human cancer cell lines were 
treated with these plant extracts and the induction of apoptosis was assessed using 
various assays that detect biochemical changes that have been associated with the 
activation of apoptosis. Using phosphatidyl serine externalisation as a marker of 
apoptosis this study shows that both extracts induce apoptosis in three of these cell lines 
(Jurkat, MCF7 and MG63) while the other two cell lines (HeLa and H157) were 
completely resistant to the effects of the extracts. Three other markers of apoptosis, 
which included, caspase-3 cleavage, mitochondrial depolarisation, and DNA 
fragmentation, was used to further characterise the induction of apoptosis in Jurkat cells. 
All three these assays demonstrated that the two plant extracts contained compounds with 
pro-apoptotic activity. Furthermore a comparison between the two extracts shows that 
there is a significant difference in the activity of the two extracts with the aqueous extract 
(TAA) showing higher pro-apoptotic activity than the chloroform extract (TAC). This 
study also demonstrates that mechanism of apoptosis induction is likely to involve the 
mitochondrial pathway. An investigation into gene expression levels by real time PCR 
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revealed that the plant extracts induce the expression of several genes (Bax, caspase-3, 
and caspase-9) previously implicated in apoptosis, which further supports the idea that 
the extracts induce apoptosis via the mitochondrial pathway. This study demonstrated 
that extracts of T. aliacea induce apoptosis in human cancer cells during in vitro 
conditions and therefore provide supporting evidence that this plant may be used as 
remedy to treat certain forms of cancer. 
 
Keywords: Garlic, Tulbaghia alliacea, apoptosis, cancer, cell cycle, caspase-3, DNA 
fragmentation, mitochondrial depolarization.
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4.2. Introduction 
 
Apoptosis is a biochemical process by which cells die through a highly regulated 
program resulting in the removal of damaged or unwanted tissue. Apoptosis make sure 
that cellular homeostasis is maintained and prevents the development of cancer (Lowe 
and Lin, 2000). Apoptosis is associated with distinct biochemical and morphological 
changes (Lawen, 2003) characterized by chromatin condensation, membrane blebbing, 
cell shrinkage, and DNA fragmentation (Wyllie, Kerr, Currie, 1980). Numerous studies 
have demonstrated that the evasion of apoptosis is one of the most important mechanisms 
of uncontrolled growth of tumour cells (Hager and Hanahan, 1999; Hanahan and 
Weinberg, 2000; Igney and Krammer, 2002; Schulze-Bergkamen and Krammer, 2004). 
The elimination of neoplastic cells through the activation of apoptosis thus represents a 
protective mechanism against cancer (Owuor and Kong, 2002) and considerable attention 
has been given to the manipulation of apoptosis as a novel and promising strategy for 
cancer chemoprevention and therapy (Cal, Garban, Jazirehi, Yeh, Mizutani, Bonavida, 
2003; Dong, 2003; Fesus, Szondy, Uray, 1995; Holzman, 1996; Krzystyniak, 2002). 
Several anti-cancer drugs have been shown to exert their effects through the activation of 
apoptosis and a substantial number of these drugs have been isolated from medicinal 
plants. 
 
Allium sativum, a member of the Lily family and commonly known as garlic, has been 
cultivated as a food plant for over 10, 000 years. Egyptian records dating back to about 
1550 BC make reference to garlic as a remedy for a variety of diseases (Block, 1985) and 
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more recently epidemiological studies showed that the enhanced consumption of garlic is 
closely related to reduced risk of cancer incidence (Buiatti, Palli, Decarli, Amadori, 
Avellini, Bianchi, Biserni, Cipriani, Cocco, Giacosa, Mrubini, Puntoni, Vindig, Frumeni, 
Blot, 1989; Fleischauer and Arab, 2001; Haenszel, Kurihara, Segi, Lee, 1972; Hsing, 
Chokkalingam, Goa, Madigan, Deng, Gridley, Fraumeni, 2002; Steinmetz, Kushi, 
Bostick, Folsom, Potter, 1994; You, Blot, Chang, Ershow, Yang, An, Henderson, 
Fraumeni, Wang, 1989). The anti-tumour activity of this plant has been associated with 
the induction of apoptosis in tumour cells (Knowles and Milner, 2001; Ledezma, Apitz-
Castro, Cardier, 2004; Oommen, Anto, Srinivas, Karunagaran, 2004; Robert, Mouille, 
Mayeur, Michaud, Blachier, 2001; Wu, Sheen, Chen, Tsai, Lii, 2001). The major active 
principles in garlic, most of which are organosulfur compounds have been shown to 
inhibit the proliferation of cancer cells, and some of them induced apoptosis in tumour 
cells of different tissue origin (Dirsch, Gerbes, Vollmar, 1998; Kwon, Yoo, Ryu, Yang, 
Rho, Kim, Park, Kim, Park, 2002; Pinto, Lapsia, Shah, Santiago, Kim, 2001; Shirin, 
Pinto, Kawabata, Soh, Delohery, Moss, Murty, Rivlin, Holt, Weinstein, 2001; Sigounas, 
Hooker, Anagnostou, Steiner, 1997).  
 
Another member of the indigenous garlic family T. violacea, also known as wild garlic, is 
used in traditional medicine as a remedy for the treatment of fever, asthma, hypertension 
and oesophageal cancer (Hutchings, Scott, Lewis, 1996; Van Wyk and Wink., 2004). A 
study by Bungu, Frost, Brauns and Van de Venter (2006), demonstrated that extracts of 
T. violacea exhibited anti-proliferative and pro-apoptotic effects in four human cancer 
cell lines. It was previously shown that another species of Tulbaghia, T. alliacea has 
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significant anti-fungal activity against the medically important opportunistic pathogen C. 
albicans (Thamburan et al., 2006). The anti-fungal agent was identified as marasmicin in 
a chloroform extract of T. alliacea. The chemical shift values for marasmicin isolated 
from T. alliacea were in agreement with those reported for the same compound, 
previously isolated from the related species, T. violacea (Kubec et al. 2002). In view of 
the fact that both T. alliacea and T. violacea belong to the same Family (Alliacea) and 
Genus (Tulbaghia) (Van Wyk et al., 1997), and since similar chemical characteristics 
have been reported for both plants (Thamburan et al., 2006; Kubec et al. 2002), the 
potential anti-tumour properties of T. alliacea extracts was investigated through 
evaluating the ability of these extracts to induce apoptosis in several human cancer cell 
lines. 
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4.3. Materials and Methods 
 
4.3.1. Plant material 
Bulbs of Tulbaghia alliacea were obtained from Rastafarian herbal traders in Cape 
Town, South Africa. The species was verified by a botanist at the University of the 
Western Cape Herbarium where a voucher specimen (Thamburan001) was deposited. 
 
4.3.2. Preparation of plant extracts 
Bulbs of T. alliacea were washed with distilled water, peeled and chopped into small 
pieces (Eloff, 1998). Aqueous and chloroform extracts were prepared by soaking the 
chopped plant material in the solvents overnight, and then vacuum filtering it. After 
filtration, the solvents were evaporated, and the extracts reconstituted in DMSO and 
stored at -20°C. 
 
4.3.3. Cell culture  
All available laboratory cell lines were used in this study. Chinese Hamster Ovary (CHO) 
cells were cultured in Hams F-12 medium containing 10% (v/v) foetal calf serum and 
0.2% (v/v) streptomycin-penicillin. MCF7 (human breast adenocarcinoma), MG63 
(human osteosarcoma), H157 (human small lung cell carcinoma) and HeLa (human 
cervical carcinoma) cells were cultured in DMEM medium supplemented with 10% (v/v) 
foetal calf serum, and 0.2% (v/v) streptomycin-penicillin. Jurkat (human leukemia T 
cells) were cultured in RPMI medium with GlutaMAX-1, 10% (v/v) foetal calf serum, 
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and 0.2% (v/v) streptomycin-penicillin. All cell lines were maintained at 37°C in an 
atmosphere of 5% CO2. Cells were plated in 6-well tissue culture plates at a cell density 
of 2.5 × 105 cells per well, or in 24-well tissue culture plates at a density of 1.5 × 105 cells 
per well. After 24 h the medium was replaced with medium containing the test extracts. 
The cells were treated for the indicated times, after which the cells were harvested and 
the extent of apoptosis was assessed.  
 
4.3.4. APOPercentage assay  
 
4.3.4.1. Microscopy 
CHO cells were cultured in 24-well cell culture plates for 24 h; thereafter the cells were 
treated with increasing doses (0, 2, 4, 6, 8, and 10mg/ml) of T. alliacea extracts. 
Following a 6 h treatment, the cells were stained with APOPercentage dye (Biocolor 
Ltd.) as described by the manufacturer. Briefly, the medium containing the plant extracts 
was removed and replaced with medium containing the APOPercentage dye. The cells 
were incubated for 30 min at 37°C. The dye was removed and the cells were washed with 
PBS to remove excess dye. The cells were evaluated by light microscopy. Photographs 
were taken with a Leica digital camera using a Nikon inverted light microscope at 20 × 
magnification. 
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4.3.4.2. Flow cytometry 
 
The cells were plated at a cell density of 1.5 × 105 cells per well in a 24-well cell culture 
plate, and were cultured for 24 h before treatment with either aqueous (TAA) or 
chloroform (TAC) extracts of T. alliacea. Staurosporine (Stp), a known inducer of 
apoptosis was used as a positive control. Following a 6 h treatment, the cells were 
removed using trypsin, washed with PBS, and stained with APOPercentage dye for 30 
min at 37°C. The cells were washed with PBS and analysed by FACS as described 
previously (Meyer et al., 2008).  
 
Cell staining was measured by flow cytometry at 670 nm (FL3) using a Becton Dickinson 
FACScan instrument (BD Biosciences). The instrument settings were as follow: voltage 
set at 470 and AmpGain set at 1. Acquisition was done in Log mode. A minimum of 10, 
000 cells per sample were acquired and analysed using CELLQuest PRO software (BD 
Biosciences). 
 
4.3.5. Caspase-3 assay 
 
The activation of caspase-3 was detected using a monoclonal antibody specific for the 
cleaved form of caspase-3 (BD Biosciences). Jurkat cells were seeded in 6-well tissue 
culture plates. The cells were treated with 6mg/ml of T. alliacea extracts or Stp (positive 
control) and incubated for different time periods (6, 12, 24 h). After incubation, the cells 
were washed with PBS, and re-suspended in Cytofix/CytopermTM (BD Biosciences). 
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Following 20 min of incubation on ice, the cells were washed twice with Perm/WashTM 
buffer (BD Biosciences) and stained for 30 min at room temperature with a FITC-
conjugated monoclonal antibody specific for active caspase-3. Cell staining was 
measured by flow cytometry at 530 nm using a Becton Dickinson FACScan instrument 
(BD Biosciences). A minimum of 10, 000 cells per sample were acquired and analyzed 
using CELLQuest PRO software (BD Biosciences).  
 
4.3.6. TMRE (Tetramethylrhodamine) assay 
 
Jurkat cells were plated in 6-well cell culture plates. The cells were treated with 6mg/ml 
of T. alliacea extracts or staurosporine (positive control) and incubated for different time 
periods (30 min, 1 h, and 2 h). The cells were incubated for 30 min in medium containing 
1 µM TMRE dye (Molecular Probes). The cells were washed with PBS and analyzed by 
flow cytometry using a Becton Dickinson FACScan instrument (BD Biosciences). Cell 
fluorescence was measured at 670 nm (FL3). A minimum of 10, 000 cells per sample 
were acquired and analysed using CELLQuest PRO software (BD Biosciences).  
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4.3.7. Terminal deoxynucleotide transferase dUTP Nick    
           End Labeling  (TUNEL) assay 
 
To analyse the occurrence of DNA fragmentation, the Terminal deoxynucleotide 
transferase dUTP Nick End Labeling (TUNEL) assay (BD Biosciences) was used. Jurkat 
cells were plated in 6-well cell culture plates at a cell density of 2.5 × 105 cells per well. 
The cells were treated with 6mg/ml of T. alliacea extracts or staurosporine (positive 
control) and incubated for different time periods (6, 12, 18, 24 h). After incubation, the 
cells were washed twice with PBS and fixed for 30 min in 1% paraformaldehyde.        
 
The cells were then washed twice with PBS and permeabilized for at least 48 h in 70% 
ethanol at -20°C. Subsequently, the cells were labelled with FITC-dUTP and propidium 
iodide (PI) as described in the manufacturer’s manual (BD Biosciences). Cell staining 
was measured by flow cytometry at 530 nm and 585 nm using a Becton Dickinson 
FACScan instrument (BD Biosciences). A minimum of 10, 000 cells per sample were 
acquired and analysed using CELLQuest PRO software (BD Biosciences). Dual 
parameter analysis (DNA area signal on the Y-axis and DNA width on the X-axis) was 
used to exclude DNA doublet events. 
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4.3.8. Cell cycle analysis 
 
Jurkat cells were plated in 6-well cell culture plates at a cell density of 2.5 × 105 cells per 
well. The cells were treated with 6mg/ml of T. alliacea extracts and incubated for 
different time periods (24h, 48h, and 72h). A negative control sample (untreated cells) 
was prepared for each time point. After treatment, the cells were washed twice with PBS 
and fixed for 30 min in 1% paraformaldehyde.  Thereafter the cells were washed twice 
with PBS again and permeabilized for at least 48 h in 70% ethanol at -20°C. After 
permeabilization, the cells were washed twice with PBS. The cell pellets were then 
resuspended in 1ml PI master mix (containing 1mg/ml Propidium iodide and 10mg/ml 
RNase A), and incubated at 37°C for 30 minutes.  
 
Samples were then analyzed by flow cytometry. Cell staining was measured by flow 
cytometry at 530 nm using a Becton Dickinson FACScan instrument (BD Biosciences). 
A minimum of 10, 000 cells per sample were acquired and analyzed using CELLQuest 
PRO software (BD Biosciences). Dual parameter analysis (DNA area signal on the Y-
axis and DNA width on the X-axis) was used to exclude DNA doublet events. 
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4.3.9. RNA isolation 
 
Jurkat cells were plated in 6-well cell culture plates at a cell density of 2.5 × 105 cells per 
well. The cells were treated with 6mg/ml of T. alliacea extracts and incubated for 
different time periods (6, 12, and 24 h). Total RNA was isolated from the cells using 
TRIzol LS (Gibco BRL). Cells were homogenized by the addition of 0.3 - 0.4ml TRIzol 
per 10 cm3 of culture flask. The homogenate was transferred to a 15ml conical centrifuge 
tube and 0.2ml chloroform per 0.75ml of TRIzol LS reagent was added. The solution was 
vigorously shaken for 15 sec and allowed to incubate at room temperature for 10 min. 
The sample was centrifuged for 30min at 3000 × g at 4°C to allow phase separation. The 
top aqueous phase was transferred to a new conical tube and mixed with 0.5ml isopropyl 
alcohol per 0.75ml of TRIzol LS reagent. The sample was incubated at room temperature 
for 15min and centrifuged for 30min at 3000 × g at 4°C. The resulting pellet was washed 
with 1ml 70% ethanol per 0.75ml of TRIzol LS reagent. The pellet was allowed to dry at 
room temperature and resuspended in 100µl DEPC treated water. The RNA was stored as 
20µl aliquots at -80°C. 
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4.3.10. cDNA synthesis 
The first strand cDNA synthesis (AMV) kit for RT (Roche Applied Science) was used. 
The reaction for the first strand synthesis consisted of the following reagents: 
 
    Table 1. Reagents used for first strand cDNA synthesis. 
Reagent Volume per sample Final Concentration 
10× Reaction Buffer 2 µl 1× 
25mm MgCl2 4 µl 5mM 
10mm dNTPs 2 µl 1mM 
Oligo dT-Primer Variable 1 picoM 
RNase inhibitor 1 µl 50 Units 
AMV reverse transcriptase 0.8 µl 20 Units 
Sterile water To final volume of 20 µl  
RNA Variable 1 µg 
 
The mixture was thoroughly mixed and centrifuged briefly. The reaction mixture was 
incubated at 25°C for 10 minutes and then 42°C for 60 minutes. The AMV reverse 
transcriptase was denatured by incubating the reaction mixture at 99°C for 5 minutes. The 
first strand cDNA preparation was stored at -20°C.  
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4.3.11. Real-Time Quantitative RT-PCR 
 
A standard PCR mixture contained 4µl of LightCycler FastStart DNA MasterPLUS SYBR 
Green Reaction Mix (Roche Applied Science) 200ng of the pre-synthesized cDNA was 
used as template and 0.5µM of each primer in a final volume of 20µl. The final 
concentration of MgCl2 was adjusted to 3mM. A negative control was included which 
contained the same mixture with the cDNA replaced by water. The PCR mixture was 
subsequently transferred to a Lightcycler capillary tube (Roche Applied Science) in a 
pre-cooled adapter block and centrifuged at 700 × g for 5 sec. The capillaries were placed 
into the LightCycler carousel instrument (Roche Applied Science) and cycled through the 
following parameters: 
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  Table 2. PCR conditions used in Real-Time Quantitative PCR 
Program Step Temp. Time 
Temperature 
Transition Rate
Fluorescence
acquisition 
Pre-incubation  95°C 10 min 20°C/sec None 
Amplification Denaturation 95°C 10 sec 20°C/sec None 
Amplification Annealing 60°C 10 sec 20°C/sec None 
Amplification Extension 72°C 10 sec 20°C/sec Single 
Melting curve Denaturation 95°C 0 20°C/sec None 
Melting curve Annealing 65°C 10 sec 20°C/sec None  
Melting curve Melting 95°C 0 0.1°C/sec Continuous 
Cooling  40°C 30 sec 20°C/sec None 
 
    Note: The Amplification program was repeated for 40 cycles. 
 
 
4.3.12. Primer sequences 
The primer sequences were designed using the Primer3 program 
(http://Frodo.wi.mit.edu). All primer sets were designed in the exon regions across 
intron-exon boundaries. This was done to eliminate additional products that could be 
amplified from genomic DNA. Primers were tested by performing a BLAST search 
against the Human Genome reference database. 
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1. Caspase-3 Forward:  5′- AAC CAG ATC ACA AAC TTC TGC-3′ 
2. Caspase-3 Reverse:  5′- TGG AGT CCA GTG AAC TTT CTT C-3′ 
3. Caspase-8 Forward:  5′- TTC TCC CTA CAG GGT CAT GC-3′ 
4. Caspase-8 Reverse:  5′- GCA GGC TCA AGT CAT CTT CC-3′ 
5. Caspase-9 Forward: 5′- AGG ATA TTC AGC AGG CAG GA -3′ 
6. Caspase-9 Reverse:  5′- GGC CTG TGT CCT CTA AGC AG -3′ 
7. Bax Forward:  5'- GCC CTT TTG CTT CAG GGT TT -3' 
8. Bax Reverse:   5'- TCC AAT GTC CAG CCC ATG AT-3' 
9. Bcl-2 Forward:  5'- GAC AGA AGA TCA TGC CGT CC-3' 
10. Bcl-2 Reverse:  5'- GGT ACC AAT GGC ACT TCA AG-3' 
11. GAPDH Forward:  5'- ACC CAC TCC TCC ACC TTT G-3' 
12. GAPDH Reverse:  5'- CTC TTG TGC TCT TGC TGG G-3' 
 
To assess the efficiency of PCR amplification, a serial dilution of the cDNA was 
prepared and used as template for the amplification of the house-keeping gene, GAPDH. 
The house-keeping gene is not expected to be affected by the experimental condition (i.e. 
treatment with the plant extracts). The expression levels of the genes that were of interest 
(Bax, Bcl2, caspase-3, caspase-8, caspase-9) were aligned to the expression levels of 
GAPDH in order to normalize cellular expression levels of these genes. Figure 1A shows 
the amplification curves for GAPDH using cDNA that was serially diluted 10-fold 
(starting at 200 ng) as the template for the PCR. Figure 1B shows a standard curve using 
the amplification cycle number at the crossing point were amplification plateau off and 
logarithmic value of the cDNA concentration generated for the amplification curves of  
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GAPDH. The efficiency of PCR amplification was calculated using the Second 
Derivative Maximum Method (Lightcycler 4.5, Roche Applied Science). PCR 
efficiencies between 91 and 96% were considered to be sufficient. This allowed for very 
accurate comparison of expression ratios between the GAPDH and the target genes. 
Figure 1C shows the melting peak analysis for GAPDH produced from the serially 
diluted cDNA. This type of analysis was performed for all 6 PCR primer pairs. 
 
4.3.13. Statistical analysis 
Effects were statistically compared by conducting an unpaired t-test using the Microsoft 
Excel programme. Differences between the mean ± SEM (standard error of the mean) of 
samples were considered significant at P<0.05. 
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4.4. RESULTS 
 
4.4.1. APOPercentage assay 
 
4.4.1.1. Dose-response study on CHO cells 
A dose-response study was undertaken to establish if T. alliacea extracts had any pro-
apoptotic activity and to determine the LD50 of these extracts. The pro-apoptotic activity 
of the extracts was evaluated using the APOPercentage assay as described in Section 
2.4.1. CHO cells were treated for 6h with increasing doses (0 – 10mg/ml) of the extracts. 
Two extracts of T. alliacea; an aqueous extract (TAA) and a chloroform extract (TAC) 
were prepared and tested. Staurosporine, a known inducer of apoptosis was used as a 
positive control. The cells were stained with the APOPercentage dye and evaluated 
under a light microscope (Figure 2) The extent of apoptosis induction was evaluated by 
flow cytometry as described in Section 2.4.2 and is shown in Figure 3. 
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Fig 3. Dose-response apoptotic effect of Tulbaghia alliacea extracts on CHO cells
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4.4.1.2. Screening different human cancer cell lines for the induction of  
             apoptosis 
 
The apoptosis inducing potential of T. alliacea extracts was evaluated in several human 
cancer cell lines (H157, HeLa, Jurkat, MCF7 and MG63). The cells were treated for 6h 
with TAA and TAC extracts (6mg/ml). The level of apoptosis was measured by flow 
cytometry using the APOPercentage assay as described in Section 2.4.2. These 
experiments were performed in triplicate and the results are shown in Figure 4. The 
histograms in Figure 4 are examples of the flow cytometric results that were acquired. 
The numbers on the histograms represent the number of events demarcated by the M2 
marker and refer to the number of apoptotic cells staining positive for the 
APOPercentage dye, while M1 refers to the unstained viable cells. The activity of the 
TAA and TAC extracts were statistically analysed by conducting an unpaired t-test using 
the Microsoft Excel programme (Table 3). The untreated controls of the various cell lines 
were also compared to each other. 
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Table 3.  The apoptosis inducing activity of Tulbaghia alliacea extracts on different cell    
                 lines 
 
Data for positive control [Staurosporine]: (apoptotic cells ± SEM) 
H157: 85 ± 5.90 
HeLa: 56 ± 1.53 
Jurkat: 79 ± 0.58 
MCF7: 90 ± 1.16 
MG63: 72.33 ± 2.03
 
Apoptotic cells (mean ± SEM) 
 
Statistical significance (P) 
 
Cell line 
Untreated 
control 
(a) 
Aqueous 
extract (TAA) 
(b) 
Chloroform 
extract (TAC) 
(c) 
 
ab 
 
ac 
 
bc 
CHO 17 ± 1.06 31 ± 1.13 45 ± 1.51 0.0004 0.0001 0.0034 
H157 4 ± 0.57 11 ± 1.33 8 ± 0.40 0.0146 0.0035 0.1595 
HeLa 7 ± 0.65 11 ± 1.26 9 ± 1.99 0.0649 0.4767 0.4159 
Jurkat 6 ± 0.63 87 ± 3.46 56 ± 1.89 0.0019 0.0016 0.0042 
MCF7 4 ± 1.18 83 ± 5.69 73 ± 6.38 0.0053 0.0086 0.2977 
MG63 20 ± 4.84 84 ± 2.41 98 ± 0.37 0.0013 0.0038 0.0270 
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4.4.2. Assessing the activation of caspase-3  
Caspase-3 is a key regulator of apoptosis. However, the activation of apoptosis can occur 
independent of caspase-3 activation. The activation of caspase-3 was assessed using a 
monoclonal antibody specific for the cleaved form of caspase-3. Jurkat T cells were 
treated for different time points (6, 12 and 24 h) with TAA and TAC extracts (6mg/ml). 
Staurosporine was used as a positive control. The cells were fixed and stained with an 
anti-active caspase-3 antibody as described in Section 2.5. Cell fluorescence was 
measured by flow cytometry.  
 
These experiments were performed in triplicate and the results are displayed in Figure 
5A. The histograms in Figure 5B are examples of the flow cytometry results that was 
acquired. The numbers on the histograms (M2) refer to the number of cells staining 
positive for the anti-active caspase-3 antibody. M1 refers to the unstained viable cells. 
The activity of the TAA and TAC extracts were statistically analysed by conducting an 
unpaired t-test using the Microsoft Excel programme (Table 4). 
 
 
 
 
 
Fig 5. Activation of caspase-3 by Tulbaghia alliacea extracts in Jurkat cells during a time-course experiment.
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Table 4. Caspase-3 activation by Tulbaghia alliacea extracts 
Extracts TAA TAC 
Treatment Time 6h (a) 12h (b) 24h (c) 6h (d) 12h (e) 24h (f) 
% cells with 
cleaved caspase-3 
(mean ± SEM) 
22 ± 1.31 51 ± 5.45 80 ± 2.81 20 ± 3.30 62 ± 5.02 86 ± 0.93 
 
Statistical significance (P) 
ab ac ad Bc be cf de df ef 
0.0339 0.0003 0.6256 0.0239 0.2219 0.1555 0.0059 0.0026 0.0409 
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4.4.3. Evaluating mitochondrial depolarization using the             
           Tetramethylrhodamine (TMRE) assay 
Decrease in mitochondrial potential is also associated with the activation of apoptosis. 
The TMRE assay was used to assess the mitochondrial depolarization potential in Jurkat 
cells following treatment with the extracts. Jurkat cells were treated for different time 
points (30, 60, and 120 min) with TAA and TAC extracts (6mg/ml). Staurosporine was 
used as a positive control. The cells were stained with TMRE dye and cell fluorescence 
was measured by flow cytometry as described in Section 2.6. These experiments were 
performed in triplicate and the results are displayed in Figure 6A. The histograms in 
Figure 6B are examples of the flow cytometry results that were acquired. The numbers 
(M2) on the histograms refer to the number of cells with depolarized mitochondria. The 
activity of the TAA and TAC extracts were statistically analysed by conducting an 
unpaired t-test using the Microsoft Excel programme (Table 5) 
 
 
 
 
 
Fig 6. Mitochondrial depolarization by Tulbaghia alliacea extracts in Jurkat cells during a time-course experiment.
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Table 5. Changes in mitochondrial depolarization potential of Jurkat cells in response to     
                Tulbaghia alliacea extracts 
 
Extracts TAA TAC 
Treatment Time 30 min (a) 60 min (b) 90 min (c) 30 min (d) 60 min (e) 90 min (f) 
% cells with 
depolarized 
mitochondria 
(mean ± SEM) 
18 ± 0.58 24 ± 1.86  63 ± 9.25 9 ± 0.33 11 ± 0.33 23 ± 7.10 
Statistical significance (P) 
ab ac ad bc be cf de df ef 
0.0219 0.0089 0.4676 0.0054 0.0972 0.0023 0.2829 0.2278 0.6886 
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4.4.4. Evaluating DNA fragmentation using the Terminal 
deoxynucleotide transferase dUTP Nick End Labeling (TUNEL) assay 
 
The fragmentation of genomic DNA is another hallmark of apoptosis. The extent of DNA 
fragmentation was analysed using the TUNEL assay. Jurkat T cells were treated for 
different time points (6, 12, 18, 24h) with TAA and TAC extracts (6mg/ml). 
Staurosporine was used as a positive control. The cells were permeabilized and labelled 
with FITC-dUTP and propidium iodide, as described in Section 2.7. The dot plots in 
Figure 7 compares the cell fluorescence of FITC-dUTP and propidium iodide (DNA 
content). The events in the R1 region of the dot plot represent cells that are negative for 
FITC-dUTP staining and therefore do not display any DNA fragmentation, while events 
in the R2 region represent cells that are positive for FITC-dUTP and DNA fragmentation. 
The numbers in the R2 region refers to the number of cells containing fragmented DNA 
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4.4.5. Quantitative PCR 
Several genes are involved in the activation and regulation of apoptosis. In order to 
evaluate whether apoptosis induced by the plant extracts is associated with the up-
regulation of certain apoptotic genes, the expression levels of several genes (Bax, Bcl2, 
capase-3, caspase-8, caspase-9) previously implicated in the regulation and execution of 
apoptosis were evaluated by real time quantitative PCR. Jurkat cells were treated for 
different time points (6h, 12h, and 24h) with the plant extracts. Thereafter total RNA was 
isolated from the cells as described in Section 2.9 and 1 µg of this RNA was used to 
synthesize cDNA as described in Section 2.10. The expression levels of Bax, Bcl2, 
caspase-3, caspase-8, caspase-9 were assessed by quantitative real time PCR as 
described in Section 2.11 and normalized against the expression levels of the 
housekeeping gene, GAPDH. Figure 8 shows the expression levels of these genes in 
Jurkat cells treated with the plant extracts. The presentation of the expression levels of all 
these genes are relative to the expression levels in the untreated control cells. The activity 
of the TAA and TAC extracts were statistically analysed by conducting an unpaired t-test 
(Tables 6.1 – 6.5). 
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Fig 8. Quantitative PCR analysis of apoptosis-related genes (a-e) in response to    
            treatment with T.alliacea (f) extracts during a time-course experiment. 
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Table 6.1. The expression levels of Bax in Jurkat cells treated with T.alliacea extracts. 
Extracts TAA TAC 
Treatment 
Time 
6h (a) 12h (b) 24h (c) 6h (d) 12h (e) 24h (f) 
Fold expression 
(X) 
(mean ± SEM) 
4.33 ± 0.19 6.93 ± 0.15 7.86 ± 0.21 4.80 ± 0.23 7.76 ± 0.06 9.64 ± 0.21 
 
Statistical significance (P) 
ab ac ad bc be cf de df ef 
0.0003 0.0003 0.2197 0.0323 0.0062 0.0053 0.0002 0.0000 0.0009 
 
 
Table 6.2. The expression levels of Bcl2 in Jurkat cells treated with T.alliacea extracts. 
Extracts TAA TAC 
Treatment 
Time 
6h (a) 12h (b) 24h (c) 6h (d) 12h (e) 24h (f) 
Fold expression 
(X) 
(mean ± SEM) 
1.24 ± 0.02 1.25 ± 0.02 1.10 ± 0.08 1.26 ± 0.18 1.26 ± 0.18 1.28 ± 0.08 
 
Statistical significance (P) 
ab ac ad bc be cf de df ef 
1.000 0.100 0.945 0.100 0.945 0.160 1.000 0.936 0.936 
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Table 6.3. The expression levels of Caspase-9 in Jurkat cells treated with T.alliacea extracts. 
Extracts TAA TAC 
Treatment 
Time 
6h (a) 12h (b) 24h (c) 6h (d) 12h (e) 24h (f) 
Fold expression 
(X) 
(mean ± SEM) 
1.43 ± 0.15   3.42 ± 0.15 6.74 ± 0.03 1.53 ± 0.09 4.50 ± 0.46 6.46 ± 0.03 
 
Statistical significance (P) 
ab ac ad bc be cf de df ef 
0.006 0.001 0.587 0.001 0.090 0.001 0.003 0.001 0.013 
 
 
Table 6.4. The expression levels of Caspase-8 in Jurkat cells treated with T.alliacea extracts. 
Extracts TAA TAC 
Treatment 
Time 
6h (a) 12h (b) 24h (c) 6h (d) 12h (e) 24h (f) 
Fold expression 
(X) 
(mean ± SEM) 
1.11 ± 0.13 1.11 ± 0.13 1.09 ± 0.10 1.20 ± 0.07 1.17 ± 0.07 1.08 ± 0.10 
 
Statistical significance (P) 
ab Ac ad bc be cf de df ef 
1.000 0.907 0.717 0.907 0.717 0.904 1.000 0.001 0.013 
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Table 6.5. The expression levels of Caspase-3 in Jurkat cells treated with T.alliacea extracts. 
Extracts TAA TAC 
Treatment 
Time 
6h (a) 12h (b) 24h (c) 6h (d) 12h (e) 24h (f) 
Fold expression 
(X) 
(mean ± SEM) 
0.97 ± 0.07 1.90 ± 0.10 5.91 ± 0.15 1.13 ± 0.03 2.27 ± 0.18 4.53 ± 0.15 
 
Statistical significance (P) 
ab ac ad bc be cf de df ef 
0.001 0.001 0.089 0.001 0.144 0.002 0.003 0.001 0.001 
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4.4.6. Cell cycle analysis 
The anti-tumour activity of several anti-cancer agents can also be associated with anti-
proliferative activity. In order to assess whether the plant extracts have an effect on cell 
cycle progression, Jurkat cells were treated with a sub-lethal dose (0.5mg/ml) of the plant 
extracts and the cell cycle profile of the cells were evaluated over a 72h period at 24h 
intervals. Cell cycle progression was investigated by studying four phases (G1, S, G2M 
and sub-G1) of cell cycle progression. The cell populations in the different phases were 
quantified by flow cytometry, and are displayed in Figure 9A. The flow cytometry data is 
shown in Figure 9B with the M1, M2, M3 and M4 markers representing sub-G1, G1, S, 
and G2-M cell populations, respectively. 
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4.5. Discussion  
 
Tulbaghia alliacea is used traditionally for a variety of ailments (Van Wyk et al., 2000). 
Some communities also claim to use it for the treatment of oesophageal cancer. This 
investigation aimed at assessing the potential of T. alliacea extracts as an anti-cancer 
phytotherapy. The cytotoxic effects of several anti-cancer drugs involve the activation of 
apoptosis in cancerous cells. To evaluate the anti-cancer potential of T. alliacea, the pro-
apoptotic activity of the aqueous (TAA) and chloroform (TAC) extracts were assessed 
using several bioassays, which detect biochemical and morphological changes that are 
associated with apoptosis. 
 
 Initial screenings of the extracts were performed on CHO cells. These cells are 
commonly used in biological and medical research. CHO cells are non-cancerous cells 
that are susceptible to apoptosis induced by a wide range of anti-cancer agents (including 
ceramide, staurosporine, doxorubicin, cisplatin, etc.), suggesting that the apoptosis 
apparatus in these cells is intact, and that this cell line is an appropriate control to 
evaluate the pro-apoptotic potential of the plant extracts. CHO cells were treated with 
both extracts and the level of apoptosis was assessed using the APOPercentage assay, 
which detects apoptosis at the stage of phosphatidyl serine exposure. The extracts 
induced morphological changes (cell shrinkage and cell detachment) in CHO cells; that 
were indicative of cells undergoing apoptosis (Figure 2).  
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The APOPercentage assay confirmed that cell death was as a result of apoptosis since 
the cells treated with the plant extracts stained positive with the APOPercentage dye. 
The quantification of apoptosis by flow cytometry demonstrated that both extracts 
induced a dose-dependant increase in the number of apoptotic cells (Figure 3). At a 
concentration of 6mg/ml, the TAA extract induced apoptosis in ~50% of the cell 
population. In comparison, the TAC extract was less effective, inducing apoptosis in 
~25% of the cells. A concentration of 6mg/ml was used in subsequent assays to assess the 
potential of both these extracts to induce apoptosis in several human cancer cell lines.  
 
A panel of human cancer cell lines, which included H157 (small lung cell carcinoma), 
HeLa (cervical carcinoma), Jurkat (leukaemia T cells), MCF7 (breast adenocarcinoma), 
and MG63 (osteosarcoma) were tested for susceptibility to these extracts. Three of these 
cell lines, which included Jurkat, MCF7 and MG63 cells, were highly susceptible to both 
the extracts, while HeLa and H157 cells were resistant (Figure 4).  
 
Since the polarity of chloroform and water is significantly different, it is expected that the 
chemical entities present in the chloroform extract (TAC) of the plant will be different 
from that in the aqueous extract (TAA). Consequently, the bioactivity of these two 
extracts may differ. A comparison of the effects of these two extracts shows that the 
MCF7 cells were equally susceptible to both the TAA and TAC extract, while Jurkat 
cells were more susceptible (P<0.05) to the TAA extract. The MG63 cells were more 
susceptible (P<0.05) to the TAC extract (Figure 4 and Table 3).  
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This suggests that the plant extracts show selectivity towards particular human cancer cell 
lines. The difference in the bioactivity may also be as a result of genetic variance between 
the different cell lines.  
 
Cancer cell lines are known to have mutations in genes that are involved in apoptosis and 
as a result these cells may be more resistant to particular apoptosis-inducing agents. 
Apoptosis can be activated through several pathways and it is therefore possible that the 
two resistant cell lines (H157 and HeLa) may have acquired genetic mutations in genes 
that are present in the pathways activated by the pro-apoptotic compounds in the extracts. 
 
Jurkat is one of the two cell lines that displayed differential susceptibility to the two 
extracts (TAA and TAC). Hence, this cell line was selected to further characterise the 
pro-apoptotic activity of these extracts. Three other markers of apoptosis (mitochondrial 
depolarisation, caspase-3 cleavage, and DNA fragmentation) were used to assess the 
bioactivity of the plant extracts. Caspases are a family of cysteine proteases that are 
involved in the induction of cell death by apoptosis (Grimm, 1996; Polverino, 1997). The 
activation of caspase-3 is central to both apoptosis pathways. Caspase-3 has many 
substrates and is known to cleave structural proteins that generate the characteristic 
apoptotic morphology (Kothakota, Azuma, Reinhard, Klippel, Tang, Chu, McGarry, 
Kirschner, Koths, Kwiatkowski, Williams, 1997); Lazebnik, Kaufmann, Desnoyers, 
Poirier, Earnshaw, 1994; Mashima, Naito, Noguchi, Miller, Nicholson, Tsuruo, 1997).  
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Jurkat cells were treated with TAA and TAC extracts and analysed for caspase-3 
activation using an anti-active caspase-3 PE conjugated antibody. Both extracts induced a 
time-dependant increase in caspase-3 activity. In contrast to the APOPercentage assay, 
which showed that the TAA extract was more active than the TAC extract, the caspase-3 
assay showed that both extracts induced similar levels of caspase-3 cleavage (Figure 5). 
This could possibly point to different mechanisms of apoptosis induction for these two 
extracts. 
 
Mitochondria have been implicated as sensors and executioners in the cell's decision to 
live or die (Kroemer, Zamzami, Susin, 1997; Murphy, Fiskum, Beal, 1999; Reed, 1997) 
and may even influence the mode of cell death chosen, which is either necrosis or 
apoptosis, depending on their functional state (Nicotera and Leist, 1997; Tsujimoto, 
1997). It has been shown that mitochondria release pro-apoptotic factors into the cytosol. 
The release of these proteins from the mitochondria is triggered by the loss of the 
mitochondrial potential. Using the potentiometric fluorescence probe, TMRE, to evaluate 
the mitochondrial potential in Jurkat cells treated with the plant extracts, it was 
demonstrated that both extracts induce mitochondrial depolarisation, but that the TAA 
extract is significantly more active (P<0.05) (Figure 6). 
 
Cleavage of chromosomal DNA into oligonucleosomal size fragments is a biochemical 
hallmark of apoptosis (Wyllie, Kerr, Currie, 1980). Several nucleases have been 
associated with DNA fragmentation during apoptosis. Amongst these nucleases is the 
Caspase Activated Deoxyribonuclease (CAD), which pre-exists in living cells as an 
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inactive complex with an inhibitory sub-unit, called ICAD. The cleavage of CAD/ICAD 
complex i.e. activation of CAD, occurs by means of caspase-3 mediated cleavage of 
ICAD. Since the caspase-3 assay confirmed that both the TAA and TAC extracts induce 
the activation of caspase-3, the TUNEL assay was used to evaluate DNA fragmentation 
in Jurkat cells treated with TAA and TAC extracts. Both extracts demonstrated a time-
dependant increase in DNA fragmentation, but the TAA extract was significantly more 
active (P<0.05) (Figure 7). This is in agreement with the APOPercentage assay and the 
TMRE assay, which showed that TAA is more active than the TAC extract. 
 
Two major apoptotic pathways have been described; the extrinsic or death receptor 
pathway and the intrinsic or mitochondrial pathway. These two pathways are distinct and 
involve different genetic components. In an effort to understand and further characterise 
the pro-apoptotic activity of the plant extracts, the expression levels of five genes (Bax, 
Bcl2, caspase-3, caspase-8 and caspase-9) that play key roles in the regulation and 
execution of apoptosis were evaluated by real time PCR. The expression levels of three 
of these genes (Bax, caspase-3, and caspase-9) were significantly up-regulated over a 24 
h period in Jurkat cells treated with the extracts (P<0.05), while the other two genes, 
caspase-8 and the anti-apoptotic gene, Bcl2 were only moderately (1-fold increase) 
increased in the treated cells (Figure 8).  
 
A comparison between the two extracts demonstrated a significant difference between the 
two extracts with regard to the induction of Bax, caspase-3, and caspase-9 expression 
(P<0.05; Tables 6.1, 6.3, 6.5). At 12 h and 24 h, the up-regulation of Bax was higher for 
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the TAC extract than the TAA extract. On the other hand, the expression levels of 
caspase-3 and caspase-9 were higher for the TAA extract at the 24 h time point. This 
demonstrates that both extracts affect the expression levels of genes that are involved in 
the regulation of apoptosis and that the mechanism of apoptosis induction may involve 
the mitochondrial pathway. Furthermore, there is a distinct difference between the two 
extracts with regard to the mechanisms by which these extracts induce apoptosis.  
 
Many conventional anti-cancer drugs are DNA damaging agents that cause double-
stranded DNA breaks in cancer cells causing the cell cycle in these cells to stop and 
resulting in the elimination of these cells by apoptosis. Cellular proliferation involves 
four sequential phases: the S or synthesis phase when DNA synthesis occurs, the M or 
mitotic phase when the cell divides into two daughter cells, and two gap phases (G1 and 
G2) which separate the S and M phases (Garrett, 2001).  G1 follows the M phase and is 
the stage when the cell is responsive to both positive and negative growth signals. G2 
follows the S phase and is the stage when the cell prepares to enter the M phase. A fifth 
stage, the G0 or quiescence phase represents a stage into which cells may reversibly exit 
from G1 when growth conditions are not favourable. It is essential that the integrity of the 
genome is protected during cell division. This is achieved through three cell cycle 
checkpoints (G1/S, S, G2/M), which prevent cells with damaged DNA from proliferating 
and producing progeny with the same errors.  
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It was already demonstrated that apoptosis induced by the plant extracts involves 
chromosomal DNA fragmentation. In order to ascertain whether the plant extracts also 
affect cell cycle progression, Jurkat cells were treated with a sub-lethal dose (0.5mg/ml) 
of the extracts and the cell cycle progression was evaluated over a 72 hour period at 24 h 
intervals. At 24 h, both extracts induced apoptosis as is evident from the increased sub-
G1 peaks (Figure 9). The TAA extract did not affect the cell cycle profile significantly 
except that the number of cells in the S phase dropped by about 10%, which may account 
for the increase in the sub-G1 population. The TAC extract on the other hand induced 
considerable changes in the cell cycle profile of the Jurkat cells. The G1 population 
decreased by about 25%, while the G2-M population increased by about 15%. The latter 
may suggest that the cell cycle progression halted in G2-M phase during the G2/M 
checkpoint. At 48 and 72 hours the cellular profile for the cells treated with the TAA 
extract still did not change significantly. However, the TAC extract demonstrated an 
increase in the sub-G1 population and a decrease in the G2-M population.  
 
 
4.6. Conclusion 
The ability of a compound or a plant extract to induce apoptosis in cancer cells can be 
used as a test to evaluate the potential use of such a compound or a plant extract to treat 
cancer. Since this study demonstrated that extracts of T. alliacea selectively induced 
apoptosis in human cancer cell lines, it can be concluded that extracts and in particular 
the aqueous extract (which is how the plant is traditionally used) shows potential as an 
anti-cancer remedy. 
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CHAPTER 5 
 
 
An assessment of the toxicity of  
Tulbaghia alliacea phytotherapy  
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5.1. Abstract 
Tulbaghia alliacea is used traditionally as a plant medicine for a variety of ailments. 
Scientific investigations have shown that this indigenous phytotherapy does indeed 
possess a variety of biological activities in vitro; it has significant antifungal activity 
against the opportunistic pathogen Candida albicans, antimycobacterial activity against a 
Mycobacterium species, is able to stimulate the immune system by modulating the 
expression of interferon-gamma, and has apoptotic-inducing capability relevant to an 
anti-cancer remedy. There is, however, no scientific information on its in vivo safety and 
toxicity. Establishment of this information is critical, as this phytotherapy has a long 
history of medicinal use in indigenous communities. In this study, the focus was on 
investigating the acute and sub-acute toxicity in mice administered different doses of the 
plant medicine, by analyzing various haematological [red blood cell (RBC), white blood 
cell (WBC), platelet count, and levels of haemoglobin, haematocrit, mean corpuscular 
volume, mean corpuscular haemoglobin concentration, lymphocytes, monocytes, 
eosinophils and neutrophils] and biochemical [glucose, cholesterol, aspartate 
transaminase (AST) and alanine transaminase(ALT)] markers. None of the animals in 
this study died, and neither did they exhibit any changes in their general appearance or 
behavior. In addition, there were no changes in body weight or food and water intake. 
The haematological analyses showed no significant differences in RBC, WBC and 
platelet counts in the control and treated groups. Likewise, the plasma biochemistry 
results showed that AST, ALT, glucose and total cholesterol were similar for the control 
and treated groups.  These values were also well within the normal physiological range, 
indicating that Tulbaghia alliacea phytotherapy at the administered doses is non-toxic in 
mice. 
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Keywords: Tulbaghia alliacea, toxicity, mice, haematology, AST, ALT, glucose, 
cholesterol.  
 
5.2. Introduction 
Tulbaghia alliacea is used traditionally as a plant medicine for a variety of ailments. Our 
scientific investigations thus far have shown this indigenous phytotherapy to indeed 
possess biological activity in vitro; it has significant antifungal activity against the 
opportunistic pathogen Candida albicans (Thamburan et al., 2006), and 
antimycobacterial activity against a Mycobacterium species, as well as being able to 
stimulate the immune system by modulating the expression of interferon-gamma, and 
showing apoptotic-inducing capability relevant to an anti-cancer remedy.  
 
Even though this indigenous phytotherapy is widely used by many communities, there is 
no information about its in vivo safety and toxicity. This study was thus designed to 
investigate the safety of the aqueous extract of Tulbaghia alliacea, by determining its 
behavioural and pharmaco-toxicological effects after acute and sub-acute administration 
in an in vivo mouse model. 
 
Investigation of the acute toxicity is the first step in the toxicological analysis of herbal 
drugs (Deciga-Campos, Rivero-Cruz, Arriaga-Alba, Castaneda-Corral, Angeles-Lopez, 
Navarrete, Mata, 2007). Acute oral toxicity is the adverse effects occurring within a short 
period of time after oral administration of a single dose of a substance (OECD, 2001).  
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In the assessment and evaluation of the toxic characteristics of a substance, determination 
of acute oral toxicity is usually the initial step. It provides information on health hazards 
likely to arise from short-term exposure by the oral route. An evaluation of acute toxicity 
data includes the relationship, if any, between the exposure of animals to the test 
substance and the incidence and severity of all abnormalities, gross lesions, body weight 
changes, effects on mortality, and any other toxic effects (USEPA, 1998; Loomis and 
Hayes, 1996; Timbrell, 2002; Pascoe, 1983).  
 
5.3. Materials and Methods 
 
5.3.1. Preparation of plant extract 
An aqueous extract of T.alliacea was prepared. Bulbs of T.alliacea were washed and 
chopped into tiny pieces, and then soaked in distilled water overnight, and then vacuum 
filtered. The crude aqueous extract was then dissolved in saline (0.9% NaCl solution) to 
make up doses of 7.5, and 10.0 g/body weight, which were administered to the mice by 
oral gavage.   
 
5.3.2. Animals and animal care 
Ethical approval for this study was granted by the Ethics Committee of the University of 
the Western Cape. Healthy BALB/C mice of both sexes, weighing between 20-30g were 
obtained from the University of Cape Town Animal Unit, where they had been bred 
under conventional conditions for research purposes. Prior to dosing and the start of the 
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experiment, the animals were kept for 5 days at the Animal Room at the School of 
Pharmacy, UWC, to allow for their acclimatization to the laboratory conditions. The 
animals were divided into three (3) groups of 6 animals each, matched for weight and 
size. The animals were housed 3 mice per sex per cage in a well ventilated room with a 
12h cycle of day and night conditions, and temperature maintained at 25ºC. All animals 
had free access to tap water and food throughout the experiment, except for the short 
fasting period before the oral administration of the Tulbaghia alliacea phytotherapy. The 
selected individual animals were weighed and identified via markings made on their tails 
with permanent ink pens. Additionally, all cages were labeled with details of the animals’ 
sex and the dose administered.  
 
5.3.3. Acute toxicity 
 
The acute toxicity of the Tulbaghia alliacea phytotherapy was evaluated in mice using 
the up and down procedure of (OECD, 2001) of the Acute Oral Toxicity (Guideline 425) 
statistical program (AOT425statPgm). The main test was conducted, whereby the first 
animal was administered a dose and observed for behavioral changes and signs of 
toxicity. This information was then fed into the computer-based program, after which the 
next dose was recommended. This method of sequential dosing continued until adverse 
effects were observed or the test was complete. 
   
The first mouse received Tulbaghia alliacea aqueous extract at 1g/kg orally by gavage. 
The general behavior of the mice were monitored for 1h after dosing, periodically during 
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the first 24h (with special attention given during the first 4 h) (Hilaly et al., 2004) and 
then daily thereafter, for a total of 14 days. Changes in the normal activity of mice and 
their weights were monitored, and the time at which signs of toxicity appeared, were 
recorded. The next dose to be recommended was 5 g/kg. As this was the limit dose, three 
animals were sequentially dosed at this level.  
 
5.3.4. Sub-acute Toxicity  
 
5.3.4.1. Experimental animals  
Mice of both sexes (weight: 17-25g, age: 6-8 weeks) were randomly assigned into three 
groups (n = 6), three males and three females in each group. Groups of three mice were 
housed together in cages (males separated from females). Treatments were administered 
orally by gavage once a day for 14 days. The first group of animals, serving as control, 
received normal saline (300µl); the second and third group received the aqueous extract 
of Tulbaghia alliacea at doses of 7.5 and 10.0 g/kg respectively. All mice were observed 
daily for physiological and behavioral changes. 
 
5.3.4.2. Haematological and biochemical analysis 
On day 15, all surviving animals  were then anaesthetized with dry ice and 
their chests quickly opened via cervical dislocation. Blood was drawn from the most 
strongly beating position of the heart, and immediately collected into two tubes; 
heparinized centrifuge tubes and EDTA tubes. The heparinized blood was used for 
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plasma biochemistry and assayed for glucose, aspartate transaminase (AST), alanine 
transaminase (ALT), and total cholesterol. Smears made from whole blood with EDTA 
anticoagulant were used for haematological analysis which included red blood count 
(RBC), white blood cell count (WBC), platelet count, haemoglobin, haematocrit, mean 
corpuscular volume, mean corpuscular haemoglobin concentration, as well as levels of 
lymphocytes, monocytes, eosinophils and neutrophils. Table 1 contains the methods used 
for individual analyses. 
 
Table 1. Analytical methods 
 
    Test Method Units 
Aspartate aminotransferase (AST) VITROS AST Slide IU/l 
Alanine aminotransferase (ALT) VITROS ALT Slide IU/l 
Glucose VITROS GLU Slide mmol/l 
Total Cholesterol VITROS CHOL Slide mmol/l 
Red blood cells (RBC) CELL-DYN®3700 System x10^12/l 
White blood cells (WBC) CELL-DYN®3700 System x10^9/l 
Haemoglobin (Hb) CELL-DYN®3700 System g/dl 
Haematocrit (Hct) CELL-DYN®3700 System % 
Mean cell volume (MCV) CELL-DYN®3700 System fl 
Mean corpuscular Hb [] (MCHC)  CELL-DYN®3700 System g/dl 
Platelet count CELL-DYN®3700 System x10^9/l 
Differentials (neutrophils, lymphocytes, 
monocytes, eosinophils) 
Cytochemical staining % 
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 5.4. Results 
 
5.4.1. Acute toxicity  
No death was recorded in the 14 days of observation period in the animals given the 1 
and 5g/kg of the T.alliacea phytotherapy (Fig. 1). The animals also did not show any 
changes in their general appearance or behavior. 
 
5.4.2. Sub-acute toxicity 
 
5.4.2.1. General observations 
No deaths or significant changes in general behavior or other physiological activities 
were observed at any point in the study. 
 
5.4.2.2. Body weight, food and water intake 
The body weights of the control and treated groups did not change significantly during 
the study (Table 2). No differences or changes in food and water intake were observed 
either. 
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            Fig 1. Acute toxicity study of T.alliacea phytotherapy; results generated  
                       by the AOT425statPgm. 
 
 
Test 
sequence 
Animal 
ID 
Dose 
(mg/kg) 
Short-term 
result 
Long-term 
result 
1 1 1000 O O 
2 2 5000 O O 
3 3 5000 O O 
4 4 5000 O O 
 
      (X = Died, O = Survived) 
 
 
               Dose Recommendation: The main test is complete. 
 
               Stopping criteria met: 3 at Limit Dose. 
 
 
                   SUMMARY OF LONG-TERM RESULTS: 
 
Dose 
(mg/kg) 
Survived
(O) 
Died 
(X) Total 
1000 1 0 1 
5000 3 0 3 
All Doses 4 0 4 
 
                    
                  Statistical Estimate based on long term outcomes: 
 
                   The LD50 is greater than 5000 mg/kg. 
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             Table 2. Body weights of mice in the sub-acute toxicity study. 
Bodyweight (g)  Group # 
Dose 
Animal  
ID Day 1 Day 14 
1 24.8 26.0 
2 23.8 25.6 
3 21.7 23.6 
4 19.0 20.4 
5 18.9 21.0 
6 17.1 19.5 
Group 1 
(0 g/kg) 
Average ± SEM 20.88 ± 1.24 22.68 ± 1.13 
1 24.0 24.4 
2 23.8 24.5 
3 23.1 22.8 
4 19.2 19.1 
5 18.8 19.1 
6 20.3 19.8 
Group 2 
(7.5 g/kg) 
Average ± SEM 21.53 ± 0.97 21.62 ± 1.06 
1 23.5 24.3 
2 24.7 23.8 
3 22.8 24.4 
4 17.2 20.1 
5 18.0 18.7 
6 19.2 19.2 
Group 3 
(10 g/kg) 
Average ± SEM 20.9 ± 1.29 21.75 ± 1.10  
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5.4.2.3. Haematological and biochemical analyses 
 
The haematological analyses showed no significant differences in RBC, WBC and 
platelet counts in the control and treated groups (Fig. 2 a-c). These values were also well 
within the normal physiological range [RBC: 7.9 – 10.0 x 10^12/L; platelets: 860 – 1400 
x 10^9/L] (Wolford et al., 1986). 
 
Figure 3 (a-d) provides the data for the haemoglobin and haematocrit levels as well the 
MCV and MCHC. No differences between the groups were detected, and these indices 
were also within the normal physiological range [haemoglobin: 13.9 – 16.7 g/dL; 
haematocrit: 37- 42 %; MCV: 44.5 – 49.7 f/L; MCHC: 34.8  -38.2 g/dL] (Wolford et al., 
1986). 
     
Slight differences were noted in the differential blood counts i.e lymphocytes, monocytes, 
neutrophils and eosinophils (Fig. 4 a-d). However, these were still within the normal 
physiological range [lymphocytes: 63 – 90%; monocytes: 0 – 5%, neutrophils: 8 – 33%] 
(Wolford et al., 1986), except for the eosinophil count in the control and 7.5 g/kg group 
which were a little above the normal range [eosinophils: 0 – 2%] (Wolford et al., 1986).   
 
The plasma biochemistry results showed that AST, ALT and total cholesterol were 
similar for the control and treated groups (Fig. 5 a-c). The 7.5 g/kg treated group had a 
lower glucose level than the untreated and 10 g/kg group (Fig. 5d); although all this was 
still within the normal range [cholesterol: 1.60 – 4.37 mmol/L; glucose: 3.11 – 11.83 
mmol/L] (Wolford et al., 1986). 
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                   Fig 2. Red blood cell (a), white blood cell (b) and platelet (c) counts of mice   
                             administered various doses of T.alliacea phytotherapy.  
                              All biochemical and haematological data are represented as means ± SEM. 
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Fig 3. The levels of haemoglobin (a), haematocrit, mean cell volume (c) and MCHC (d) of mice    
           administered various doses of T.alliacea phytotherapy. 
            All biochemical and haematological data are represented as means ± SEM. 
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Fig 4. The levels of neutrophils (a), lymphocytes (b),  monocytes (c) and eosinophils (d) of mice   
           administered different doses of T.alliacea phytotherapy. 
            All biochemical and haematological data are represented as means ± SEM. 
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Fig 5. Serum levels of total AST (a), total ALT (b), cholesterol (c) and glucose (d) of mice   
           administered different doses of T.alliacea phytotherapy. 
            All biochemical and haematological data are represented as means ± SEM. 
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5.5. Discussion 
The use of herbal medicines and medicinal plants is on the increase, as consumers seek 
an alternative to conventional clinical therapy. Such remedies are often believed to be 
harmless, since these treatments are “natural” and commonly used for self-medication 
without supervision (Rosidah, Yam, Sadikun, Ahmad, Akowuah, Asmawi, 2009). 
Experimental screening to ascertain safety, efficacy and toxicity of traditional and herbal 
products is thus crucial (Veerappan, Miyazaki, Kadarkaraisamy Ranganathan, 2007). 
Tulbaghia alliacea, an indigenous species of garlic is a plant that is used traditionally for 
a variety of ailments (Van Wyk et al., 2000; Bamuamba et al., 2008) has also shown 
promising biological activity in vitro (Thamburan et al., 2006). To date, there is no 
information available on its safety or toxicity. 
 
This study therefore aimed to assess the effect of oral administration of Tulbaghia 
alliacea phytotherapy on haematological and biochemical parameters in mice. An acute 
toxicity study (up-and-down procedure) was carried out to assess the toxicity of 
Tulbaghia alliacea phytotherapy. The concept of the up-and-down testing approach for 
the determination of acute toxicity of chemicals was first described by Dixon and Mood 
(Dixon and Mood, 1948; Dixon, 1965; Dixon, 1991a; Dixon, 1991b). The AOT 425 
(Acute Oral Toxicity) procedure [which utilizes the up-and-down testing approach] is of 
value in minimizing the numbers required to estimate the acute oral toxicity of a chemical 
(OECD, 2001). In addition to the estimation of LD50 and confidence intervals, the test 
allows for the observation of signs of toxicity (OECD, 2001). 
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Using the AOT425 procedure, the first animal received 1 g/kg of T.alliacea aqueous 
extract. After showing no signs of toxicity or mortality after 24 h, the next set of 3 
animals received a dose of 5g/ kg. No toxic symptoms, changes in behavior, or mortality, 
were observed in these animals for the next 14 days after administration of the extract. 
This was the limit dose per the AOT425statPgm (OECD, 2001), and the LD50 was thus 
estimated to be higher than 5 g/kg. Hence, the selection of the higher doses of 7.5 and 
10.0 g/kg for the subsequent sub-acute toxicity study.  
 
In the sub-acute toxicity study, it appeared that the aqueous extract of T.alliacea did not 
induce any marked changes in the animals, as evidenced by the absence of toxic 
symptoms, no changes in water or food ingestion, or abnormal weight loss or gain. The 
acute toxicity study indicated that Tulbaghia alliacea aqueous extract at a dose of 5000 
mg/kg caused neither visible signs of toxicity nor mortality. Generally, significant 
reduction in body weight is a simple and sensitive index of toxicity after exposure to 
potentially toxic substances (Teo, Stirling, Thomas, Hoberman, Kiorpes, Khetani, 2002). 
In the present study, Tulbaghia alliacea aqueous extract (1000, 5000, 7500 and 10 000 
mg/kg, p.o.) did not significantly affect body weight as compared to the control group, 
which suggests that the extract did not hinder animal growth. This analysis is based on 
the toxicity classification proposed by Loomis and Hayes (1996), viz., that substances 
with an LD50 between 5000 and 15 000 mg/kg bodyweight are regarded as practically 
non-toxic.  
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All animals survived until the scheduled euthanasia, and no gross pathological alteration 
was found in the internal organs (no organ swelling, atrophy or hypertrophy). The 
haematological and biochemical analyses did not show much variation between the 
control and treated groups. Furthermore, these parameters were within the normal 
physiological reference ranges for mice (Wolford, Schroer, Gohs, Gallo, Brodeck, Falk, 
Ruhren, 1986).  
 
Since there were no changes in animal behavior, body weights, and haematological and 
biochemical parameters at both doses of the treated animals when compared to the 
control group, the present results suggest that at the oral doses administered (7.5 g/kg and 
10.0 g/kg), T.alliacea phytotherapy is non-toxic. This study however, was qualitative and 
not powered for statistical analysis. A more detailed study is recommended for further 
analysis of the toxicity (and long-term toxicity) of T.alliacea phytotherapy. 
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CHAPTER 6 
 
 
General Summary  
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6.1. Introduction 
 
Medicinal plants have been used, since times immemorial in virtually all cultures as a 
source of medicine. Herbal remedies and plant-based healthcare preparations obtained 
from traditionally used plants have been traced to the occurrence of natural products with 
medicinal properties. It is estimated that more than 80% of the world’s population utilise 
plants as their primary source of medicinal agents (Cordell, 1995) and that moreover, 
traditional medicine is still the only health resource available to about 60% of the world 
population (Le Grand and Wondergem, 1989).  
 
The majority of the population in urban South Africa as well as in smaller rural 
communities, are reliant on herbal medicines for their health care needs. Apart from their 
cultural significance, this is because herbal medicines are generally more accessible and 
affordable (Fennel et al., 2004). As a consequence, there is an increasing trend, 
worldwide, to integrate traditional medicine with primary health care. 
 
Commercial garlic (Allium sativum) is one of the edible plants, which has generated a lot 
of interest throughout human history as a medicinal panacea. A variety of biological 
activities have been reported for garlic including effects on tumorigenesis, 
atherosclerosis, microbial growth, blood sugar modulation and immuno-stimulatory 
properties (Milner, 2001; Siegel, 2004; Tsao, 2001; Iimuro, 2002). The anti-tumorigenic 
effects of garlic have been related to induction of apoptosis in tumor cells (Ledezma, 
2004; Knowles, 2001; Oommen, 2004; Robert, 2001; Wu, 2001). Garlic also has diverse 
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antimicrobial activity; a wide range of microorganisms, including bacteria, fungi, 
protozoa and viruses, have been shown to be sensitive to crushed garlic preparations 
(Ankri and Mirelman, 1999). 
 
Tulbaghia alliaceae is an indigenous garlic species that occurs mainly in the Eastern 
Cape and southern KwaZulu-Natal (Van Wyk et al., 2000). It is used traditionally for 
fever, colds, asthma, tuberculosis and stomach problems. In Cape Dutch tradition, it is 
used as a purgative, and for fits, rheumatism and paralysis (Van Wyk et al., 2000). 
 
The aim of this study was to investigate the medicinal properties of Tulbaghia alliacea 
extracts with a focus on the assessment of its potential as an antifungal and 
antimycobacterial agent; its ability to modulate the immune system during infection, its 
potential to induce apoptosis in cancer cells, and finally an assessment of its in vivo safety 
and toxicity.  
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Table 1. Summary of the key findings of this investigation. 
 
AIMS OUTCOMES 
1. Antifungal Evaluation 
? To establish if T.alliacea extracts have 
anti-infective activity against 
opportunistic pathogenic fungi. 
? The chloroform extract of T.alliacea 
was most potent in inhibiting the 
growth of Candidal species. 
? To determine its mechanism of 
antifungal activity. 
? T.alliacea extracts are fungicidal 
(kills yeast cells). 
? To identify the active compound/s. ? Methyl and methylene groups of 
Marasmicin were indentified in the
T.alliacea inhibitory fraction. 
2. Antimycobacterial Evaluation  
? To determine if T.alliacea extracts have 
antimycobacterial activity. 
?  The chloroform extract of T.alliacea 
was most potent in inhibiting the 
growth of M.smegmatis. 
3. Immune Modulation Assessment 
? To assess the potential of T.alliacea 
extracts to modulate the immune system 
response during infection. 
? Aqueous extracts of T.alliacea 
modulated the immune system by 
inducing increased expression of 
IFN-γ during infection. 
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4. Investigation of anti-cancer properties 
? To evaluate the apoptosis-inducing 
potential of T.alliacea extracts in human 
cancer cell lines. 
? Aqueous and chloroform extracts of 
T.alliacea induced apoptosis in 
human cancer cell lines differentially. 
5. Assessment of in vivo safety and toxicity 
? To assess the effects of oral consumption 
of T.alliacea extracts on physiological 
parameters in vivo. 
? No toxic symptoms were observed in 
mice treated with the extracts. 
? Haematological and biochemical 
parameters were within the normal 
physiological ranges, indicating that 
the phytotherapy is safe. 
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6.2. Antifungal Evaluation 
 
Oral candidiasis, caused by Candida albicans, is the most prevalent oral complication in 
HIV/AIDS patients. A comparative study of the antifungal effects of the indigenous 
South African garlic plants T.alliacea and T.violacea, to the commercial variety 
A.sativum, was conducted. This comparison was made because of the reputed 
antimicrobial effects of the commercial garlic species (Uchida et al. 1975) and traditional 
use of the indigenous varieties (van Wyk et al., 2000; Motsei, et al., 2003). Aqueous, 
methanol and chloroform extracts of the garlic plants were evaluated for antifungal 
activity against a variety of pathogenic fungi (Candida albicans, Candida glabrata, 
Candida krusei, Cryptococcus neoformans).  
 
All extracts of T.alliacea were more potent than the other two garlic species, in inhibiting 
the growth of C.albicans, and in most cases the difference was statistically significant i.e. 
P<0.05 (Table 2). A preliminary viability assay revealed the T.alliacea extract to be 
fungicidal (kills yeast cells rather than merely inhibiting growth). 
 
TLC-bioautography separation of the chloroform extract separated into three major 
fractions, with one predominant inhibitory fraction (Fig 1). NMR spectral analysis of this 
inhibitory fraction indicated the presence of the methyl and methylene groups of 
Marasmicin. These chemical shift values were in agreement with those reported for the 
same compound, previously isolated from the related Tulbaghia violacea (Kubec et al. 
2002).  
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Table 2. The anti-infective activity of Tulbaghia alliacea,  Tulbaghia violacea and  Allium  
                sativum extracts against Candida albicans* 
 
Zone of Inhibition (mm ± SEM) 
Statistical significance* 
  
Extract 
Concentration    
        (%) 
A. sativum (a) T. alliacea (b) T. violacea (c) ab ac bc 
0.06 3.33 ± 0.33 4.33 ± 0.33 0 0.1012 0.0006 0.0002 
0.15 4.00 ± 0.00 6.33 ± 0.33 0 0.0022 0.0002 0.0001 
Aqueous 
(H2O) 
0.30 5.33 ± 0.33 8.33 ± 0.33 1.00 ± 0.00 0.0031 0.0002 0.0001 
0.06 1.67 ± 0.33 4.00 ± 0.00 0 0.0023 0.0075 0.0002 
0.15 3.67 ± 0.33 5.33 ± 0.33 0.66 ± 0.33 0.0241 0.0031 0.0006 
Methanol 
(MeOH) 
0.30 5.33 ± 0.33 7.33 ± 0.33 3.33 ± 0.33 0.0132 0.0132 0.0011 
0.06 4.00 ± 0.00 5.33 ± 0.33 0 0.1012 0.0006 0.0002 
0.15 4.33 ± 0.33 7.33 ± 0.33 0 0.0031 0.0002 0.0001 
Chloroform 
(CHCl3) 
0.30 5.33 ± 0.33 10.67 ± 0.33 2.33 ± 0.33 0.0004 0.0031 0.0001 
 
* P values for comparing main effects: ab = A. sativum and T. alliacea, ac = A. sativum and T. violacea,    
bc = T. alliacea and T. violacea.   
 
         # Fluconazole (2%) inhibited C.albicans with a 7mm zone of inhibition.  
Negative controls (water, methanol and chloroform) did not inhibit C.albicans, hence no  zone of inhibition 
was observed.                             
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(i) Developed TLC plate of the T.alliacea chloroform extract sprayed with  
      vanillin-sulphuric acid reagent. NMR analysis identified  the active  
      compound as Marasmicin , with chemical shift values (ppm) of 2.38, 4.07,  
       4.18, 4.25 and 2.27. 
 
(ii) Developed TLC plate of the T.alliacea chloroform extract inoculated with  
                  Candida albiacans and sprayed with 2,5-diphenyltetrazolium bromide. 
 
 
 
Compound 
Active 
Compound 
Compound 
Zone of 
inhibition 
Fig 1. TLC-bioautography of T.alliacea phytotherapy  
           showing antifungal activity. 
  (i)                        (ii)
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6.3. Antimycobacterial Evaluation 
 
It is believed that indigenous garlic, Tulbaghia alliacea might have some 
antimycobacterial activity since it is traditionally used for fever, colds, asthma and 
tuberculosis (TB) more specifically (Van Wyk et al., 2000; Bamuamba et al., 2008).  
 
For the antimycobacterial screening of T.alliacea extracts, Mycobacterium smegmatis 
was used as a test model organism due to its genetic similarity to Mycobacterium 
tuberculosis. In comparison to A.sativum, the chloroform extract of T.alliacea was more 
potent in inhibiting the growth of M.smegmatis (P<0.05). Further phytochemical analyses 
showed three major inhibitory compounds present in the T.alliacea chloroform extract. 
One of the compounds could tentatively be identified as Marasmicin as it had the same Rf 
value (Fig 2). This is indeed a very important finding as it indicates that in addition to 
possessing antifungal activity (Thamburan et al., 2006), Marasmicin also has 
antimycobacterial activity.  
 
A further two compounds that exhibit strong antimycobacterial activity have also been 
located in this extract. The structural analysis of these moieties presents the basis for a 
more advanced phytochemical study of T.alliacea. Consequently, Marasmicin may act 
singularly or in concert with synergistic compounds in Tulbaghia alliacea, as a very 
significant natural antibiotic. The results of this study prove that Tulbaghia alliacea does 
indeed have antimycobacterial activity and thereby validates the traditional use of this 
plant remedy for TB. 
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(i)  Developed TLC plate of the T.alliacea chloroform extract sprayed with vanillin-sulphuric acid reagent. 
NMR analysis identified the active compound A as Marasmicin, with chemical shift values (ppm) of 2.38, 
4.07, 4.18, 4.25 and 2.27, which have been previously reported for this entity (Thamburan et al., 2006). 
 
(ii) Developed TLC plate of the T.alliacea chloroform extract inoculated with Mycobacterium smegmatis 
and sprayed with 2,5-diphenyltetrazolium bromide. 
 
 
 
 
Compound C 
(Rf  0.92) 
 Compound B 
 (Rf  0.55) 
Compound A 
(Rf  0.44) 
Inhibition zone 
Inhibition zone 
Inhibition zone 
     (i)                      (ii)
Fig 2. TLC-bioautography of T.alliacea phytotherapy showing antimycobacterial activity. 
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6.4. Immune Modulation Assessment 
IFN-γ is a multipotent cytokine and its biological functions are complex. Deficiency of 
IFN-γ has been associated with the pathogenesis of many diseases (Chen and Liu, 2009). 
IFN-γ plays important roles both in the innate and adaptive immune responses. Its 
deficiency will therefore lead to susceptibility to microbial infections and tumor 
development (Dunn, Old and Schreiber, 2004). Mutation in the IFN-γ gene has been 
shown to lower the body’s ability to resist mycobacterial infection (Patel, Doffinger, 
Barcenas-Morales, Kumararatne, 2008).  
 
To assess the immune-modulatory effects of Tulbaghia alliacea extracts on IFN-γ 
expression, diluted whole blood was stimulated with the non-specific mitogen PHA and 
the TB-specific antigen PPD, and exposed to varying concentrations of Tulbaghia 
alliacea aqueous and chloroform extracts. 
 
A noteworthy finding in this study is that the aqueous extract of Tulbaghia alliacea was 
more active than the chloroform extract, in stimulating the expression of IFN-γ (Fig 3). 
This is significant because an aqueous extract is the form in which this phytotherpay is 
used in indigenous cultures, as a remedy for various ailments including TB and TB-
related conditions (Van Wyk et al., 2000; Bamuamba et al., 2008). The aqueous extract 
also showed considerable antimycobacterial activity against Mycobacterium smegmatis in 
vitro, indicating that administration of the phytotherapy during infection could work 
either by eradicating the pathogen, or by stimulating the host’s immune system to mount 
a protective response via expression of IFN-γ.  
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6.5. Investigation of anti-cancer properties 
 
Considerable attention has been given to the manipulation of apoptosis as a novel and 
promising strategy for cancer chemoprevention and therapy (Cal et al., 2003; Dong, 
2003; Fesus et al., 1995; Holzman, 1996; Krzystyniak, 2002). Several anti-cancer drugs 
have been shown to exert their effects through the activation of apoptosis and a 
substantial number of these drugs have been isolated from medicinal plants. To evaluate 
the anti-cancer potential of T. alliacea, the pro-apoptotic activity of the aqueous (TAA) 
and chloroform (TAC) extracts were assessed using several bioassays, which detect 
biochemical and morphological changes that are associated with apoptosis. 
 
Using the APOPercentage assay, CHO cells treated with the extracts showed 
morphological changes (cell shrinkage and cell detachment); that were indicative of cells 
undergoing apoptosis. A panel of human cancer cell lines, which included H157 (small 
lung cell carcinoma), HeLa (cervical carcinoma), Jurkat (leukaemia T cells), MCF7 
(breast adenocarcinoma), and MG63 (osteosarcoma) were tested for susceptibility to 
these extracts. Three of these cell lines, which included Jurkat, MCF7 and MG63 cells, 
were highly susceptible to both the extracts, while HeLa and H157 cells were resistant 
(Fig 4). 
 
A comparison of the effects of the two extracts shows that the MCF7 cells were equally 
susceptible to both the TAA and TAC extract, while Jurkat cells were more susceptible 
(P<0.05) to the TAA extract. The MG63 cells were more susceptible (P<0.05) to the  
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TAC extract. This suggests that the plant extracts show selectivity towards particular 
human cancer cell lines. The difference in the bioactivity may also be as a result of 
genetic variance between the different cell lines. 
 
Jurkat is one of the two cell lines that displayed differential susceptibility to the two 
extracts (TAA and TAC), and was hence selected to further characterise the pro-apoptotic 
activity of these extracts. Three other markers of apoptosis (mitochondrial depolarisation, 
caspase-3 cleavage, and DNA fragmentation) were used to assess the bioactivity of the 
plant extracts. 
 
In contrast to the APOPercentage assay, which showed that the TAA extract was more 
active than the TAC extract, the caspase-3 assay showed that both extracts induced 
similar levels of caspase-3 cleavage. This could possibly point to different mechanisms of 
apoptosis induction for these two extracts.                      
 
Since the caspase-3 assay confirmed that both the TAA and TAC extracts induce the 
activation of caspase-3, the TUNEL assay was used to evaluate DNA fragmentation in 
Jurkat cells treated with TAA and TAC extracts. Both extracts demonstrated a time-
dependant increase in DNA fragmentation (Fig 5), but the TAA extract was significantly 
more active (P<0.05). This is in agreement with the APOPercentage assay and the 
TMRE assay, which showed that TAA is more active than the TAC extract. 
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In an effort to understand and further characterise the pro-apoptotic activity of the plant 
extracts, the expression levels of five genes (Bax, Bcl2, caspase-3, caspase-8 and 
caspase-9) that play key roles in the regulation and execution of apoptosis were evaluated 
by real time PCR. The expression levels of three of these genes (Bax, caspase-3, and 
caspase-9) were significantly up-regulated over a 24 h period in Jurkat cells treated with 
the extracts (P<0.05), while the other two genes, caspase-8 and the anti-apoptotic gene, 
Bcl2 were only moderately (1-fold increase) increased in the treated cells (Fig 6). 
 
The ability of a compound or a plant extract to induce apoptosis in cancer cells can be 
used as a test to evaluate the potential use of such a compound or a plant extract to treat 
cancer. Since this study demonstrated that extracts of T. alliacea selectively induced 
apoptosis in human cancer cell lines, it can be concluded that extracts and in particular 
the aqueous extract (which is how the plant is traditionally used) shows potential as an 
anti-cancer remedy. 
 
 
 
 
 
 
 
 
 
Fig 6. Quantitative PCR analysis of apoptosis-related genes (a-e) in response to    
           treatment with T.alliacea (f) extracts during a time-course experiment. 
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6.6. Assessment of in vivo safety and toxicity 
 
Even though Tulbaghia alliacea, an indigenous phytotherapy, is widely used by many 
communities, there is no information about its in vivo safety and toxicity. This study was 
thus designed to investigate the safety of the aqueous extract of Tulbaghia alliacea, by 
determining its behavioural and pharmaco-toxicological effects after acute and sub-acute 
administration in an in vivo mouse model. 
 
In the sub-acute toxicity study, it appeared that the aqueous extract of T.alliacea did not 
induce any marked changes in the animals, as evidenced by the absence of toxic 
symptoms, no changes in water or food ingestion, or abnormal weight loss or gain. 
 
The haematological and biochemical analyses did not show much variation between the 
control and treated groups. Furthermore, these parameters were within the normal 
physiological reference ranges for mice (Wolford et al., 1986). 
 
The results of this study suggest that at the oral doses administered (7.5 g/kg and 10.0 
g/kg), T.alliacea phytotherapy is non-toxic. This study however, was qualitative and not 
powered for statistical analysis. A more detailed study is recommended for further 
analysis of the toxicity of T.alliacea phytotherapy. 
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Planta Medica (2009) In Press
Tulbaghia alliacea: A potential anti-tuberculosis phytotherapy
Thamburan S1, Cannon J2, Mabusela W1, Folk W2 and Johnson Q1
1SA Herbal Science and Medicine Institute, University of the Western Cape, P/Bag X17, Bellville, 7535, South Africa
2Departments of Microbiology and Biochemistry, School of Medicine, Missouri University, Columbia, 65211, Missouri, USA.
Tulbaghia alliacea is used in traditional medicine to combat infections. Extracts of T.alliacea (0-10mg/ml),
were comparatively assessed for in vitro activity against Mycobacterium smegmatis using a disk diffusion
assay, and IFN-γ in human cells using ELISA technology.  T.alliacea aqueous (P<0.002) and ethanolic
(P<0.003) extracts inhibit the pathogen in a dose-dependent fashion compared to controls. More specifically,
the 10 mg/ml chloroform extract of T. alliacea most potently inhibited the growth of the pathogen (P<0.0001).
Developed TLC plates of the T.alliacea chloroform extract inoculated with Mycobacterium smegmatis were
sprayed with 2,5-diphenyltetrazolium bromide. Comparatively, developed TLC plates of the T.alliacea
chloroform extract were sprayed with vanillin-sulphuric acid reagent. NMR analysis identified the active
compound A as Marasmicin, with chemical shift values (ppm) of 2.38, 4.07, 4.18, 4.25 and 2.27, which have
been previously reported for this entity1.
The inhibitory effect of Tulbaghia alliacea against Mycobacterium smegmatis, is due to three active
compounds, observed using TLC. Through NMR, one of these compounds was identified as Marasmicin (Rf
0.44), a potent anti-infective compound previously identified in T. alliacea1. In addition, the aqueous extracts
of Tulbaghia alliacea showed greater potency in stimulating the expression of IFN-γ, when compared with 
the chloroform extract (P<0.05). Tulbaghia alliacea phytotherapy is antimycobacterial and modulates IFN-γ,
which is vital in fighting TB infection.
1. Thamburan S., Klaasen J., Mabusela WT., Cannon JF., Folk W. and Johnson Q. (2006). Tulbaghia alliacea phytotherapy: a
potential anti- infective remedy for candidiasis. Phytother. Res. 20 (10): 844-50
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Planta Medica (2009) In Press
Tulbaghia alliacae: A potential anti-cancer phytotherapy
Thamburan S1, February, F2, Meyer M2 , Rees, J. and Johnson Q1
1SA Herbal Science and Medicine Institute, University of the Western Cape, P/Bag X17, Bellville, 7535, South Africa
2Department of Biotechnology, University of the Western Cape, P/Bag X17, Bellville, 7535, South Africa.
Tulbaghia alliacea is an indigenous garlic plant used in traditional medicine as an anti-cancer remedy. To
evaluate this claim, five human cancer cell lines were treated with Tulbaghia alliacea aqueous (TAA) and
chloroform extract (TAC), for their potential to induce apoptosis (0-10mg/ml over 24 hours) in vitro. Using
phosphatidyl serine externalisation, Caspase-3 cleavage, mitochondrial depolarisation and DNA fragmentation
as markers, this study showed that both extracts induced apoptosis in three of these cell lines (Jurkat, MCF7
and MG63) while the other two cell lines (HeLa and H157) were completely resistant.
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Figure 1: FLTR-Effects of TAA and TAC (6mg/ml) on Bax, Caspase 3 and Caspase 9
Gene product studies through real time PCR revealed that TAA and TAC significantly induced the expression
of Caspase-3, Caspase-9 and Bax, over time (P<0.001). Whilst a previous study showed that Tulbaghia
violacea extracts induced apoptosis1, this is the first report on the apoptotic effects of T. alliacea in Jurkat,
MCF7 and MG63 cancer cells during in vitro conditions.
1. Bungu L, Frost CL, Brauns SC, Van de Venter M (2006). Tulbaghia violacea inhibits growth and induces apoptosis in cancer cells in
vitro. Afr. J. Biotech 5, 1936-1943.
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